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Abstract 
In bacteria, multidrug efflux systems have been identified as significant determinants 
of resistance recently. These resistance pumps are widely distributed in bacterial 
species and many pathogenic bacteria posses them, which play an important role in 
their intrinsic and acquired multidrug resistances. The RND and MATE family 
transporters have also been shown to be involved in the pathogenicity of bacteria. 
Knowledge of the structure and mechanism of these transporter proteins would be 
exceedingly useful in the design of inhibitors. 
In Gram-negative bacteria, multidrug resistance is conferred in part by the tripartite 
multidrug efflux pumps that are composed of an inner membrane transpo~ protein, a 
membrane fusion protein and an outer membrane protein. One such tripartite pump, 
V ceeAB of Vibrio cholerae, is composed of an inner membrane H+ -anti porter V ceB, 
a membrane fusion protein VceA and an outer membrane channel Vcee. To 
investigate the role of this pump in the multidrug resistance of Vibrio cholerae, we 
have characterized functionally and structurally the three components of the V ceeAB 
pump and the regulator V ceR. 
The crystal structure of V cee was determined at 1.8 A resolutions. Despite the very 
low degree of sequence identity between them, V cee shares the same overall 
architecture as Tole, consisting ofthree domains: the ~-domain, the a-domain and the 
equatorial domain. The trim eric V cee packs in laminar sheets in the crystal that 
resemble membranes. Like Tole, the a-barrel of the V cee channel at the peri plasmic 
end is closed through the packing interactions of coiled-coil helices, but the residues 
that maintain the closed state of the channels of V cee and Tole are different. The 
~-barrel region of V cee is also closed, whereas the ~-barrel region of Tole is open to 
the extracellular medium. The channel interior of V cee is generally electronegative 
and contains two rings of clusters negative charge. The ring made by residues Glu397 
and Glu303 is conserved in OprM, but is not in Tole. Mutagenesis assay of this 
II 
negative charged ring indicated its functional role during transport. The optimal 
desolvation area (ODA) on the surface of V ceC is different from that of TolC, 
suggesting distinct architectures ofVceC-based and TolC-based tripartite pumps. 
Sub-cellular fractionation of cells expressmg full length and truncated VceA 
suggested that V ceA is anchored to the IM via a transmembrane helix. Analytical gel 
filtration chromatography experiments revealed that the peri plasmic domain of V ceA 
that was expressed in the peri plasm of E. coil forms a trimer, which could represent its 
oligomeric state in the V ceCAB pump. 
The three components of tripartite pumps are easy to dissociate in vitro, making it 
difficult to co-crystallize them. We overproduced the protein complex in which V ceA 
I, 
(12-406) is in complex with the VceB-VceA fusion protein. This complex was stable 
during purification, which could provide an invaluable way for co-crystallization of 
these two components of the V ceCAB pump. 
An analytical gel filtration and DLS experiments indicated that the basic functional 
unit of V ceR is a dimer; the binding of substrate CCCP to V ceR has been determined 
to occur with a Hill coefficient of about four, and thus each V ceR dimer binds four 
CCCP molecules. This stoichiometry of drugNceR-subunit is different from that of 
other transcriptional regulators in the TetR/CamR family. 
There are differences between MtrD and other RND family multidrug efflux pumps. 
The knowledge of difference will be important for understanding the mechanism of 
these family transporters. In this study, we successfully overexpressed, purified and 
crystallized MtrD. The resolution of MtrD crystals was optimised to 7-10 A at 
present. 
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Chapter 1 General introduction 
Structure and mechanism of multidrug efflux pumps in bacteria 
Microorganisms have developed vanous strategies to resist the toxic effects of 
antibiotics and other drugs (Putman et al., 2001). One of these mechanisms involves 
the inactivation of antibiotics by enzymatic modification. A well-known example of 
resistance in bacteria is the hydrolytic deactivation of the ~-lactam ring in the 
penicillins and cephalosporins by the hydrolytic enzyme ~-lactamase (Bush et a!., 
1995). The aminoglycoside antibiotics can be modified by aminoglycoside-resistance 
enzymes to an inactive form (Shaw et a!., 1993 ). A second mechanism of resistance 
focuses not on destruction of the antibiotic but on a reprogramming of the cellular 
target of the antibiotic. This may occur by mutation or enzymatic modification of the 
target in such a way that the affinity of the antibiotic for the target is reduced 
(Bussiere et al., 1998). A third resistance strategy of microorganisms is the inhibition 
of drug entry into the cell (Nikaido, 2001). The peptidoglycan cell wall in both Gram-
positive and Gram-negative bacteria, and the outer membrane and layers of 
lipopolysaccharide of Gram-negative bacteria can prevent drugs from diffusion across 
the cell envelope. The permeability of the outer membrane of Gram-negative bacteria 
can be further decreased by the loss or mutation of genes encoding porins (Nikaido, 
1994; Nikaido, 2001 ). These barriers, however, cannot prevent the toxic effects of 
drugs once they have entered the cell. A fourth mechanism of resistance is the active 
efflux of antibiotics and other drugs from the cell by multidrug resistance proteins 
(MDRs) to ensure significant levels of drug resistance (Putman et a/., 2001; Borges-
Walmsley et al., 2003). 
Five families of transporters have been found to be involved in multidrug resistance in 
prokaryotic/eukaryotic organisms, which can be categorized into primary transporters 
and secondary transporters. ATP-binding cassette (ABC) superfamily transporters are 
the pnmary transport proteins that exploit the free energy by A TP hydrolysis to 
catalyze the extrusion of drugs (Davidson et a/., 2004). The secondary multidrug 
transporters are proton or sodium motive force-driven antiporters in which the drug 
efflux process is coupled to the influx of protons or sodium ions, respectively. These 
multidrug transporters comprise of four protein families: the major facilitator 
superfamily (MFS), the small multidrug resistance (SMR) family, the 
resistance/nodulation/cell division (RND) family, and the multidrug and toxic 
compounds extrusion (MATE) family (Putman et a!., 2001; Borges-Walmsley et a!., 
2003). 
The ABC family of multidrug transporters plays an important role in drug resistance 
in eukaryotic cells, including human cells. However, in prokaryotes, drug rxtrusion is 
largely conferred by H+-antiporters that belong to the MF superfamily, the SMR 
family or RND family. Hundreds ofmultidrug transporters have been characterized in 
bacteria (reviewed by Markham et al., 2001; Borges-Walmsley et al., 2003; Poole, 
2004). These resistance pumps are widely distributed in bacterial species and many 
pathogenic bacteria posses them. Some of them can extrude a very large range of 
compounds, including antibiotics, antiseptics, dyes, detergents and solvents, as well as 
virulence determinants of bacteria, such as adhesins, toxins or other proteins, which 
are important for the colonization and infection of human and animal cells (Piddock et 
a/., 2006). The RND and MATE family transporters have been shown to be involved 
in the pathogenicity of bacteria (Piddock et al., 2006). Knowledge of the structure and 
mechanism of these multi drug transporters would be exceedingly useful in the design 
of new drugs. 
2 
1.1 Major facilitator superfamily 
The major facilitator superfamily (MFS) comprises of membrane transport proteins 
which are found in prokaryotic and eukaryotic cells. To date, more than 3600 
members of MFS have been identified (Ren et al., 2004). The MFS consists of five 
subfamilies, which are involved in drug resistance, phosphate ester/phosphate antiport, 
sugar and oligosaccharide uptake as well as uptake of Krebs cycle intermediates, 
respectively (Marger et al., 1993). 
MFS transporters are typically composed of approximately 400 amino acid residues. 
Hydropathy analysis and alignment of conserved motifs of MFS transport proteins 
reveal that the drug resistance subfamily proteins can be divided into two separate 
~ 
clusters with either 12 or 14 transmembrane segments (TMS) (Paulsen et al., 1993), 
while the remaining four subfamily proteins contain 12 TMS. 
The structures of four MFS transporters have been determined: the X-ray 
crystallographic structures of the multidrug transporter EmrD (Yin et al., 2006), the 
lactose/proton symporter (lactose permease, LacY) (Abramson et al., 2003) and the 
. . 
morgamc phosphate/glycerol-3-phosphate anti porter (glycerol-3-phosphate 
transporter, GlpT) (Huang et al., 2003), as well as the cryo-EM map of 
oxalate/formate anti porter (OxlT) (Heymann et al., 2003; Hirai eta/., 2004). 
1.1.1 Crystal structure of EmrD 
EmrD is a proton-dependent MFS transporter from E. coli. The crystal structure of 
EmrD has been determined at 3.5 A resolution, which is illustrated in figure 1.1 (Yin 
et al., 2006). The functional unit of EmrD is a monomer that is composed of 12 
transmembrane helices. The 12 transmembrane helices are divided into two distinct 
domains, forming N- and C-terminal six-helix bundles connected by a loop between 
3 
helices 6 and 7. The transmembrane helix topology of the two domains, which are 
related by an intramolecular pseudo-twofold axis normal to the membrane plane, is 
well conserved. The superimposition of the N- and C-terminal domains yields an 
RMS deviation of 0.78 A for 116 Ca atoms, indicating that the N- and C-terminal 
domains are likely to have the same genetic origin. 
At the interface between the two domains, a hydrophobic cavity is formed from 
helices 1, 2, 4 and 5 of theN-terminal domain and helices 7, 8, 10 and 11 of the C-
terminal domain. The helices 3, 6, 9 and 12 face toward the lipid bilayer and are not 
exposed to solvent. The internal cavity is rich in bulky and aromatic amino-acid 
residues (Ile28, Ile217, Ile253, Tyr52, Tyr56, Trp300 and Phe249). These aromatic 
side chains may interact with the drug molecule by hydrophobic or aromatic-aromatic 
interactions, which may play an important role in dictating a level of drug specificity 
(Figure 1.2). 
The two long helical regions (Helix 4, Loop 4-5, Helix 5 and Helix 10, Loop 10-11 
and Helix 11 ), the so-called selectivity filter, could provide additional substrate 
specificity. Functional studies of EmrD homologues, such as MdfA and LmrP (Adler 
et al., 2004; Adler et al., 2005; Mazurkiewicz et al., 2002), indicated that several 
residues in this region are important for substrate recognition (Figure 1.2). The 
charged residues (Arg118, Arg122, Asp123, Glu126, Arg127 and Arg131) at the 
cytoplasmic end of Helix 4 may play a role both in defining the topology of the 
transporter and in substrate recognition. 
The residues Thr25, Asp33 and Glu227 on the periplasmic side could easily 
reorientate into the cavity during the transport cycle, which may participate in H+ 
translocation. 
4 
A B 
H5 H8 H10 
Cytoplasm c 
Figure 1.1 Ribbon representation of EmrD. (A) Side view of EmrD along the membrane 
plane. (B) Top view of EmrD perpendicular to the membrane plane from extracellular 
side. Transmembrane helices are indicated (Adapted from Yin et al. , 2006). 
B 
H10 
T128 
Figure 1.2 (A) The hydrophobic internal cavity of EmrD. The N- and C-terminal halves 
of EmrD and the corresponding hydrophobic residues are colored blue and orange, 
respectively. (B) The selectivity filter region of EmrD. The residues displayed are 
supposed to be involved in substrate recognition according to the mutagenesis assays of 
the EmrD homolog proteins (Adapted from Yin eta!., 2006). 
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1.1.2 Proposed transport mechanism ofEmrD 
EmrD is supposed to undergo structural changes between inward and outward-facing 
conformations during the transport cycle (Yin et al., 2006). In the inward-facing 
conformation of EmrD, the hydrophobic substrates in the inner leaflet of the 
cytoplasmic membrane or in the cytoplasm could gain access to the intemal cavity of 
the transporter. The specificity of substrate recognition and binding could be 
detem1ined by the selectivity filter and the hydrophobic residues in the internal cavity. 
Then the drug is transported across the lipid bilayer through a rocker-switch between 
the N- and C-terminal domains coupled with H+ antiport. The residues Thr25, Asp33 
and Glu227 may participate in H+ translocation (Abramson et al., 2003; Huang et al., 
2003; Yin et al., 2006). 
The crystal structures of LacY and GlpT share the same overall fold as EmrD, despite 
the low degree of sequence identity. The major difference between them lies in that 
LacY and GlpT have hydrophilic internal cavities, while that of EmrD is primarily 
lined with hydrophobic residues (Abramson et al., 2003; Huang et al., 2003; 
Abramson et al., 2004a; Abramson et al., 2004b; Yin et al., 2006). Such a difference 
is consistent with the properties of the substrates they transport. The projection 
structure of the bacterial oxalate transporter OxlT also suggests a similar architecture 
with EmrD, LacY and GlpT. Yang et a/. (2005) devised a homology model for OxlT 
based upon the structure of GlpT. Despite the low sequence identity between OxlT 
and GlpT (with 18-20% sequence identity), the model of OxlT accords well with their 
Oregon green maleimide accessibility and cross-linking assays in their studies. The 
model also accommodates earlier biochemical information on OxlT. These evidences 
suggest that MFS transporters with 12-TMS maintain the same basic architecture 
(Abramson et al., 2004a; Abramson et al., 2004b). 
The 14-TMS MFS multidrug efflux proteins QacA and QacB have seven nucleotide 
differences only. QacB confers resistance to monovalent organic cations but 
6 
characteristically differs from QacA by conferring lower or no resistance to divalent 
cations. These phenotypic differences between QacA and QacB are due solely to the 
presence of an acidic residue (Asp) at position 323 in QacA instead of an uncharged 
residue (Ala) in QacB (Paulsen et al., 1996). It is likely that only a few key residues 
are involved in substrate recognition and the substitution of the corresponding 
residues can change the specificity of MFS transporters. This may explain the 
substrate diversity of the MFS. 
1.2 The resistance/nodulation/division (RND) superfamily 
The resistance/nodulation/division (RND) superfamily transporters ar~ found in 
bacteria, archaea and eukaryotes (Saier et al. 2001 ). Characterized members of the 
RND superfamily are all H+ -anti porters. The RND superfamily transporters are 
composed typically of approximately 1000 amino acid residues and the first half of 
the proteins usually resembles to the second half, suggesting that the proteins arose as 
a result of an intragenic tandem duplication event that occurred in the primordial 
system prior to divergence of the family members. The RND superfamily transporters 
are predicted to contain 12 transmembrane helices (per monomer) and 
characteristically have two large periplasmic loops between transmembrane helices 1 
and 2 and between 7 and 8 (Saier eta/., 2001; Putman et al., 2000). 
The RND family of transporters tend to play maJor roles in the intrinsic drug 
resistance of Gram-negative bacteria (Nikaido 1998). Some of them can extrude a 
very large range of compounds. The well-studied RND family multidrug efflux pump 
AcrB is the inner membrane component of the tripartite pump AcrAB/TolC of 
Escherichia coli. AcrB confers resistance to the antibiotics tetracycline, 
chloramphenicol, ~-lactams, novobiocin, fusidic acid, nalidixic acid, and 
fluoroquinolones; the chemotherapeutic agents, SDS and Triton X-100, bile salts that 
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act as detergents, various cationic dyes, disinfectants, and even solvents (Tsukagoshi 
et al., 2000; White et al., 1997). 
The crystal structure of AcrB has been determined in several conformational states 
with/without bound substrates (Murakami et al., 2002; Yu et al., 2003; Murakami et 
al., 2006; Seeger et al., 2006), which gave us the clues to structure-function 
relationships in multidrug transporters that underlie the transport mechanism of RND 
family proteins. 
1.2.1 Crystal structure of AcrB 
The first crystal structure of AcrB, belonging to R32 space group, was obtained at 3.5 
A resolution. The three protomers are fixed symmetrically by the crystal packing 
force (Murakami et al., 2002). The new crystal forms of AcrB, belonging to C2 and 
Pl space group, were determined at 2.8 A and 2.9 A resolution. These space groups 
allow each protomer to take a different conformation (Murakami et al., 2006; Seeger 
et al., 2006). 
The functional unit of AcrB is a trimer that has a superficial jellyfish-like appearance. 
The three protomers adopt different conformations, termed binding protomer, 
extrusion protomer and access protomer, respectively. AcrB comprises an extra-
membrane (peri plasmic) headpiece and a transmembrane region approximately 70A 
and 50A thick, respectively. The AcrB structure contains three domains: the 
transmembrane (TM) domain, the porter domain and the TolC docking domain 
(Figure 1.3). 
The porter domain locates at the lower part of the headpiece, which is composed of 
four subdomains, PNl, PN2, PCl and PC2, for each protomer. PNl and PN2 locate 
between TMl and TM2, while PCl and PC2 locate between TM7 and TM8. Each 
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subdomain contains two characteristic P-strand-a-helix-P-strand motifs. These four 
subdomains are packed with their P-sheets surrounding a substrate binding pocket. 
Three a-helices (the second a-helix of PN1 of each protomer) form a pore at the 
centre of the porter domain. There is a central cavity between the proximal end of the 
porter domain and TM domain. Three channels are open from the central cavity into 
the peri plasm at the side of the headpiece between PN2 and PC2, which could provide 
access to periplasmic substrates. In the binding protomer, the channel is branched at a 
vestibule near the entrance and continues through the space between the P-sheets in 
the porter domain to the binding pocket. The helix from the extrusion protomer is 
inclined nearly 15° towards the binding protomer, blocking a gap between PN1 and 
PN2 of its binding pocket, which is a possible path from the binding pock~t to the top 
funnel. The inclination of this helix also creates a space between PNl and PN2 in the 
extrusion protomer, opening to the top funnel, however, the uptake channel for the 
extrusion protomer has disappeared. The movement of PC2 and partial unwinding and 
rewinding of the upper end of transmembrane helix 8 (TM8) result in the opening and 
shutting of the pathway branched at the vestibule (Figure 1.3). 
The TM domain compnses 36 TM a-helices (12 from each protomer) and an 
additional extra-membrane a-helix for each protomer located between TM6 and TM7, 
which attaches to the cytoplasmic membrane surface. The TM domain seems to be 
loosely packed. A central hole with a diameter of about 30 A is formed by the TM 
domain ofthe protomers, which is thought to be filled with lipid. The TM4 and TMlO 
form the centre of the transmembrane helix bundles, which are suggested to be the 
proton translocation pathway. The residues Asp407, Asp408 and Lys940 that locate in 
the middle ofTM4 and TM10 are possibly central to gating. In the access and binding 
protomers, the Lys 940 residue is coordinated by salt bridges with Asp 407 and Asp 
408; in the extrusion protomer, however, Lys 940 is turned nearly 45° towards Thr 
978 of TMll an'd the salt bridges are abolished. This movement result in the twisting 
ofTM4 and TMlO. 
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Figure 1.3 Ribbon representation of the AcrB-minocycline complex. The three AcrB 
protomers are colored blue, red and green, respectively.The minocycline molecule is 
shown in CPK. (A) Side view of AcrB along the membrane plane. (B) Top view of AcrB 
perpendicular to the membrane plane from extracellular side (Adapted from Murakami et 
al., 2006). 
A B 
Figure 1.4 Ribbon representation of the drug binding site of AcrB in complex with (A) 
minocycline and (B) doxorubicin, respectively (Adapted from Murakami et al., 2006). 
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On the membrane-exposed surface of the TM domain is a vertical groove between 
helices TM7 and TM8. It extends across the whole membrane-embedded surface. The 
base of the groove is a tilted helix TM9. This groove perhaps provides access for 
substrates located at the cytoplasmic side of the membrane. 
The TolC docking domain locates at the upper part of the headpiece, which is 
composed of two subdomains, DN and DC. Each subdomain contains a four-stranded 
mixed ~-sheet. Two antiparallel ~-strands are placed parallel to a hairpin structure 
from the other half or from the other protomer. The TolC docking domain is open like 
a funnel with an internal diameter of about 30 A, similar to the diameter of the 
modelled open state ofthe TolC entrance. 
1.2.2 Molecular basis for substrate recognition 
The crystal structure of AcrB indicates that it is likely to capture substrates from both 
the periplasm and cytoplasm. Aires et a!. (2005) reconstituted the purified RND 
transporter AcrD of E. coli into unilamellar proteoliposomes, established that they 
could take up a hydrophilic substrate aminoglycosides, indicating that AcrD captures 
its substrate aminoglycosides from both the periplasm and cytoplasm. This activity 
required the presence of AcrA within the proteoliposomes. 
The periplasmic headpiece of RND family transporters has been shown to play a 
major role in determining substrate specificity. Elkins and Nikaido (2002) swapped 
sections of the periplasmic loops between two RND family transporters AcrB and 
AcrD. AcrB conferred resistance only to the typical substrates of AcrD when the two 
loops of AcrB were replaced with those of AcrD, and vice versa. Tikhonova et al. 
(2002) produced a chimeric AcrB/MexB transporter by fusing theN-terminal regions 
of AcrB and the' C-terminal residues of MexB from P. aeruginosa, which contained 
both loops of AcrB. This chimaeric transporter conferred resistance to all AcrB 
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substrates. Mao et a/. (2002) isolated spontaneous mutants of a RND family pump 
MexD from P. aeruginosa, which allow the pump to efflux the previously non-
transported antibiotic carbenicillin. These mutants were all mapped to the periplasmic 
loops of the pump, indicating that the large periplasmic loops of MexD from P. 
aeruginosa are involved in substrate recognition. 
The crystal structure of AcrB in complex with minocycline and doxorubicin provides 
a structural basis of the periplasmic headpiece in substrate recognition and transport 
(Figure 1.4 ). In the C2 crystals, the four subdomains of the porter domain are packed 
with their B-sheets surrounding a substrate binding pocket, which is rich in aromatic 
amino-acid residues: Phe 136 and Phe 178 (PN2), and Phe 610, Phe615, Phe617 and 
Phe628 (PC 1 ). The substrate binding pockets of the three protom~rs have a 
conformational difference, which is caused by the movement of PN2 and PC 1. The 
pocket of the binding protomer has an expanded structure. The phenylalanine side 
chains in this expanded pocket are favourable for hydrophobic interaction with 
substrates. The bound minocycline and doxorubicin are observed at the distal end of 
the pocket between the B-sheets of PN2 and PC 1. The vacant binding pockets of the 
access protomer and the extrusion protomer have shrunken structure and the 
phenylalanine side chains in them are moved towards each other, which are 
unfavourable for drug binding. 
The crystal structures of AcrB in complex with four substrates, rhodamine 6G (R6G), 
ethidium (Et), dequalinium (Dq), and ciprofloxacin (Cip ), have also been determined 
at 3.5 to 3.8 A resolutions (Yu et a/., 2003). All four substrates are bound to the 
periphery of the central cavity, which is surrounded by many hydrophobic residues, 
including 12 well-conserved phenylalanine residues, each protomer contributing 
Phe386, Phe388, Phe458 and Phe459. In every case, the trimeric AcrB bound three 
drug molecules. These drug binding sites in the transmembrane domain of AcrB may 
be a snapshot of'a transient point in the efflux process. 
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1.2.3 Proposed transport mechanism of AcrB 
The asymmetric structure of the AcrB trimer provides a structural basis for 
considering the molecular mechanism of RND family multidrug transporters 
(Murakami et al., 2006; Seeger et al., 2006; Schuldiner, 2006). 
The three protomer conformations of AcrB may represent the consecutive states of a 
transport cycle (Figure 1.5). The substrates could first gain access to the binding 
domain of AcrB when it is in the access protomer conformation. The conversion of 
the PN1/PC2 subdomains from the access to binding protomer conformation enables 
the substrates to move through the uptake channel and bind in the large internal 
pocket. At this point, the exit of the binding pocket is blocked by the inclit;ted helix of 
the extrusion protomer. Then the PN1/PC2 subdomains converse from the binding to 
extrusion protomer conformation, the drug binding pocket is shrunken and the exit is 
opened so that the substrates are squeezed out. The PN1 subdomains play an 
important role to such an ordered binding change mechanism (Murakami et al., 2006; 
Seeger et al., 2006; Schuldiner, 2006). 
Murakami et al. (2005) constructed cysteine-scanning mutants as to the twenty-one 
residues comprising the pore helix. Five of the twenty-one mutants, D 101 C, V 1 05C, 
N109C, Q112C, and P116C, which are localized on the wall of the pore, showed 
significantly reduced drug resistance and drug-exporting activity, indicating the 
important role of this pore in the drug transport process. Two residues, V105C and 
Q112C, are close to the corresponding residues in the next protomer of AcrB trimer. 
The formation of disulfide cross-linking between these residues prevent any 
conformational change of the pore, resulting in the greatest loss of activity in all of the 
pore mutants. These findings suggest that a conformational change of the pore is 
indispensable during the transport process. 
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The TM4 and TMlO helices have been suggested to form the proton translocation 
pathway. The residues Asp407, Asp408 and Lys940 that locate in the middle ofTM4 
and TMlO are possible candidates for the transmembrane proton translocation site. 
The protonation of aspartic acids would disrupt the ion pairs between them, resulting 
in a conformational change of the helices TM4 and TMl 0. However, how this 
conformational change of the transmembrane helices causes the movements of 
subdomains (including those in the porter domain), rewinding of the upper part of 
TM8, and the inclination of the central a-helix is still unclear. 
Two putative pathways exist for substrates to enter the drug binding pocket of AcrB. 
The groove at the periphery of each transmembrane domain perhaps could provide 
access for substrates located in the cytoplasm or inner leaflet of the ~membrane; 
substrates located on the outer surface or in the outer leaflet of the membrane could 
gain access to the cavity through the vestibules that open into the periplasm. 
The diameter of the top of Tole docking domain is about the same as that of the 
modelled open state of the Tole entrance, and they fit well with each other by manual 
docking, suggesting the possibility of a direct interaction between Tole and AcrB. 
Tamura et al. (2005) introduced cysteine mutations at the tops of the vertical hairpins 
of AcrB and the bottoms of the coiled coils of Tole molecules. The AcrB-Tole 
complex formed through disulfide cross-linking in vivo when a specific pair of 
mutants was coexpressed in E. coli, indicating direct interaction between Tole and 
AcrB. 
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Figure 1.5 Schematic representation of the transport mechanism of AcrB. 'A', 'B' and 
'E' represent the access, binding and extrusion conformation, respectively. (a) Side view 
of the tripartite efflux pump AcrAB-TolC. (b) The proposed consecutively 
conformational change of the three protomers during a transport cycle (Adapted from 
Murakami et al., 2006; Seeger et al., 2006; Schuldiner, 2006). 
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1.3 Small multidrug resistance family 
Small multidrug resistance (SMR) family belongs to the drug/metabolite transporters 
superfamily. Its members constitute the smallest known secondary transporters. These 
proteins are typically composed of around 110 amino acid residues with four 
predicted TMS and function as homooligomers. Some SMR family transporters, such 
as EbrAB and YkkCD, are composed of two dissimilar but homologous subunits: a 
short subunit with 1 05 to 1 06 amino acids and a long subunit with 111 to 11 7 amino 
acids (Putman et al., 2000). This difference is due to a C-terminal hydrophilic 
extension (Jacket al., 2000). 
Multiple-sequence alignment of SMR family proteins reveals a number of conserved 
residues, which may play essential structural or functional roles (Putman et al., 2000). 
EmrE from E.coli is one of the best-characterized SMR family transporters, which 
confers resistance to monovalent cations, such as ethidium, proflavine, pyronin Y, 
safranin 0, and methyl viologen as well as to erythromycin, sulfadiazine, TPP, and 
tetracycline (Yerushalmi et al., 1995; Paulsen et al., 1996). 
The structure of EmrE has been determined by cryo-electron microscopy ( cryo-EM) 
(Ubarretxena-Belandia et al., 2003). 
1.3.1 Cryo-electron microscopy structure of EmrE 
The three-dimensional structure of EmrE with bound TPP+ derived from cryo-electron 
microscopy of two-dimensional crystal has been determined at 7 A resolution 
(Ubarretxena-Belandia et al., 2003). The structure suggested an EmrE antiparallel 
dimer consisting' of eight a-helix bundles (Figure 1.6). 
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TPP+ was bound in a chamber formed by six tilted a-helices (helices A-C and F-H). 
The helices D and E were nearly perpendicular to the membrane and were separated 
from the chamber by two of the highly tilted helices C and F in the wall of the 
chamber. The chamber appears to be closed by the convergence of helices F and H 
just past the membrane centre. The density for TPP+ merged to the main density for 
helix H. Two openings of the substrate binding chamber face the aqueous medium 
and the lipid bilayer, respectively, which could provide an access for hydrophobic 
substrates in one leaflet of the E.coli inner membrane to the EmrE binding site. 
1.3.2 Substrate recognition by EmrE 
Site-directed mutagenesis and chemical modification experiments have provided 
insights into the identity of the amino acid residues of EmrE in the substrate binding 
pocket and translocation pathway. 
EmrE includes eight charged residues, seven of which are located in putative loops 
and can be replaced with either cysteine or other amino acids bearing the same charge 
without significantly impairing transport activity. A conserved residue Glu14 in the 
putative trasnmembrane helix-1 is essential for activity, as it constitutes the site at 
which both protons and cationic substrates bind in a mutually exclusive fashion 
(Yerushalmi et al., 2000). 
Gutman et al. (2003) constructed cysteine-scanning mutants as to the residues in the 
transmembrane helix-1of EmrE, revealing an amino acid cluster on the same face of 
helix-1 as Glu-14 that is part of the substrate- and proton-binding domain. 
Substitutions at most of these positions yielded mutants with reduced substrate-
exporting activity or modified affinity to substrates. Substitutions at the Ala-1 0 
position yielded 'mutants with modified affinity to protons and thereby impaired in the 
coupling of substrate and proton fluxes. These results indicate the important role of 
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one face of helix-1 in substrate recognition, binding, and H+ -coupled transport and the 
existence of a common binding site for substrates and protons. 
Sharoni et a!. (2005) explored the binding domain by alkylation of Cys replacements 
of EmrE, indicating that the existence of a binding cavity accessible to alkylating 
reagents where at least Leu-7, Ala-10, and Ile-11 from TM1, Tyr-40 from TM2, and 
Trp-63 in TM3 are involved in substrate binding. 
Rotem et a!. (2004) compared transport of monovalent and divalent substrates by 
EmrE in intact cells and in proteoliposomes reconstituted with the purified protein, 
demonstrating that the transport of monovalent substrates involves charge movement 
(i.e. electrogenic), while the transport of divalent substrate does~ not (i.e. 
electroneutral), indicating that an EmrE dimer exchanges two protons per substrate 
molecule during each transport cycle. 
1.3.3 Transport mechanism of EmrE 
Ubarretxena-Belandia et al. (2003) proposed a drug-efflux mechanism based on the 
cryo-EM structure of EmrE (Figure 1.7). The substrate binding pocket and 
translocation pathway are proposed to be the chamber formed by six helices (A-C and 
F-H). The hydrophobic substrates in the inner leaflet of the cytoplasmic membrane or 
in the cytoplasm could gain access to the chamber through the openings that laterally 
face the lipid bilayer or face the aqueous medium and bind to the drug-binding site 
composed of two Glu-14s from helix-1 s (Figure 1. 7-1 ). The conformational change 
could then re-orient the binding chamber to open towards the periplasm and the direct 
binding of protons to both Glu-14 residues induces the release of substrate at the 
periplasmic surface (Figure.1.7-2, 3). A second proton-driven conformation change() 
re-orients the binding site to face the cytoplasm (Figure 1. 7-4 ). 
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Ninio et al. (2004) probed the membrane topology ofEmrE, focusing on the carboxy-
terminus of the protein, supporting a secondary structure where the carboxy-terminus 
faces the cytoplasm. Soskine et al. (2006) introduced two cysteine mutations into 
TM4 of EmrE: D84C and Tl08C. Crosslinking experiments suggested a parallel 
arrangement of TM4 between the EmrE monomers. These findings argue for an 
anti parallel topology of EmrE. Fleishman et a!. (2006) proposed an EmrE model with 
parallel topology by assignment of the transmembrane segments in EmrE to the 
densities seen in the cryo-EM structure. This model accommodates much of the 
earlier biochemical information on EmrE. 
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Figure 1.6. The three-dimensional structure ofEmrE with bound TPP+ derived from cryo-
electron microscopy of two-dimensional crystal. (A) and (C) Top and side view of the 
density contoured at 1.2cr, respectively. (B) Schematic of top view of the EmrE. (D) Side 
view of a slice along the membrane plane of the density contoured at 0.8cr (Adapted from 
Ubarretxena-Belandia et al., 2003). 
Cytoplasm 
4 1 
·t I· 
3 2 
Perlplasm 
Figure 1.7. Transport mechanism ofEmrE. TPP+ is represented as a red ball and protons 
as blue balls, labelled '+' (Adapted from Ubarretxena-Belandia et al., 2003). 
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1.4 The multidrug and toxic compound extrusion family transporter 
The multi drug and toxic compound extrusion (MATE) family of transporters are 
found in bacteria and yeast. Similar to the MFS transporters, the bacterial MATE 
family transporters are typically composed of approximately 450 amino acid residues 
with 12 predicted TMS and short loops between them; however, they do not have 
sequence homology with the MFS transporters. The yeast MATE family transporters 
are larger (up to 700 amino acid residues) but they are also putatively arranged into 12 
transmembrane helices. Phylogenetic analysis of the MATE family has revealed the 
presence of three distinct clusters (Brown et al., 1999). 
Most of the characterized MATE family pumps, such as NorM and VmrA of Vibrio 
I, 
parahaemolyticus (Morita et al., 2000; Chen et al., 2001), YdhE of Escherichia coli 
(Nishino et al., 2001), VemA and VcrM of Vibrio cholerae non-01 (Huda et al., 2001; 
Huda et al., 2003), CdeA of Clostridium difficile (Dridi et al., 2004), HmrM of 
Haemophilus injluenzae (Xu et al., 2003) and MepR of Staphylococcus aureus (Kaatz 
et al., 2005), utilize an electrochemical potential of Na+ across membranes as the 
driving force; however, two MATE family pumps, PmpM of Pseudomonas 
aeruginosa (He et al., 2004) and AbeM of Acinetobacter baumannii (Su et al., 2005), 
were identified recently to utilize an electrochemical potential of H+ across their 
membranes as the driving force. 
The MATE family transporters exhibit a broad range of substrates. For instance, the 
V crM confers resistance to acriflavine, 4' ,6-diamidino-2-phenylindole, rhodamine 60, 
ethidium bromide, etc (Huda et al., 2003). Mutagenesis experiments indicated that the 
acidic amino acid residues Asp32, Glu251, and Asp367 in the transmembrane region 
of NorM, which are conserved in the clusters containing NorM, are involved in the 
Na+-dependent drug transport process (Otsuka et al., 2005). 
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The MATE family transporters are the least well characterized. Structural or 
functional information on the molecular mechanism underlying the Na + (or 
H+)/multidrug anti port by the MATE family is very limited at present. 
1.5 ATP Binding Cassette Transporters 
The ATP-binding cassette (ABC) superfamily is one of the largest superfamilies of 
proteins known, which couple the energy released from A TP hydrolysis to the 
translocation of a wide variety of substances into or out of cells and organelles 
(Davidson eta!., 2004). 
The ABC transporter proteins are generally composed of four protein domains or 
subunits: two hydrophobic transmembrane domains (TMDs) that are supposed to 
provide a translocation pathway across the membrane and two hydrophilic nucleotide-
binding domains (NBDs) that break down the ATP nucleotide to supply the energy 
for active transport (Davidson eta!., 2004). 
The individual domains can be expressed as separate proteins or may be fused into 
multidomain polypeptides in a variety of ways. For example, a single gene encodes 
the four domains of P-glycoprotein (Gottesman et al., 1996); the lmrA and msbA 
genes encode proteins with a single combined TMD and NBD, and the drrA and drrB 
genes encode the NBD and TMD as individual proteins. While the NBD of MsbA is 
located at the N-terminus of TMD, the NBD of LmrA is located at the C-terminus of 
TMD (Dawson eta!., 2006; van Veen et al., 1996). 
The predicted transmembrane helical number in the TMD between subfamilies is 
different. MacB and DrrB are predicted to have four and eight transmembrane helices 
in the TMD respectively, while MsbA and BtuC have six and ten transmembrane 
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helices in the TMD respectively (Kobayashi et a/.,2003; Gandlur et al., 2004; Locher 
eta/., 2002). 
The homology between TMDs in different subfamilies is lower, however, the NBD 
sequence of the entire superfamily shares 25% to 30% identity and contains some 
highly conserved motifs, such as Walker A/Walker B motifs, LSGGQ signature motif, 
H motif, P loop and Q loop, suggesting that a similar mechanism for coupling of 
transport to A TP hydrolysis is employed (Diederichs eta!., 2000; Gaudet et al., 2001; 
Yuan et al., 2001; Karpowich et al., 2001; Schmitt et al., 2003; Verdon et al., 2003). 
The ABC superfamily contains both uptake and efflux transport systems. All A TP-
dependent drug efflux proteins known to date are members of the ABC superfamily. 
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Most bacterial ABC drug transporters mediate the export of specific antibiotics 
(Barrasa et al., 1995; Guilfoile et al., 1991; Linton et al., 1994; Olano et al., 1995; 
Podlesek eta!., 1995; Ross et a!., 1990). Some bacterial ABC transport proteins, such 
as LmrA and MsbA, share up to 35% sequence identity to the mammalian multidrug 
efflux pump P-glycoprotein. The region of homology exists in not only NBD but also 
TMD, indicating that these ABC proteins may recognize and extrude similar 
substrates (Davidson et al., 2004). 
The crystal structures of intact ABC family transporters Sav1866, BtuCD and 
HI1470/1 (Pinkett et al., 2007), as well as the structures of isolated NBDs of 
transporters, have given an insight into their mechanism. 
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1.5.1 Structure of Sav1866 
Sav1866 is a multidrug ABC transporter from Staphylococcus aureus. The crystal 
structure of Sav1866 in complex with ADP has been determined at 3 A resolution 
(Dawson et al., 2006), which is shown in Figure 1.8. The structure represents an 
outward-facing conformation. The functional unit of Sav1866 is a homodimer and 
each subunit is composed of two domains: an amino-terminal transmembrane domain 
(TMD, amino-acid residues 1-320) and a carboxy-terminal nucleotide-binding 
domain (NBD, residues 337-578). The two subunits twist and embrace each other. 
Both the TMDs and the NBDs interact tightly. Two ADP molecules are bound by the 
P-loops and the ABC signature motifs of opposing subunits. 
The six transmembrane a-helices bundles of each subunit are connected by long 
intracellular and short extracellular loops (ICLs and ECLs, respectively). Around the 
middle of the membrane, bundles of transmembrane helices diverge into two discrete 
'wings' that point away from one another and consist of helices TM1-TM2 from one 
subunit and TM3-TM6 from the other subunit. The ICLs extend the helical secondary 
structure beyond the lipid bilayer, which protrude approximately 25 A into the 
cytoplasm. 
The large cavity at the interface of the two transmembrane domains is accessible from 
the outer leaflet and exposed to the extracellular space. The bottom of the cavity 
reaches beyond the intracellular membrane boundary without connection to the 
cytoplasm and the inner leaflet. At the level of the inner leaflet, the cavity is formed 
from helices TM2-TM5 and is rich in polar and charged amino-acid residues, while at 
the level of the outer leaflet, the cavity is formed from helices TM 1, TM3 and TM6. 
The coupling helices of ICLs, which orient roughly parallel to the membrane plane, 
provide the bulk of the contacts to NBDs: the coupling helix 1 contacts the NBDs of 
both subunits, while coupling helix 2 interacts with that of the opposite subunit. The 
24 
residues around the Q-loop of NBD form the contact surface with the TMD. Two 
conserved residues, Tyr 391 and Glu 473, are exceptional. The Glu 473 interacts with 
both ICLs and is part of the x-loop motifs (TEVGERG), which precede the ABC 
signature motifs (Figure 1.9). 
1.5.2 Proposed transport mechanism of Sav1866 
Sav1866 is supposed to undergo structural changes between inward and outward-
facing conformations during the transport cycle. The proposed transport mechanism 
of Sav1866 is based on the outward-facing crystal structure. In the outward-facing 
conformation, an extrusion pocket exposes to the external medium. The polar and 
A 
changed amino acids in the extrusion pocket have little or no affinity for hydrophobic 
drugs, so that the bound substrates are released into the outer leaflet of the lipid 
bilayer or into the aqueous medium. Hydrolysis of A TP induces a transition to the 
inward-facing conformation, granting access to the binding site from the cell interior, 
and the transporter is ready for another cycle (Dawson et al., 2006). 
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Figure 1.8. Two perpendicular views of the crystal structure of Sav1866. The two 
protomers are colored yellow and turquoise, respectively. The ADP molecules are shown 
in ball-and-stick (Adapted from Dawson et al., 2006). 
Figure 1.9. Ribbon representation of the transmission interface of Sav1866. The ADP 
molecules and the side chains of the conserved residues Tyr391 and Glu4 73 are shown in 
ball-and-stick. The 'coupling helices' are coloured red (Adapted from Dawson et al., 
2006). 
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1.6 Polyspecific substrate recognition by multidrug efflux pumps, implied by 
multidrug-binding regulatory proteins 
The structural determination of multidrug efflux pumps could be critical for us to 
understand their mechanism; however, membrane transport proteins are quite difficult 
to purify and crystallize. In bacteria, the expression of multidrug efflux pump genes is 
tightly regulated by transcriptional activators and/or repressors. These cytosolic 
multidrug-binding transcriptional regulators often bind the same substrate as that of 
the pumps they regulate and thus, these proteins are themselves multidrug binding 
proteins. The transcriptional regulators of multidrug efflux pumps provide an 
alternative in studying the multidrug recognition mechanisms (Schumacher et al., 
2003; Paulsen, 2003). 
The crystal structures of several multidrug-binding regulatory proteins in complex 
with their operator DNA and/or substrates have been determined, which provide 
insight into the molecular basis of multidrug recognition (Schumacher et al., 2001; 
Heldwein et al., 2001; Godsey et al., 2001; Schumacher et al., 2002; Grkovic et al., 
2002; Newberry et al., 2004; Murray et al., 2004; Schumacher et al., 2004). 
1.6.1 Molecular basis of substrate recognition by QacR 
The Staphylococcus aureus protein QacR is a transcriptional repressor of the qacA 
gene, a MF family multidrug transporter. The crystal structures of QacR bound to 
structurally diverse cytotoxic agents, rhodamine 6G (R6G), ethidium (Et), 
dequalinium (Dq), crystal violet (CV), malachite green (MG), berberine (Be), 
pentamidine, hexamidine and 3,6-diaminoacridine (Pt) have been determined 
(Schumacher et al., 2001; Grkovic et al., 2002; Murray et al., 2004; Schumacher et al., 
2004). 
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The structure of QacR comprises nine helices. The first three helices form a three 
helix bundle DNA binding domain, which contains a helix-tum-helix (HTH) motif 
(a2 and a3). Helices 4 to 9 form the drug binding/dimerization domain. 
The ligand-binding to QacR triggers a coil-to-helix transition of residues Thr89-
Tyr93 of the drug-bound subunit, resulting in extension of the C-terminus of aS by 4 
residues. This coil-to-helix transition expulses the Tyr92 and Tyr93 from the 
hydrophobic core of QacR, which is composed of the side chains of residues Trp61, 
Trp6S, Phe79, Tyr82, Tyr92, Tyr93, Tyr123, Tyr127, Phe131, Trp140, Phe178 and 
Phe 182, thereby increasing the volume of the binding pocket for drug binding. The 
coil-to-helix transition of aS also relocates residue Glu90 into the drug binding pocket 
so that it could assist with drug binding. In the absence of a drug, the side chains of 
~ 
residues Tyr92 and Tyr93 play an essential role of structural drug surrogates 
(Schumacher et al., 2001; Grkovic et al., 2002). 
The binding of six structurally diverse compounds in the extended QacR ligand-
binding pocket is shown in Figure 1.1 0. The drug binding pocket created by tyrosine 
expulsion is composed of residues from a4 to a8 from one subunit and a8' from the 
other subunit of the dimeric QacR. Two drug binding pockets are present within the 
large QacR drug binding pocket: the R6G binding pocket and the Et binding pocket, 
which are distinct but partially overlap. The monovalent compounds R6G and 
ethidium bromide were found to bind to the R6G binding pocket and Et binding 
pocket, respectively, while the positively charged aminomethylquinolinium moieties 
of the bivalent compound dequalinium that have a flexible decamethylene linker was 
found to bind in both of these binding pocket. Crystal violet was bound at an 
intermediate position between the R6G binding pocket and Et binding pocket, 
demonstrating the versatility of the extended QacR ligand-binding pocket 
(Schumacher et al., 2001; Grkovic et al., 2002; Schumacher eta!., 2003). 
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The large number of aromatic and hydrophobic residues lining the QacR drug-binding 
pocket present incoming drugs with a broad range of possibilities for the formation of 
hydrophobic interactions or the stacking of phenyl rings. Several polar residues 
located within the pocket serve as hydrogen bond donors and acceptors, including 
asparagme, glutamine, threonine and serine residues that add versatility for drug 
binding by contacting the polar moieties of different drugs. For example, in the 
QacR-R6G complex, the R6G phenyl moiety stacks and makes hydrophobic 
interaction with Tyr123 and Leu54. The three-ring system of R6G makes stacking 
with the side chains of Trp61 from a4 and Tyr93 from a5. The polar residues Gln64 
and Thr89 of QacR contact the R6G N2 and Gln96 contacts R6G Nl. The R6G 
central ring 01 atom contacts the Oy of residue Thr89, further securing the R6G ring 
system (Schumacher eta!., 2001; Grkovic eta!., 2002; Schumacher eta!., 2003). 
! 
Four negatively charged glutamate residues, Glu57, Glu58, Glu90 and Glu120, line 
the QacR ligand-binding pocket roughly equidistant from the centre of the large 
pocket, which are available for forming electrostatic interactions with drugs. The 
Glu90 neutralizes the positive charge of R6G and Glu120 is for neutralization of 
ethidium bromide; the positively charged nitrogen moiety of dequalinium in R6G 
binding pocket was neutralized by Glu57 and Glu58, while the other one in Et binding 
pocket was neutralized by Glu120. The single delocalized positive charge of crystal 
violet was neutralized by Glu90 and Glu120 (Schumacher eta!., 2001; Grkovic eta!., 
2002; Schumacher et al., 2003). 
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The structure of the QacR-Pf-Et ternary complex demonstrates the structural 
mechanism for simultaneous binding of two different drugs by a multidrug-binding 
protein (Figure 1.11 A-C). The near-UVCD binding assays together with relevant 
QacR-drug complex structures provide insight into the possible structural basis of 
competitive, noncompetitive, uncompetitive and cooperative multidrug binding 
(Schumacher eta!., 2004). For example, both R6G and Pf bind to the R6G binding 
pocket and sterically interfere with the binding of the other, so as to display 
competitive binding; Pf and Et display noncompetitive binding because of partial 
overlap of their binding pockets (Schumacher et al., 2004). 
Two bivalent diamidines, pentamidine and hexamidine, structurally differ by only one 
methylene carbon in the alkyl chain linker. The binding mode of hexamidine to QacR 
! 
is similar to dequaliniurn, while pentamidine adopts a novel binding mode, with one 
of its benzamidine groups interacting with residue Glu63, and the other is neutralized 
by carbonyl and side chain oxygen atoms, demonstrating that a formal negative 
charge is not a prerequisite for binding positively charged drugs and underscoring the 
versatility of the QacR, which may also be the case for other multidrug-binding 
pockets (Fig.1.11 D, E. Murray eta/., 2004). 
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Figure 1.1 0. Binding of substrates in the extended QacR ligand-binding pocket. The key 
QacR residues and relevant a.-helices in the ligand-binding site are shown. The acidic 
residues are colored red. A to F represent QacR in complex with R6G, Et, Dq, CV, MG 
and Be, respectively (Adapted from Schumacher et al., 2001; Murray et al., 2004 and 
Schumacher et al., 2004). 
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Figure 1.11. Multidrug recognition by QacR. (A) QacR- Pfbinary complex. (B) QacR- Et 
binary complex. (C) QacR- Pf- Et ternary complex. (D) QacR-hexamidine complex. 
(E) QacR-pentamidine complex (Adapted from Schumacher et al., 2004 and Murray et 
al. , 2004). 
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1. 7 Tripartite multidrug efflux pumps in Gram negative bacteria 
The envelope of Gram-negative bacteria contains two distinct membrane lipid 
bilayers. The inner membrane layer is a phospholipid bilayer, consisting largely of 
phosphatidylethanolamine (PE), phosphatidylglycerol, and cardiolipin; the outer 
membrane layer is asymmetric bilayer: the lipids on the inner and outer surface are 
glycerophospholipids and lipopolysaccharides, respectively. The shell between the 
inner and outer membranes layer, so-called periplasm, composes of peptidoglycan 
that confers mechanical robustness to the dual membrane system (Sharff et al., 2001; 
Yu et al., 2003). 
The two membrane layers of Gram-negative bacteria can drastically slow down the 
,\ 
influx of most antibiotics; however, these barriers cannot prevent the toxic effects of 
the drugs once they have entered the cell. The multidrug transporters in the inner 
membrane could form a complex with its partner proteins and actively transport 
antibiotics across the two membrane layers and the intervening periplasmic spaces in 
order to achieve their characteristic levels of intrinsic resistance (Nikaido, 2001 ). 
Generally these transport systems consist of an inner-membrane protein (IMP), 
usually a MF (Furukawa et al., 1993; Lee et al., 1999) or RND (Mokhonov et al., 
2005) or ABC (Rouquette-Loughlin et al., 2005) family transporter, a membrane 
fusion protein (MFP), such as AcrA (Mikolosko eta!., 2006), MexA (Higgins eta!., 
2004; Akama et a!., 2004), and an outer membrane protein (OMP), such as TolC 
(Koronakis et a!., 2000), forming a tripartite multidrug efflux pump. Hundreds of 
these tripartite pumps have been identified in Gram-negative bacteria (Schweizer, 
2003; Poole, 2004). The structure of three components, TolC, AcrA and AcrB, 
provide us with clues to the function of these tripartite efflux complexes. 
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1.7.1 Structure and mechanism ofTolC 
Tole is the outer membrane component of the tripartite multidrug efflux pump from 
E.coli. The crystal structure of Tole was determined at 2.1A resolution, which is 
shown in Figure 1.12 (Koronakis eta/., 2000). 
The functional unit of Tole is a homotrimer with a long axis measuring 140A. The 
Tole molecule is composed of three domains: a ~-barrel domain, a a-helical barrel 
domain, and a mixed a/~-domain (equatorial domain). The body has a large interior 
cavity that is mostly solvent-filled with an average accessible interior diameter of 19.8 
A and a volume of roughly 43,000A3. 
The 12-stranded ~-barrel domain of Tole is assembled from three protomers, with 
each protomer contributing four ~-strands. The ~-barrel domain is 40 A in length. It 
inserts into the outer membrane and is wide open to the external medium. 
The 100 A-long a-helical barrel domain is contiguous with the ~-barrel and protrudes 
. into the periplasm. The a-helices also form a 12-stranded antiparallel barrel, with each 
protomer contributing four a-helices (two continuous long helices and two pairs of 
shorter helices). While the 12-stranded ~-barrel is right-twisted, this a-helical barrel is 
left twisted. The superhelical twist at upper section of the a-helical· domain (near the 
~-barrel) tends to untwist at the distal end compared with conventional coiled coils. 
The a-helices in the lower W-barrel distal) half of a-helical barrel form six pairs of 
conventional antiparallel coiled-coils, with one pair from each protomer folding 
inward, which constricts the periplasmic entrance to a resting closed state with an 
effective diameter of ~3.9 A. 
The equatorial domain is connected to the helical barrel at the junction of short helices. 
The helices and' strands of this mixed a/~ structure pack against the helices of the 
helical barrel. 
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Figure 1.12. Structure of TolC. (a) Side view of a ribbon representation. Three protomers 
are individually colored (yellow, blue and red). (b) Ribbon representation of a TolC 
protomer. The ~-barrel domain is yellow, the a-helix domain is green and the equatorial 
domain is red (Adapted from Koronakis et al., 2000). 
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The substrates are presumed to channel through the translocase to the periplasmic 
entrance of Tole. Tole must undergo a conformational change to open the entrance, 
as it is too small for the substrates to enter the channel. An allosteric mechanism has 
been proposed for Tole opening (Koronakis et al., 2000; Koronakis et a!., 2004). 
According to this proposed model, the inner coil (comprising helices H7 and H8) of 
each protomer realign relative to the outer coil, thereby enlarging the aperture 
diameter. The intra-monomer hydrogen bonds between residues Asp 153-Try382 and 
Gln136 -Glu359, and the inter-monomer salt bridge interaction between Asp153 of a 
monomer and Arg367 of the adjacent one, were shown to stabilize the closed state of 
Tole (Andersen et al. 2002). By disrupting these interactions, the conductance of 
purified Tole proteins in black lipid bilayers increases six to ten times over wild-type 
conductance, which would be compatible with an aperture of 16 A (Andersen et a!. 
,, 
2002). Eswaran et al. (2003) found that the function of Tole was abolished by 
introducing disulphide bonds to constrain the entrance coiled coils in the close state. 
These evidences of in vivo and in vitro experiments support the proposed mechanism 
of Tole opening. Vediyappan et a!. (2006) found that the hybrid system VceAB-
Tole is functional, while AcrAB-V cee is not functional; however, some point 
mutations at the peri plasmic tip of V cee restored the functionality of the AcrAB-
Vcee pump. Bokma et a!. (2006) identified several MexAB-adapted Tole mutants 
with amino acid substitutions in the lower a-helical barrel of Tole. These mutations 
converge to the MexAB partner OprM. The interaction variations between V cee and 
Vcee mutants with AcrAB, as well as Tole and Tole variants with MexAB, may 
give us the clues that underlie the functional assembly and specificity of OMPs with 
their partner proteins IMPs-MFPs. 
1.7. 2 Structure and mechanism ofMexA and AcrA 
MexA is a MFP component of the tripartite multidrug efflux pump MexAB-OprM 
from P. aeruginosa. The structure of residues 29-259 of the 360 residues mature 
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processed form of MexA has been solved at 2.4 A and 3 A resolution (Higgins et al., 
2004; Akama et al., 2004). The crystal structure of MexA is illustrated in Figure 1.13. 
+9-- 90° 
Figure 1.13. Two perpendicular views of the crystal stmcture ofMexA monomer. The a-
helices are green, the ~-strands are blue. The a-helical hairpin is to the right; the lipoyl 
domain is central, and the ~-barrel to the left (Adapted from Higgins et al., 2004). 
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The asymmetric unit of the MexA crystal contained 13 molecules, which have the 
same conformation. The monomer of MexA has an elongated structure and is 
composed of three linearly arranged subdomains: a ~-barrel domain, a lipoyl domain, 
and a 47-A-long a-helical hairpin domain comprising a straight C-terminal helix and a 
N-terminalleft handed superhelical twist. 
The ~-barrel domain contains six anti-parallel ~-strands and a single a-helix situated 
at one entrance to the barrel. 
The lipoyl domain consists of two interlocking lipoyl motifs of four ~-strands, which 
is structurally homologous to the lipoyl domain of pyruvate dehydrogenase. Although 
these motifs are conserved throughout the family of adaptor proteins, they are 
'· 
separated by variable lengths of intervening sequence. 
The a-helical hairpin domain forms a conventional antiparallel coiled-coil, with four 
heptad repeats in each of its helices. The large, hydrophobic side chains in the a and d 
positions, Ala residues in the f position and hydrophilic residues such as Ser or Glu in 
the c position, are conserved throughout the family of peri plasmic adaptors. 
AcrA is a MFP component ofthe tripartite multidrug efflux pump AcrAB-TolC form 
E. coli. The crystal structure of a 28 kDa core of AcrA (residues 45-312) has been 
solved at 2.7 A resolution (Figure 1.14. Mikolosko eta/., 2006). The asymmetric unit 
of the AcrA crystal contained four molecules. The three domains of AcrA ( 45-312) 
monomer, a ~-barrel domain, a lipoyl domain and a a-helical hairpin domain, share 
the same overall fold as that ofMexA. The a-helical hairpin of the four monomers has 
different orientations. A hinge between the a-helical hairpin and lipoyl domain is 
composed of residues 99-106 in a-helix 1 and residues 169-173 in a-helix 2. The 
helical winding of the hinge causes such flexibility, which may play a functional role 
in coupling between AcrA conformations and TolC channel opening (Mikolosko eta!., 
2006). 
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Figure 1.14. (A) Two perpendicular views of the crystal structure of AcrA (45-312) 
monomer, with the a-helical hairpin domain in red, lipoyl domain in green and ~-barrel 
domain in cyan. (B) Superimposed AcrA (45-312) of four conformations in the 
asymmetric unit of the crystals show the orientations difference of the a-helical hairpin 
(Adapted from Mikolosko et al., 2006). 
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The mechanism~ of MFP have been studied intensely. Stegmeier et al. (2006) found 
that the hybrid system AcrAB-OprM is not functional; however, exchange of the 
hairpin domain of AcrA with that of MexA restored the function of the pump, 
indicating that the MexA hairpin domain is involved in the functional interaction with 
OprM. Elkins et al. (2003) swapped sections between two MFPs, AcrA and YhiU. 
The 290-residucs N-terminal segment and the residues from 357 to 397 of the 398-
residue protein AcrA could be replaced with a sequence coding for the corresponding 
region of YhiU, but replacement of the region between residues 290 and 357 
produced a protein incapable of functioning with AcrB, indicating that a small region 
of AcrA close to its C terminus is involved in the interaction with AcrB. Ip et al. 
(2003) found that AcrA undergoes reversible conformational changes induced by a 
narrow pH range, suggesting that the fluctuations of pH in the periplasm 
~ 
accompanying the AcrB-mediated drug efflux could act as a signal to trigger the 
action of AcrA. Borges-Walmsley et al. (2003) identified drug-binding domains of a 
MFP EmrA from E. coli, indicating that MFP could not only act as a channel between 
the IMP and OMP, but also involve in drug translocation. Y oneyama et al. (2000) 
revealed that the periplasmic domain of MexA expressed in the periplasm has the 
same function as that of the wide-type MexA protein. Cross-linking of in vivo 
complexes has identified MFP trimers in both drug efflux and protein export 
(Thanabalu et al., 1998; Zgurskaya et al., 2000), but the oligomeric state of the MFP 
in active pumps unclear yet. 
1.7.3 The three components of tripartite multidrug efflux pumps form a stable 
intermembrane complex 
The assembly of three components of type I protein translocation apparatus in Gram 
negative bacteria has been studied in three distinct systems: Has, Prt and Hly (Letoffe 
et al., 1996; Thanabalu et al., 1998). In these cases, the substrate triggers the stepwise 
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recruitment of the three components to form an intermembrane channel and the 
complex disintegrated after translocation. 
The assembly of three components of tripartite multidrug efflux pumps has been 
studied in the AcrAB-TolC and MexAB-TolC systems recently. 
Tikhonova et al. (2004) analyzed the AcrAB-TolC complex in vivo using sucrose 
gradient fractionation and pull-down assays. The sucrose gradient fractionation study 
revealed that in the absence of AcrA, the amount of AcrB detected in the OM fraction 
was far smaller then that in the presence of AcrA, indicating the important role of 
AcrA in complex formation. TolC is required for AcrB fractionation with the OM, 
suggesting tight adhesion between AcrAB and TolC. In the pull-down assay, the 
! 
affinity tag is attached to only one of the three components of A crAB-Tol C and tested 
the assembly of complex with or without substrates and proton-motive force. All the 
three components co-purified when the His6 tag is fused to AcrA, AcrB or TolC, 
indicating that the AcrAB-TolC form a stable intermembrane complex in vivo. 
Touze et al. (2004) used in vivo cross-linking to detect interactions between the 
components of AcrAB-TolC, indicating that AcrA could be cross-linked 
independently to AcrB and TolC, and TolC could be cross-linked independently to 
AcrB. Isothermal titration calorimetry (ITC) was applied to characterize purified 
proteins in vitro, suggesting that the AcrA-AcrB and AcrA-TolC interactions occurred 
spontaneously as they were associated with favourable free energy changes. lTC 
showed no association between AcrB and TolC, implying that AcrA is required to 
link these two components stably in the tripartite pump. 
Tamura et al. (2005) examined the interaction sites of AcrB and TolC using in vivo 
disulfide cross-linking between cysteine residues introduced to AcrB and TolC. The 
formation of spontaneous disulfide bonds between positions 255, 256, 257 in AcrB 
and position 147 in TolC suggests that the tops of the vertical hairpins of AcrB and 
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the bottoms of the coiled coils of Tole are in close proximity, supporting the direct 
docking model. 
Gerken et al. (2004) found that mutant AcrA can be stabilized by Tole and vice versa, 
and the functional interaction between Tolep246R, s350c and AcrA are dependent on 
AcrB, which provide genetic evidence that a functional complex exists between Tole 
and AcrAB in vivo. 
Mokhonov et al. (2004) also used in vivo cross-linking and pull-down assays to 
analyze the MexAB-OprM complex from P. aeruginosa and gave similar overall 
results with that of the AcrAB-Tole system. 
All the interactions between the components in vivo exist even in the absence of 
substrates and proton-motive force. Taken together, these data suggest that the three 
components of tripartite multidrug efflux pumps form a stable inter-membrane 
complex. 
1.7.4 The structural models for tripartite multidrug efflux pumps 
The crystal structures of the three components of tripartite multidrug efflux pump, 
AcrB, AcrA and Tole, have been determined. The question remains as to how the 
three components assemble to form a functional pump. Different models based on 
these crystal structures have been proposed. 
Higgins et al. (2004) proposed a sheath-like model in which nine MexA monomers 
form a ring. The a-helical hairpins in the ring interact by means of the stripes of 
conserved small residues to form an a-barrel. The ring could form a sheath around the 
open state model of Tole and the inner membrane transporter, generating an 
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intermembrane channel. The IMP:MFP:OMP ratio was predicted to be 1:3:1 in this 
model (Figure 1.15). 
Akama et al. (2004) devised homology models for MexB and OprM based upon the 
structures of AcrB and Tole. In the proposed model, the helical hairpins of three pairs 
of MexA dimers are inclined with the surface of OprM with an angle of about 20°. 
The lipoyl domain fits within the gap between MexB-OprM contact regions. The B-
barrel domain and disordered domain may have interacted with the MexB trimer. The 
IMP:MFP:OMP ratio was predicted to be I :2:1 in this model (Figure 1.16). 
Fernandez-Recio et al. (2004) devised a homology model for AcrA based upon the 
structure ofMexA. In the model proposed by Fernandez-Recio Jet al., AcrB present a 
! 
canyon-like domain along the interface of the periplasmic domain which can leave 
space for AcrA to bind. Three AcrA fit simultaneously in the interprotomer grooves 
of AcrB and the open state of Tole with modest structural adjustment. The 
IMP:MFP:OMP ratio was predicted to be 1:1:1 in this model (Figure 1.17). 
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Figure 1.15. Model of the assembled tripartite drug efflux pump. (A) The open-state 
model of TolC (green) contacts the TolC docking domain of AcrB (white). Nine MexA 
molecules (blue) form a sheath around AcrB and the a-barrel of TolC. (B) Two 
perpendicular views of the sheath formed by nine MexA molecules (Adapted from 
Higgins et al., 2004). 
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Figure 1.16. Side and top view of the model of assembled tripartite drug efflux pump. 
The helical hairpins of three pairs of MexA dimers (blue and red) are inclined with the 
surface of OprM (light sky blue). The lipoyl domain fits with the gap between MexB-
OprM contact regions. The P-barrel domain and disordered domain interact with MexB 
(pink) (Adapted from Akama et al., 2004). 
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Figure 1.17. Side and top view of the model of assembled tripartite drug efflux pump. 
Three AcrA (red) molecules fit simultaneously in the interprotomer grooves of AcrB 
(green) and the open state ofTolC (light sky blue) (Adapted from Fernandez-Recio eta!., 
2004). 
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1.8 Perspective 
The lack of structure of multidrug efflux pumps has hindered our understanding of 
these transporters. The structural determination of multidrug efflux pumps EmrD, 
AcrB, Sav1866, and the outer membrane protein TolC, as well as the membrane 
fusion protein AcrA and MexA etc, probably represent the most significant progress 
that has been made recently. The combined biochemical and structural data have 
provided us a closer vision to structure-function relationships in these multidrug 
transporters. 
The structure of EmrD is likely to act as a paradigm for other MFS transporters with 
12-TMS; however, the structure of MFS transporters with 14-TMS is not available. 
! 
The structure of EmrD in complex with substrate will also be essential for us to 
understand the mechanism of substrate recognition and translocation of these family 
transporters. 
The structural asymmetry of AcrB trimer suggests an ordered binding change 
mechanism (Seeger et al., 2006). Biochemical evidence is necessary to support such a 
proposed mechanism. Multiple alignments of amino acid sequences and phylogenetic 
analysis indicate that there are structural and/or functional differences between AcrB 
and other RND family transporter, such as MtrD (Paulsen et al., 1996). The 
knowledge of the difference between them will be critical for understanding the 
mechanism of these family transporters. 
The crystal structure of EmrE is not yet solved. There are still debates as to the 
membrane topology and functional unit of EmrE (Tate, 2006; Soskine et a!., 2006). 
The crystal structure of SMR family transporters with two dissimilar but homologous 
subunits, such as EbrAB and YkkCD, will be helpful for solving these debates. 
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The homology between TMDs in different subfamilies of ABC transporters is lower, 
indicating that a different transport mechanism is employed. The crystal structures of 
ABC transporters in different subfamilies will be critical for understanding their 
mechanism. 
The MATE family transporters are the least well characterized. Structural or 
functional information on the molecular mechanism underlying the Na + (or 
H+)/multidrug antiport by the MATE family is still very limited at present. 
In addition, it is not clear yet how multidrug efflux pumps couple transport to proton 
or sodium motive force or free energy by A TP hydrolysis. Future studies to pursue 
will be to solve the crystal structure of the pumps that represents an intermediate point 
' 
in the efflux process. 
The protomer stoichiometry for the tripartite efflux pump of Gram-negative bacteria 
is still uncertain. It is likely that different arrangement of MFPs can be expected in 
MFS, RND and ABC-based tripartite pump. The crystal structure of these tripartite 
efflux pumps and the details underlying the dynamics (e.g. key coiled-coil 
interactions and channel gating) will be critical for deciphering their mechanism 
(Eswaran eta!., 2004). 
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Chapter 2 
Materials and Methods 
2. 1 Reagents and equipments 
2. 1. 1 Sources of reagents 
General chemical reagents such as salts with analytical purity grade were acquired 
from Sigma (UK) Ltd. Microbiological growth media was supplied by Oxoid, Difco 
or Melford Laboratories. Enzymes used in molecular biology protpcols were 
purchased from Promega (UK) Ltd unless otherwise stated. Detergents such as 
n-dodecyl-B-D-maltoside (DDM) were purchased from Calbiochem. 
The sources of additional reagents used in specialised applications are detailed in 
association with specific protocols. 
2. 1. 2 Preparation of solutions 
Gross quantities of reagents were weighed on a Sartorius digital balance whilst 
smaller quantities were measured using a Mettler Toledo digital analytical balance. 
Microbiological growth media and molecular biology reagents were prepared using 
milliQ distilled/deionized water where appropriate. Recipes of stock solutions are 
' shown in table 2.1. 
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Table 2.1 stock solutions 
Carbenicillin (dis odium salt) 1 00 mg/ml in deionized water. Filter sterilize and 
store at -20°C. Use at 100 ).lglml. 
Kanamycin (sulfate) 20 mg/ml in deionized water. Filter sterilize and 
store at -20°C. Use at 25 ).lglml for cells containing 
kanR plasmids, and at 15 ).lg/ml for cells with a 
chromosomal kanR gene. 
Chloramphenicol 34 mg/ml in ethanol. Store at -20°C. Use at 34 
).lglml. ! 
1M IPTG 2.38 g IPTG in 10 ml deionized water. Filter 
(isopropy 1-D-thio galactopyrano sterilize and store at -20°C. 
side) 
20% L-arabinose (w/vol) L-arabinose solution in deionized water. Filter 
sterilize and store at -20°C. 
Rifampicin 10 mg/ml in 67% methanol, 0.17 N NaOH. Use at 
200 ).lglml within 5 days. Protect from light. 
Tetracycline 5 mg/ml in ethanol. Store at -20°C. Use at 12.5 
).lglml. 
20% Glucose (w/vol) D-glucose solution in H20. Autoclave. 
Store sterile solution at room temperature. 
80% Glycerol (v/v) Mix 80 ml glycerol with 20 ml deionized water. 
Autoclave. Store sterile solution at room 
temperature. 
X-gal 50 mg/ml in DSMO, Store at -20°C. Protect from 
light. 
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2. 1. 3 Sterilization of chemical and media solution 
Media and reagents to be sterilised were either autoclaved or filter sterilized 
depending on their stability to heating. Heat stable materials, such as growth media, 
were heated to 121 °C for 15 minutes at 4 atmospheres pressure in a Priorclave 
electrically heated autoclave set on liquid cycle. Solutions of heat labile reagents, 
such as antibiotics, were sterilized by filtration through 0.22 J.!m syringe filters. 
Non-autoclavable items such as centrifuge tubes were sterilized by washing 
thoroughly in 100% ethanol followed by a drying period in a laminar flow hood. 
2. 1. 4 Centrifugation 
Routine centrifugation of materials in microcentrifuge tubes was performed in a 
Sigma benchtop microfuge fitted with a 24 place fixed angle rotor, and a Jouan CR3 
refrigerated benchtop centrifuge was used where there was a requirement for cooling. 
Larger volumes of liquids were processed in a Beckman-Coulter Avanti J-E 
refrigerated centrifuge using different fixed angle rotors. A Beckman JA-1 0 rotor was 
used to process volumes up to 3 liters in 500 ml tubes and a Beckman JA-20 rotor 
was used to process up to 300 ml in 40 ml tubes. High-speed ultracentrifugation was 
performed in a Beckman L8M ultracentrifuge using a Beckman Ti50 fixed angle 
rotor. 
2. 2 Bacterial strains 
All bacterial strains used are listed in table 2.2. 
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Table 2.2- Bacterial strains used in these studies 
Strains or Genotype Source Description/ Applica 
Plasmids -tion 
V cholerae CT-A- CT-B+ deletion 1. B. Kaper Used as the source of 
vaccine strain derivative of classical V genomic DNA for 
CVDlOl cholerae strain Ogawa 395 PCR 
E. coli recA1 endA1 gyrA96 thi-1 Stratagene General cloning, 
XLl-Blue hsdR17 supE44 re!A1 lac Site-directed 
[F' proAB lacflZM£15 mutagenesis 
Tn10 (Te{)]. 
E. coli endA1 hsdR17(rK1T Novagen non-expre~sion host, 
NovaBlue mK12+) supE44 thi-1 general purpose 
recAJ gyrA96 re!A1 cloning, plasmid 
lacF'[ pro A+ B+ preparation. 
laclqZI1M15 ::Tn10(TcR)] 
E. coli p- ompT hsdSB (rB- mB-) Avidis S.A. Mutant strain from 
C41(DE3) gal dcm (DE3) BL21(DE3), general 
purpose expressiOn 
host T7 Expression 
systems. 
E. coli p- ompT hsdSB (rB- mB-) Avidis S.A. Mutant strain from 
C43(DE3) gal dcm (DE3) BL21 (DE3), general 
purpose expression 
host for T7 
Expression systems. 
E. coli F" ompT hsdS8 (r8 -m8 -) gal Invitrogen High-stringency 
BL21-AI dcm araB::T7RNAP-tetA expression host for 
T7 Expression 
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systems 
E. coliTOP10 FmcrA Invitrogen General cloning, 
~(mrr-hsdRMS-mcrBC) High-stringency 
<p80lacZ~M15 ~lacX74 expression host for 
recA1 araD139 PsAD Expression 
~(araleu)7697 ga!U galK systems 
rpsL (StrR) endA1 nupG 
E. coli NafStl Ri/ Th1 Qiagen High-stringency 
M15(pREP4) Lac-Ara+Gat Mtr expression host for 
YRecA + Uvr +Lon+ /pREP 4 T5 Expression 
systems 
E. coli N43 F acr A I lac ara xyl rpsL E. coli Complem~ntation 
Genetic Stock studies 
Centre 
2. 2.1 Growth media for bacteria 
The growth media for liquid cultures of the Escherichia coli strains were listed as 
follows: 
Luria-Bertani (LB) broth (per Liter) 
10 g ofNaCl 
1 0 g of tryptone 
5 g of yeast extract 
Add deionized H20 to a final volume 
of 1 liter, Adjust pH to 7.0 with 5 N 
NaOH, Autoclave. 
2x YT broth (per Liter) 
5g of NaCl 
16g of Tryptone 
1 Og of Yeast extract 
Add deionized H20 to a final volume 
of 1 liter, Adjust pH to 7.0 with 5 N 
NaOH, Autoclave. 
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SOB Medium (per Liter) 
20.0 g oftryptone 
5. 0 g of yeast extract 
0.5 g ofNaCl 
Add deionized H20 to a final volume of 
1 liter, autoclave. Add 10 ml of 
filter-sterilized 1 M MgCh and 10 ml 
of filter-sterilized 1 M MgS04 prior to 
use. 
NZY+ Broth (per Liter) 
10 g of NZ amine (casein hydrolysate) 
5 g of yeast extract 
5 g ofNaCl 
Add deionized H20 to a final volume of 
1 liter, adjust to pH 7.5 using NaOH, 
autoclave. 
Add the following filer-sterilized 
supplements prior to use: 
12.5 ml of 1M MgC12 
12.5 ml of 1M MgS04 
20 ml of20% (w/v) glucose (or 10 ml 
of 2 M glucose) 
SOC Medium (per 100 ml) 
Note: This medium should be 
prepared immediately before use. 
Add 2 to ml of filter-sterilized 20% 
(w/v) glucose or 1 ml of 
filter-sterilized 2M glucose SOB 
medium (autoclaved) to a final 
volume of 100 ml. 
LB agar plate was prepared by adding 1.5% w/v agar to liquid LB medium prior to 
autoclaving. 
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2.2.2 Storage of bacterial strains 
Permanent stocks of bacterial strains were kept as glycerol stocks. Note that high 
glycerol concentrations(> 1 0%) may lead to plasmid instability. 
2.2.2.1 Preparation stock cultures of bacterial strains 
A single colony was inoculated into 20 ml LB medium containing appropriate 
antibiotic(s) in a 50 ml centrifuge tube. The incubation was shaken vigorously at 37°C 
during the day until the OD600 reached 0.6-0.8. Then 0.9 ml of the culture was ~ 
removed and transferred to a cryovial, 0.1 ml 80% glycerol was added, mixed well 
and stored at -70°C. 
Plasmid-bearing strains, particularly those having any tendency toward instability, 
were titered at the time of freezing to be sure that the vast majority of cells in the 
culture have the intended host-plasmid combination. 
2.2.2.2 Inoculation of a culture from the frozen stock 
A few microliters of the frozen stock were scraped or melted from the surface (use a 
sterile pipettete tip or plastic culture loop) and streaked on an agar plate or inoculated 
into liquid medium (containing appropriate antibiotic(s)). The remainder was returned 
to the -70°C freezer without thawing. 
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2.3 Isolation and analysis of nucleic acids 
2.3.1 Plasmid DNA purification 
Small-scale purification of plasmid DNA from E.coli host strains was performed 
using the QIAprep Spin Miniprep Kit (Qiagen) and the protocol provided, which is 
summarised below. 
Ten ml ofLuria-Bertani (LB) broth containing appropriate antibiotics were inoculated 
with a single colony of transformed bacteria. The culture was incubated at 37°C with 
vigorous shaking for 12-16 hours. Bacterial cells were harvested by centrifugation at 
4000 xg at 4 °C for 10 min and the culture medium was decanted away from the cell 
! 
pellet. The pelleted cells were resuspended in 250 J.t.l Buffer P 1 supplied with the kit 
and transferred to a microcentrifuge tube. The cells were then lysed by adding 250 J.t.l 
Buffer P2 and mixing thoroughly by inverting the tube 4-6 times. The mixture was 
then neutralised by adding 350 J.t.l Buffer N3 and mixing immediately and thoroughly 
by inverting the tube 4-6 times. The insoluble and soluble components were separated 
by centrifuging for 10 min at 13,000 xg in a table-top microcentrifuge. The 
supernatant fraction, which contains the soluble plasmid DNA, was applied to the 
QIAprep spin column by pipetteting. The supernatant was spun through the column 
for 30-60 s; the flow-through was discarded. The column contains a positively 
charged silica-based matrix upon which plasmid DNA becomes immobilised. The 
immobilised plasmid DNA was washed by adding 0.75 ml Buffer PB and centrifuging 
for 30-60 s, the flow-through was discarded. The column was washed again by 
adding 0.75 ml Buffer PE and centrifuging for 30-60 s, the flow-through was 
discarded and the column was centrifuged for an additional 1 min to remove residual 
wash buffer. The column was placed in a clean 1.5 ml microcentrifuge tube. To elute 
DNA, 50 J.t.l Buffer EB (10 mM Tris·Cl, pH 8.5) or deionized water was added to the 
centre of each column and the column was allowed to sit at room temperature for 1 
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min, and then the column was centrifuged for 1 min. Plasmid DNA was then analyzed 
by agarose gel electrophoresis. Purified Plasmid DNA was stored at -20°C. 
2.3.2 Agarose gel electrophoresis of DNA 
Electrophoresis buffer: 
T AE: 40 mM Tris-acetate 1 mM EDT A 
Stock solution: 25x 
121 g Tris base 
28.6 ml of glacial acetic acid 
50 ml of 0.5 M EDTA (pH: 8.0) 
6x Gel-loading buffers 
0.25% bromophenol blue 
0.25 xylene cyanol FF 
30% glycerol in dH20 
'· 
Storage temperature: 4 °C 
The protocol of agarose gel electrophoresis (Molecular Cloning, Handbook) was used 
to analyze the results of nucleic acid manipulations. Agarose was dissolved in 1 xT AE 
buffer at a concentration appropriate for separating the particular size fragment 
expected in the DNA samples by heating the T AE/agarose mixture in a microwave 
oven. The molten gel was allowed to cool to about 55°C, and then ethidium bromide 
was added to a final concentration of 0.51J.glml. An appropriate comb was positioned 
0.5-1.0 mm above a horizontal gel-tray to form the sample slots in the gel, and the 
warm agarose solution was poured into the gel-tray. The gel was set for about 30 min 
at room temperature. After the gel had solidified, the comb was removed· and the gel 
slab was placed in the electrophoresis tank containing 1 xT AE buffer allowing for 
approximately 5 mm depth over the gel. Each DNA sample was mixed with 0.2 
volume of 6xgel-loading buffers, and then the sample mixture was loaded into a 
separate well of the submerged gel. The DNA size standard (1 KB Plus DNA Ladder, 
Invitrogen) was •loaded into one well. The lid of the gel tank was closed and the 
electrical leads were attached so that the DNA will migrate toward the positive anode, 
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and a voltage of 1-5 V /em was applied. Progress of DNA through the gel was 
monitored by the migration of xylene cyanol and bromophenol blue. When the DNA 
samples had migrated a sufficient distance through the gel, the gel was examined by 
UV light and photographed using a Gene Genius Bio Imaging System (SYNGRNE). 
2.3.3 Extraction and purification of DNA from agarose gels 
Double-stranded DNA fragments from PCR and other enzymatic reactions need to be 
separated by agarose gel eletrophoresis. Extraction and purification of DNA from 
agarose gels was performed using a QIAquick Gel Extraction Kit (Qiagen). The 
manufacturer's protocol was adopted, which is summarised below. 
A gel slice containing a desired DNA fragment was excised from the agarose gel slab 
with a clean, sharp scalpel. The size of gel slice was minimized by removing extra 
agarose and was weighed in a microcentrifuge tube. Three volumes of buffer QG 
were added to one volume of gel (1 00 mg ~ 100 Ill). The gel slice was then dissolved 
in buffer QG by incubating in a 50°C water bath for about 10 min, with vortexing 
every 2-3 min during the incubation to help dissolve the gel. A QIAquick spin 
column was placed in a provided 2 ml collection tube. The DNA/buffer QG mixture 
was applied to the QIAquick column and centrifuged for 1 min toimmobilize DNA. 
0.5 ml of Buffer QG was added to QIAquick column and centrifuged for 1 min to 
remove any remaining traces of agarose which may interfere with subsequent steps. 
The immobilised DNA was washed by adding 0.75 ml of Buffer PE to QIAquick 
column and centrifuging for 1 min. The flow-through was discarded and the column 
was centrifuged for an additional 1 min to remove residual Buffer PE. The QIAquick 
column was place into a clean 1.5 ml microcentrifuge tube. The DNA was eluted by 
the addition of 50 ).tl of Buffer EB (1 0 mM Tris, pH 8.5) or deionized H20 to the 
centre of the QI'l\quick membrane. The column was incubated at room temperature 
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for 1 min and then centrifuged for 1 min to collect the purified DNA solution. The 
eluted DNA was stored at -20°C. 
2.4 In vitro amplification of DNA by the polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) was used to amplify and modify specific genes 
from genomic DNA. The desired restriction sites were added to both termini of the 
target template by PCR using oligonucleotide primers to allow the ligation of 
amplified fragments from the initial cloning vector pOEM-T Easy into the expression 
vector. 
Oligonucleotides used in this study were designed according to the published DNA 
sequence and synthesized by Invitrogen Custom Primers (Table 2.3). 
Table 2. 3 -Oligonucleotides 
Primer Name Sequence ( 5' to 3 ') Use (reference) 
VceCF1 CAT ATG AAA AAT AGC GTT CAA PCR (chapter III) 
ACG GTA GGT TTG TTG 
VceCR CTC GAG AGA TTC TGT TGT TTC PCR (chapter III) 
AAA ACC GCC GCC TAG 
VceCF2 GAG CTC AAA AA T AGC GTT CAA PCR (chapter III) 
ACG GTA GGT TTG TTG 
VceBR1 AAG CTT TTA ATG AAC AGC AGA PCR (chapter III) 
GGT ATC CAC CGC TTG 
VceC-E92CF CAG CAC TCA CCA TCG TTA TGC Mutagenesis 
ATG GCA ATG GCT CGG C (chapter III) 
V ceC-E92CR ' GCC GAG CCA TTG CCA TGC ATA Mutagenesis 
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ACG ATG GTG AGT GCT G (chapter III) 
VceC-D115AF CGC AAT TCG ATC ATT TGC GCT Mutagenesis 
CGG GTT AGC GGC ATC C (chapter III) 
VceC-D115AR GGA TGC CGC TAA CCC GAG CGC Mutagenesis 
AAA TGA TCG AAT TGC G (chapter III) 
VceC-D153AF CCT TGA ATT TTC AGT ATG CGT Mutagenesis 
TTG ACT TTT GGG GAA AAA ATC (chapter III) 
GCG 
VceC-D153AR CGC GAT TTT TIC CCC AAA AGT Mutagenesis 
CAA ACG CAT ACT GAA AAT TCA (chapter III) 
AGG 
VceC-D303AF CTG GGG CAT CGT GCT GCG ATC Mutageqesis 
ACC GCT GCG CGT TG (chapter III) 
VceC-D303AR CAA CGC GCA GCG GTG A TC GCA Mutagenesis 
GCA CGA TGC CCC AG (chapter III) 
VceC-D328AF CGC AAG CAC AAT TCT ATC CAG Mutagenesis 
CGG TCA CTT TGT CAG CGT TTA (chapter III) 
TTG 
VceC-D328AR CAA T AA ACG CTG ACA AAG TGA Mutagenesis 
CCG CTG GAT AGA ATT GTG CTT (chapter III) 
GCG 
VceC-E382AF CAG AAG CTC GTT ACC AAG CGG Mutagenesis 
CGG TCG CTC AA T ACA A TG (chapter III) 
VceC-E382AR CAT TGT A TT GAG CGA CCG CCG Mutagenesis 
CTT GGT AAC GAG CTT CTG (chapter III) 
VceC-E397AF GTG CAA GCC TTG CAT GCG ATC Mutagenesis 
GCC GAT GTG GTG AC (chapter III) 
VceC-E397AR GTC ACC ACA TCG GCG ATC GCA Mutagenesis 
. 
TGC AAG GCT TGC AC (chapter III) 
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VceC-M93AF GCA CTC ACC A TC GTT AGA GGC Mutagenesis 
GGC AAT GGC TCG GCT TAA AG (chapter III) 
VceC-M93AR CTT TAA GCC GAG CCA TTG CCG Mutagenesis 
CCT CTA ACG ATG GTG AGT GC (chapter III) 
V ceC-M93R97 AF GTT AGA GGC GGC AAT GGC TGC Mutagenesis 
GCT TAA AGG GGC ACA AGG (chapter III) 
V ceC-M93R97 AR CCT TGT GCC CCT TTA AGC GCA Mutagenesis 
GCC A TT GCC GCC TCT AAC (chapter III) 
VceAF GAG CTC AAA CAA CAG AA T CTT PCR (chapter V) 
AAT AGG TT A TCT TCA 
VceA12F GAG CTC ATG AAT TCA AAT AAT PCR (chapter V) 
AGC AAC ACC GAA TTT ~ 
VceA53F GAG CTC CAC TTT ATC GGT TCA PCR (chapter V) 
CGC TAC ATT TCC ACC 
ECFP-F GGA TCC GTG AGC AAG GGC GAG PCR (chapter V) 
GAG CTG TTC ACC GGG 
ECFP-R GAG CTC CTT GTA CAG CTC GTC PCR (chapter V) 
CAT GCC GAG AGT GAT 
EYFP-F GTC GAC GTG AGC AAG GGC GAG PCR (chapter V) 
GAG CTG TTC ACC GGG 
EYFP-R AAG CTT TTA CTT GTA CAG CTC PCR (chapter V) 
GTC CAT GCC GAG AGT GAT 
VceARl GTC GAC GCC TTG CTC TGA AAC PCR (chapter V) 
TTT GGC GGC GCG 
VceApF GAG CTC CAT CAT CAT CAT CAT PCR (chapter V) 
CAT GAC GAT GAC GAT AAG CAC 
TTT ATC GGT TCA CGC TAC ATT 
TCCACC 
. 
VceR-PF AGT ATA ACT GTA CGG TAC GGT DNA binding 
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TTA GTT AT (Chapter VI) 
VceR-PR ATA ACT AAA CCG TAC CGT ACA DNA binding 
GTTATACT (Chapter VI) 
VceBF CAT ATG AGT CAT AAC GCT GAC PCR (chapter VI) 
AAT GAG A TG CAA CCT 
VceBR2 CTC GAG ATG AAC AGC AGA GGT PCR (chapter VI) 
A TC CAC CGC TTG CTT 
HisR GAG CTC GTG GTG GTG GTG GTG PCR (chapter VI) 
GTGCTCGAG 
VceA-EKF GAG CTC GAT GAC GAT GAC AAG PCR (chapter VI) 
AAA CAA CAG AAT CTT AA T AGG 
TTA TCTTCA ,, 
VceAR2 AAG CTT TTA GCC TTG CTC TGA PCR (chapter VI) 
AAC TTT GGC GGC GCG 
VceRF GGA TCC CGG GTA AAA AGT GAA PCR (chapter VI) 
GAA AAA AGG CAA GCA 
VceRR CTC GAG ATC AGC TGC GTA CAG PCR (chapter VI) 
GCA TAA AAA GGC CTC 
In table 2.3, the oligonucleotide names that end with 'F' and 'R' represent pairs of 
forward and reverse primers used for the amplification or mutagenesis of specific 
genes; the underlined sequences correspond to the restriction enzyme sites that were 
incorporated into amplicons in order to facilitate downstream manipulation of the 
amplified fragments. 
The oligonucleotides were supplied on a 50 nmol scale and in a desalted, lyophilised 
form. The oligonucleotides were resuspended in high purity deionized water to a final 
concentration of 50 pmol/~1 and stored at -20°C. 
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The HotStarTaq TM DNA polymerase (Qiagen) was used to amplify DNA templates 
less then 2 kb, which is a modified form of the recombinant 94 kDa Taq DNA 
polymerase from Thermus aquatic us (Qiagen). HotStarTaq TM DNA Polymerase has 
no polymerase activity at ambient temperatures, which may prevent the formation of 
misprimed products and primer-dimers at low temperatures. It can be activated by 
incubation at 95°C for 15-minute before thermal cycling. These features of 
HotStarTaq ™ DNA Polymerase usually result in high PCR specificity and increase 
the yield of the specific PCR product (Qiagen). The reaction compositions using 
HotstarTaq ™ DNA Polymerase were listed in table 2.4 (Qiagen). 
Table 2.4 PCR components for HotstarTaq TM DNA Polymerase 
Component Volume/reaction Final concentration 
Master mix 
1 Ox PCR Buffer* 10 !-11 1x 
dNTP mix (10 mM of 2 !-11 200 !1M of each dNTP 
each) 
Primer A 1 !-11 0.5 !1M 
Primer B 1 !-11 0.5 !1M 
HotStarTaq DNA 0.5 !-11 2.5 units/reaction 
Polymerase 
Distilled water Variable 
Template DNA Variable S1 !lg/reaction 
Total volume 100 !-11 
* Contains 15 mM MgC/2 
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A typical PCR cycling program was outlined below (Qiagen). 
Initial activation step: 15 min 95°C 
3-step cycling 
Denaturation: 0.5-1 min 94°C 
Annealing: 0.5-1 min 50-68°C 
Extension: 1 min/kb 72°C 
Number of cycles: 30-35 
Final extension: 10 min 72°C 
The ProofStart™ DNA polymerase (Qiagen) was used to amplify DNA templates 
more then 2 kb to avoid base pair mismatch. ProofStart™ DNA polyrp.erase is a 
recombinant 90 kDa DNA polymerase containing a 3' --+5' exonuclease activity, 
which functions by recogmzmg and removmg incorrectly incorporated 
deoxynucleotides. The reaction compositions using ProofStart™ DNA polymerase 
were listed in table 2.5 (Qiagen). 
Table 2.5 PCR components for ProofStart™ DNA polymerase 
Component Volume/reaction Final concentration 
Master mix 
1 Ox PCR Buffer* 5 J.!l 1x 
dNTP mix (1 0 mM of 1.5 J.!l 300 J.!M of each dNTP 
each) 
Primer A 1 J.!l 1 J.!M 
Primer B 1 J.!l 1 J.!M 
ProofStart DNA 2 J.!l 5 units 
Polymerase 
Distilled water Variable 
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Template DNA Variable 100 ng - 11-lg genomic 
DNA 
1-50 ng plasmid DNA 
Total volume 
* Contains 15 mM MgC/2 
A typical PCR cycling program was outlined below (Qiagen). 
Initial activation step: 5 min 95°C 
3-step cycling 
Denaturation: 0.5-1 min 94°C 
Annealing: 0.5-1 min 50-68°C 
Extension: 2 min/kb noc 
Number of cycles: 35-45 
Final extension: 10 min noc 
Thermal cycling parameters used in PCR were variable depending on the primer pairs 
in use and the nature of template DNA, etc. Optimal reaction conditions such as 
incubation time, temperature, and amount of template DNA were individually 
determined. 
Thermal cycling was performed in an Eppendorf Gradient Thermocycler. This PCR 
machine is fitted with heated lid to prevent evaporation of the reaction mixture during 
the cycling process. The lid was pre-heated to 105 °C before thermal cycling begins. 
After amplification, the PCR sample contains a complex mixture of specific PCR 
product and residual reaction components such as primers, unincorporated nucleotides, 
enzyme, salts, and probably nonspecific amplification products. It is necessary to 
. 
remove these contaminants before the specific PCR product can be used in subsequent 
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experiments. PCR products were separated by agarose gel eletrophoresis. Extraction 
and purification of PCR product from agarose gels was performed using a QIAquick 
Gel Extraction Kit (Qiagen). 
2.5 Directional cloning into plasmid vectors 
2.5.1 Cloning PCR products into pGEM-T Easy vector 
The PCR amplified DNA fragment was ligated into the pGEM®-T Easy Vector 
(Promega), allowing the amplified gene sequence to be maintained in a stable form in 
a heterologous host (E. coli). 
Taq DNA polymerases such as the HotStarTaq TM DNA polymerase often add a single 
deoxyadenosine to the 3 '-ends of the amplified fragments, which is independent of 
template. The pGEM®-T Easy Vector possesses complementary 3' terminal thymidine 
to both ends. This vector system is convenient for the cloning of PCR products. 
The ligation reaction was set up according to the protocol of the kit, which IS 
described below. 
2X Rapid Ligation Buffer, T4 DNA Ligase 5~-tl 
pGEM®-T Easy Vector (SOng) 1~-tl 
PCR product 1-3~-tl 
T4 DNA Ligase (3 Weiss units/~-tl) 1~-tl 
deionized water to a final volume of 1 0~-tl 
The reaction mixture was incubate at 16°C for 1-2 hours and then at 4 °C overnight. 
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Thermostable DNA polymerases with proofreading activity, such as ProofStart DNA 
polymerase generate blunt-ended fragments during PCR amplification. PCR 
fragments generated using these polymerases were modified using the A-tailing 
procedure and ligated into the pOEM®-T Easy Vector, which were outlined below 
(Promega). 
Start with 1-7 !J.l of purified PCR fragment generated by 
ProofStart DNA polymerase 
~ 
Add 1 ul Taq DNA Polymerase 1 OX Reaction Buffer with MgCh. 
~ 
Add dATP to a final concentration of0.2mM. 
~ 
Add 5 units ofTaq DNA Polymerase. 
l 
Add deionized water to a final reaction volume of 10 !J.l. 
l 
Incubate at 70°C for 15-30 minutes. 
~ 
Use 1-2 !J.l in a ligation reaction with 
pGE~-T Easy Vector. 
2.5.2 Cohesive end DNA cloning 
The desired restriction sites were usually added to both termini of the target gene 
sequence by PCR using oligonucleotide primers. The gene sequence on pGEM®-T 
Easy Vector was cut out by two appropriate restriction enzymes that cleave different 
sequence and generate different cohesive termini. Then the gene was separated by 
agarose gel eletrophoresis. Extraction and purification of the gene sequence from 
agarose gels was performed using a QIAquick Gel Extraction Kit. The purified gene 
sequence was then ligated into an expression vector digested by the same restriction 
enzymes to express heterologous protein in E.coli. The ligation of two fragments was 
performed usin~ T4 DNA ligase (Promega). The ligation reaction was set up as 
described below. 
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1 OX Ligation Buffer, T4 DNA Ligase 
Vector DNA 
Insert DNA 
T4 DNA Ligase (10 Weiss units/J..Ll) 
deionized water to a final volume of 
l.5J..Ll 
l-6J..Ll 
1-6J..Ll 
1.5 J..Ll 
15J..Ll 
The reaction mixture was incubate at 16°C for 1-2 hours and then at 4°C overnight. 
2.6 Preparation and transformation of competent E. coli 
2.6.1 Preparation of competent E. coli 
Chemically competent E. coli cells were used throughout this work to produce strains 
for cloning and expression by transformation of recombinant plasmids into the cells. 
The competent cells NovaBlue, TOPlO and XLl-Blue were obtained from a 
commercial source, whilst other competent cells were produced in the laboratory. The 
procedure below was used to prepare competent cells (Qiagen). 
A trace of desired E. coli cells was removed from the vial with an inoculating loop, 
and streaked out on LB agar containing appropriate antibiotics. The LB plate was 
incubated at 37°C overnight. A single colony was picked and used to inoculate 10 ml 
of LB-antibiotics and grown at 37°C, 220 rpm, overnight. 1 ml overnight culture was 
used to inoculate 100 ml prewarmed LB medium containing appropriate antibiotics in 
a 250 ml baffled conical flask. The cell suspension was shaken at 37°C, 220 rpm until 
it reached an OD600 of 0.5, then the culture was immediately transferred to a sterile, 
round-bottom centrifuge tube and kept on ice for 5 min. The cells were pelleted in a 
refrigerated centrifuge at low speed (5 min, 4000 x g, 4°C). The cell pellets were 
resuspended gently in 50 ml of ice-cold TFB 1 buffer (1 00 mM RbCl, 50 mM MnCh, 
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30 mM potassium acetate, 10 mM CaC}z, 15% glycerol, pH 5.8) and the suspension 
was kept on ice for an additional 90 min. Then the cells were pelleted in a refrigerated 
centrifuge at low speed (5 min, 4000 x g, 4°C). The cell pellets were resuspended 
gently in 30 ml if ice-cold TFB2 buffer (1 0 mM MOPS, 10 mM RbCl, 75 mM CaClz, 
15% glycerol, adjust to pH 6.8 with KOH) and the suspension was kept on ice for a 
further 30 min. Then the cells were pelleted in a refrigerated centrifuge at low speed 
(5 min, 4000 x g, 4°C). The cell pellets were resuspended carefully in 4 ml ice-cold 
TFB2 buffer. The cell suspension was split into 100-200 111 aliquots in sterile 
microcentrifuge tubes and frozen in liquid nitrogen. The competent cells were stored 
at -80°C. 
2.6.2 Transformation of competent E. coli cells 
Recombinant plasmids were transformed into commercial competent cells according 
to the manufacturer's procedure. Competent cells produced in the laboratory by the 
previously described procedure were transformed according to the protocol below 
(Qiagen). 
An aliquot of the ligation mixture was transferred into a ice-cold sterile 1.5 ml 
microcentrifuge tube. An aliquot of frozen competent E. coli cells was removed from 
storage at -80°C and was allowed to thaw on ice. The cells were gently resuspended 
and 100-150 111 of the cell suspension was transferred into the microcentrifuge tube 
with the ligation mixture. The mixture was incubated on ice for 20-30 min. After the 
incubation period the cells were subjected to heat-shock in a 42°C water bath for 90 
sec, and then the cells were returned to ice for 2 min. 500 111 Psi broth (LB medium, 4 
mM MgS04, 10 mM KCl) were added to the cells and the cells were incubated for 
60-90 min at 37°C, 220 rpm. Subsequently, 50, 100, and 200 111 aliquots were spread 
onto LB-agar plates containing appropriate antibiotics. The plates were incubated in 
an inverted position at 37°C overnight. 
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2.6.3 Screening transformants for inserts 
Transformants were initially screened using a LB-agar plate containing appropriate 
antibiotic(s) on the basis of the vector-encoded antibiotic resistance determinants. 
After this initial screening, the procedures below were used to further identify the 
presence of the recombinant insert, and then plasmid was prepared to confirm the 
construct by DNA sequencing. 
2.6.3.1 Screening bacterial colonies using X-gal and IPTG: a-complementation 
Successful cloning of an insert in the pGEM®-T Easy Vectors disrupts the coding 
! 
sequence of galactosidase. Cells bearing self-ligated pGEM®-T Easy Vector are 
capable to hydrolyse the artificial lactose analogue X-Gal, producing a blue pigment; 
whereas cells bearing recombinant plasmids can not do so and thus remain white in 
colour. The recombinant clones can be identified by this white/blue colour screening 
on indicator plates with IPTG and X-Gal (Novagen). 
2.6.3.2 PCR screening 
The PCR reaction composition for amplification of the inserted gene usmg the 
HotStarTaq TM DNA polymerase was prepared. A colony was picked from an agar 
plate using a 200 J ..d pipettete tip and mixed with the PCR reaction composition by 
gently aspirating and dispensing. Then the thermal cycle was processed for 30 cycles. 
The result of amplification was analyzed by agarose gel electrophoresis. 
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2.6.3.3 Restriction enzyme digestion screening 
Transformed colonies were selected using a LB-agar plate containing appropriate 
antibiotic(s), and then plasmids were isolated from a single colony to screen for the 
presence of the inserted sequence by restriction digestion. 
2.7 In vitro site-directed mutagenesis 
The QuikChange® Site~Directed Mutagenesis Kits and procedure (Stratagene) were 
used to make point mutations in target genes. 
2.7.1 Mutagenic primer design 
The mutagenic oligonucleotide pnmers for use in this work were designed 
individually according to the desired mutation. The following considerations were 
made for designing mutagenic primers. 
Both of the mutagenic primers contained the desired mutation and annealed to the 
same sequence on opposite strands of the plasmid. Primers were between 25 and 45 
bases in length, with a melting temperature (Tm) of2:78°C. The desired mutation was 
in the middle of the primer with ~ 10-15 bases of correct sequence on both sides. The 
primers had a minimum GC content of 40% and terminated in one or more C or G 
bases. 
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2.7.2 Mutant strand synthesis reaction (Thermal Cycling) 
The plasmid DNA template used for mutant strand synthesis reactions was isolated 
from dam+ E. coli strains, such as NovaBlue and XL1-Blue. The sample reaction was 
prepared as indicated below: 
5 J.!l of 1 Ox reaction buffer 
X J.!l (5-50 ng) of dsDNA template 
X J.!l ( 125 ng) of oligonucleotide primer # 1 
X J.!l ( 125 ng) of oligonucleotide primer #2 
1 J.!l of dNTP mix 
ddH20 to a final volume of 50 J.!l 
Then add 1 J.!l of PfuTurbo DNA polymerase (2.5 U/J..tl) 
Cycling parameters for the QuikChange Site-Directed Mutagenesis Method were 
outlined in table below. 
Segment Cycles Temperature Time 
1 1 95°C 30 seconds 
2 16 95°C 30 seconds 
55°C 1 minute 
68°C 1 minute/kb of plasmid length 
2.7. 3 Dpnl digestion of the amplification products 
One J.!l of the Dpnl restriction enzyme ( 10 U/J..tl, Stratagene) was added directly to 
each amplification reaction and the reaction mixture was mixed gently by pipetteting 
the solution up imd down several times. The reaction mixtures were spun down in a 
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microcentrifuge for 1 minute and then immediately incubated at 3rC for 1 hour to 
digest the parental (i.e., the nonmutated) supercoiled dsDNA. 
2.7. 4 Transformation of XLl-Blue supercompetent cells 
The mutated plasmids were transformed into XLl-Blue supercompetent cells 
according to the manufacturer's procedure (Stratagene ), which is outlined below. 
The XL1-Blue supercompetent cells were gently thawed on ice and resuspended 
gently. 50 J.ll of the supercompetent cells were transferred to an ice-cold 1.5 ml 
micrcentrifugate tube. One J.ll of the Dpn!-treated DNA from the reaction mixture was 
'· 
added to the micrcentrifugate tube with supercompetent cells. The transformation 
reaction was mixed carefully and incubated on ice for 30 minutes. The transformation 
reaction was subjected to heat-shock for 45 seconds at 42°C and then placed on ice 
for 2 minutes. 0.5 ml of NZY+ broth preheated to 42°C was added to the 
transformation reaction and the cells were incubated at 37°C, 220 rpm for 1 hour. The 
appropriate volume of each transformation reaction was spread onto agar plates 
containing the appropriate antibiotic for the plasmid vector. The transformation plates 
were incubated at 37°C for over 16 hours. 
2.8 Expression of cloned genes in E. coli 
Several expression plasmid systems, such as pET, pBAD and pQE series plasmids, 
have been used to express cloned genes in different E.coli strains (Table 2.2). 
Expression constructs were transformed into an appropriate expression host. The 
general methods to overexpress recombinant proteins were used as summarized below. 
Different proteirts have subtle differences in their expression and purification, which 
are indicated in the relevant chapter. 
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A single colony from a freshly streaked plate was picked and used to inoculate 1 0 ml 
2xYT broth containing the appropriate antibiotic(s) in a 25 ml universal container. 
The cells were grown in an orbital shaker at 37 °C, 220 r.p.m. overnight. A liter of 
prewarmed 2xYT broth (with antibiotic) in a 2 liter baffled flask was inoculated with 
2-4 ml of the overnight cultures. The cells were grown in an orbital shaker at 3 7 °C, 
220 rpm, and their growth was monitored by measuring the absorbance of the culture 
at 600 nm (A6oo). The cells were induced at mid log phase (approx. A6oo=0.5-0.6) with 
0.1-0.5 mM IPTG (for pET and pQE series vector) or 0.01%-0.05% L-arabinose (for 
pBAD series vector). The temperature was dropped to 25°C-30 °C and the growth was 
continued with shaking at 200 rpm for several hours or overnight. The cells were 
harvested by centrifugation and stored as a frozen pellet at -80 °C or purification 
continued. 
2.9 Purification of hexahistidine-tagged proteins by immobilized metal affinity 
chromatography (IMAC) 
2.9.1 Cell lysis and sub-cellular fractionation by differential centrifugation 
Sub-cellular fractionation was adopted to identify the cellular location of particular 
proteins. It was also performed as an initial crude purification procedure. 
Bacterial cells were harvested by centrifugation at 4,350 xg (Beckman JA-10 rotor) 
for 8 min at 4 °C, resuspended in lysis buffer typically containing 100-300 mM 
NaCl, 10-20% glycerol and a buffering salt (e.g. Tris-HCl) at 20mM, and then stored 
at -80 °C or purification continued. Cell pellets were typically resuspended with 5-10 
ml of ice-cold buffer per gram (wet weight) of cells. DNase I was added t~ the cell 
suspension to a' final concentration of 5 U/ml and EDTA-free protease inhibitor 
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mixture tablet (Roche Molecular Biochemicals) was added at 1 tablet /50ml before 
lysis ofthe cells. 
The cells were lysed by three passages through a Constant System Cell Disrupter 
(model Z-plus 1.1 kW, Constant System) at a pressure of 15-20 KPsi and the cell 
lysate was kept on ice to avoid proteolysis. Cellular debris was sedimented by 
centrifugation at 24,000 xg in a Beckman JA-20 rotor for 30 min at 4 °C. The 
supernatant liquid was further separated into two fractions, the soluble cytosolic 
components of the cell and the membrane vesicles, by high-speed ultracentrifugation 
at 122,400 xg (Beckman Ti-50 rotor) for 90 min at 4°C. The soluble cytosolic 
components of the cell were used as the starting material for protein purification if the 
target is a soluble protein. 
The membrane pellet was emulsified in a small volume of buffer by repeated passage 
through a syringe needle and then the emulsified membrane was diluted by 
solubilization buffer to a final concentration of total protein of about 5-10 mg/ml. The 
integral membrane proteins were extracted from membrane lipids using detergent, 
such as DDM. The cellular membrane/detergent mixture was gently stirred at 4 °C for 
1-3 hours and was then ultracentrifuged at 122,400 xg for 60 min to sediment 
insoluble membrane debris. The membrane solution was processed according to the 
protocol for protein purification. 
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2.9.2 Batch purification of His6-tagged proteins from E. coli using IMAC 
One ml of the 50% Ni-NTA slurry was equilibrated with buffer and then added to 50 
ml cleared lysate (or membrane solution) and mixed gently by shaking at 4 oc for 2-3 
hours. The lysate (or membrane solution)-Ni-NTA mixture was loaded into a column 
with the bottom outlet capped. The bottom cap was removed and the column 
flow-through was collected. The column was washed twice with 20 ml wash buffer 
containing imidazole (the concentration of imidazole in wash buffer was optimized 
according to individual protein), the wash fractions were collected for SDS-PAGE 
analysis. The protein was eluted 4 times with 0.5 ml elution buffer. The eluate was 
collected in four tubes and analyzed by SDS-PAGE (Qiagen). 
2.9.3 Purification of 6xHis-tagged proteins from E. coli using HiTrap Chelating 
column 
The HiTrap Chelating column and procedure for this column (Amersham Biosciences) 
were adopted to purify His6-tagged proteins, which are outlined below. 
2.9.3.1 Column preparation 
The peristaltic pump tubing was filled with distilled water. The column stopper was 
removed and the column was connected to the pump tubing (with the provided 
adaptor), "drop to drop" to avoid introducing air into the system. The snap-off end at 
the column outlet was removed. The column was washed with 5 ml distilled water. 1 
ml of 0.1 M NiS04 in distilled water was loaded on column. Then the column was 
washed with 5 ml distilled water. 
76 
2.9.3.2 Purification 
The column was equilibrated with 5-10 column volumes of buffer at a flow rate of0.8 
ml/min. The sample was applied to the column using a peristaltic pump at a flow rate 
of 0.8 ml/min. The HiTrap Chelating column was then connected onto an AKTA 
Purifier. The column was washed using a step gradient with buffer containing 30-100 
mM imidazole until the A280 was stable. Then the column was eluted with buffer 
containing 300-400 mM imidazole with 2-5 column volumes. 
2.10 Purification of recombinant proteins by gel filtration chromatography 
Gel filtration chromatography was used to polish the proteins initially purified by 
IMAC. The HiLoad 16/60 Superdex 200 prep grade column (Amersham Biosciences) 
was used in this study. The column was run according to the specification provided 
(Amersham Biosciences), which is outlined below. 
Before connecting the column to a chromatography system, the pump was started to 
remove all air from the system, particularly in tubing and valves. The column was 
mounted vertically, the domed nut was removed, and the inlet tubing was connected 
to the system "drop-to-drop". The transport syringe was removed and the column 
outlet tubing was connected to a monitor cell. The column was equilibrated with three 
column volume of dH20 at 30 cm/h (1 ml/min), and three column volumes of buffer 
at 30 cm/h (1 ml/min). Initially the following conditions were tried: 
Flow rate: 30 cmlh (1 ml/min). 
Sample volume: 1% of the column volume (1.2 ml). 
Buffer: The buffur type and pH were compatible with protein stability and activity, 
and buffer concentration was sufficient to maintain buffering capacity and 
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constant pH. Ionic strength in the buffer was equivalent to at least 0.15 M 
NaCl, to avoid nonspecific ionic interactions with the matrix. 
If the results obtained were unsatisfactory, flow rate and (or) sample volume were 
decreased to improve resolution. 
2.11 Purification of recombinant proteins by ion exchange chromatography 
Ion exchange chromatography was also used to polish the proteins purified by IMAC. 
A RESOURCE Q 6 ml column (Amersham Biosciences) was used in this study. The 
column was run according to the specification provided (Amersham B\osciences), 
which is outlined below. 
2.11.1 Equilibrating the column 
The RESOURCE Q column is stored in 20% ethanol. The steps below were followed 
when equilibrating the column. 
The column was flushed with two to five column volumes of dH20. This washes out 
most of the storage solution. Two column volumes of elution buffer were run through 
the column. Then the column was equilibrated with five column volumes of start 
buffer. 
2.11.2 Applying and eluting the sample 
The protein binding capacity for the RESOURCE Q 6 ml column is up to 150 mg. 
The practical protein loading range may vary depending on the proteins to be 
separated and ori the running conditions and the detection wavelength used. There is 
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no limit for the sample volume loaded on the column when a gradient elution is used, 
however, it could affect the resolution of early eluting components. 
2.11.3 Optimizing the gradient shape 
The shape of the elution gradient was optimized to give the best separation. These 
conditions were tried first: starting with a linear gradient of 0-1 00% elution buffer in 
a volume of 120 mi. If the results obtained were unsatisfactory, the resolution was 
improved using lower flow rates and more shallow gradients. If the protein of interest 
was not eluted in the gradient, the elution buffer was changed to one with a higher salt 
concentration. 
2.12 Analysis of recombinant expression 
2.12.1 SDS-PAGE 
NuPAGE® LDS Sample Buffer (4X) 
106 mM Tris HCl 
141 mM Tris base 
2%LDS 
10% Glycerol 
0.51 mMEDTA 
0.22 mM SERV A® Blue G250 
0.175 mM Phenol Red 
pH 8.5 
NuP AGE® MOPS SDS 
Running Buffer (20X) 
50mMMOPS 
50 mM Tris base 
0.1% SDS 
1 mMEDTA 
pH7.7 
The recombinant protein expressiOn and the efficacy of protein purification 
procedures were routinely monitored by SDS-PAGE. All SDS-PAGE experiments 
were performed using the NuPAGE® Novex Pre-Cast Gels (4-12% gradient gels for 
79 
samples containing proteins of widely variant molecular weights, or 12% gels for less 
complex samples) and XCell SureLock Mini-Cell (Invitrogen). The NuPAGE® LDS 
Sample Buffer ( 4X) (Invitrogen) was used for preparing samples for denaturing gel 
electrophoresis with the NuP AGE® Gels. The procedure for electrophoresis of 
NuP AGE® Gels is outlined below (Invitrogen). 
2.12.1.1 Electrophoresis of NuPAGE® gels 
The NuPAGE® gel was vertically mounted. The comb was gently pulled out of the 
cassette and the sample wells were rinsed with IX NuPAGE® SDS Running Buffer. 
5-30 J..Ll of protein samples were mixed with 10 J..Ll NuPAGE® LDS Sample Buffer (4X) 
and an appropriate volume of deionized water to give a final volume of 4p J.tl. 1 0-40 
J.!l of the mixture were loaded into each well of the gel. 20 J..Ll of protein molecular 
weight markers (SeeBlue Markers, Invitrogen) were loaded in one well. The gel 
cassette was then clamped vertically in the Mini-Cell such that the notched well side 
of the cassette faces inwards toward the Buffer Core. The Upper and Lower Buffer 
Chamber were filled with 200 ml and 600 ml of running buffer, respectively. Then the 
gel was run at 200 V constantly for 50 minutes. After completion of the 
electrophoresis procedure the gel was removed gently from the cassette using a Gel 
Knife and rinsed for 10 minutes in de-ionised water to remove the running buffer. 
2.12.1.2 Coomassie® R-250 microwave staining of SDS-PAGE 
Staining solution: 
0.1% Coomassie® R-250 in 40% ethanol, 
1 0% acetic acid 
Destain solution: 
10% ethanol and 7.5% acetic acid. 
The Coomassie® R-250 microwave staining procedure was used to stain SDS-PAGE 
gel (Invitrogen): One gel was incubated in a staining container containing 100 ml of 
staining solution and heated in a microwave oven at full power for 1 minute. Then the 
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gel was gently shaken for 15 minutes at room temperature on an orbital shaker in the 
fume cupboard. The stain solution was decanted and the gel was rinsed once with 
deionized water. Then the gel was soaked in 100 ml of destain solution and heated in 
a microwave oven at full power for 1 minute. Subsequently, the gel was gently shaken 
at room temperature on an orbital shaker in the fume cupboard until the desired 
background was achieved. 
2.12.2 Western blotting 
ELISA wash buffer: Phosphate stock: 
Phosphate stock 30 ml KH2P04 2.586 g 
NaCl 4.38 g K2HP04 14!12 g 
Tween 20 250 ul ddH20 to 400 ml 
ddH20 to 500 ml 
Transfer Buffer: 
Glycine 2.9 g 
Tris Base 5.8 g 
SDS 0.37 g 
Methanol 200 ml 
ddH20 to 1000 ml 
A section of PVDF (0.2 urn, Bio-Rad) was cut to fit the size of the gel. The top right 
hand comer was marked with a biro. PVDF was placed in methanol for approximately 
10 seconds and left to soak in the methanol-transfer buffer for 15 minutes or longer. 
Two pieces of Whatman Chromatography paper (3 MM Chr) were cut slightly larger 
then the size of the gel. The protein gel was run using SeeBlue Markers (Invitrogen). 
The gel was soaked in the methanol-transfer buffer for 15-30 minutes. The blotting 
apparatus was set up as follows in a tray with buffer (Figure 2.1 ). The cage was 
rapidly transferred to the blotting chamber which was about half full with buffer. The 
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blotting chamber was topped up with transfer buffer and run at 170 rnA for 1.5 hours. 
Then the blotted gel was stained to check for successful transfer. The PVDF 
membrane was transferred to 25 ml Blocking Buffer (ELISA wash buffer plus 3% 
BSA) in a square Petri dish; the membrane was blocked for 90 minutes at room 
temperature with gentle agitation, and then was held at a 4 °C overnight. The 
membrane was washed three times with ELISA wash buffer at room temperature, five 
minutes each time. The membrane was incubated with the first antibody (1:3000 
dilutions) in 25 ml fresh blocking buffer (ELISA wash buffer plus 0.5% BSA and 8 )ll 
monoclonal antipolyhistidine antibody [Sigma]) at room temperature for 1 hour. The 
membrane was rinsed in ELISA wash buffer three times, for 10 minutes each time, 
and incubated with the second antibody (1 :3000 dilutions) in 25 ml fresh blocking 
buffer (ELISA wash buffer plus 0.5% BSA and 8 )ll goat anti-mouse IgG-AP 
conjugate, [Sigma]) at room temperature for 1 hour. The membrane was rinsed in 
ELISA wash buffer three times, for 10 minutes each time. The membrane was 
transferred to a sheet of clear film and 2 ml substrate was added. The membrane was 
wrapped with the film, and left on a bench for 5 minutes. The membrane was 
transferred to between two sheets of plastic and taped around the four sides in a 
developing case, and developed in the dark for 2 minutes. 
cage 
sponge 
sponge 
cage 
'+ 
3MM paper 
PVDF 
gel 
3MM paper 
Figure 2.1 Schematic representation for setting up the blotting apparatus 
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2.13 Protein buffer change and concentration 
HiTrap Desalting 5 ml column (Amersham Biosciences) and Slide-A-Lyzer® 10K 
MWCO Dialysis Cassettes (Pierce) were used to remove low molecular weight 
contaminants and perform buffer exchange. 
2.13.1 Buffer changes using a HiTrap Desalting 5 ml column 
The HiTrap Desalting column is packed with the size exclusion medium Sephadex 
G-25 Superfine, which has a fractionation range for globular proteins between Mr 1 
000-5 000 and an exclusion limit of approximately Mr 5 000. This feature ensures 
I 
group separations of proteins/peptides larger then Mr 5 000 from molecules with a 
molecular weight less than Mr 1 000. The column was run according to the 
specification provided (Amersham Biosciences), which is outlined below. 
The desalting column was collected onto an AKTA Purifier. The column was washed 
with 25 ml of deionized water at 4 mllmin to completely remove the ethanol and then 
equilibrated with 25 ml buffer. The column was disconnected from the AKTA Purifier 
and then connected "drop to drop" to a syringe via the adaptor and 1.5 ml of the 
protein sample was applied to column; the eluted buffer from the column was 
discarded. Then 2 ml of buffer were applied to column and 2 ml eluates were 
collected. 
2.13.2 Buffer changes using Slide-A-Lyzer® 10 k.Da MWCO dialysis cassettes 
The procedure for the Slide-A-Lyzer® 10 kDa MWCO dialysis cassettes (Pierce), 
used for buffer change, is summarized below. 
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A Slide-A-Lyzer® dialysis cassette was carefully loaded with protein sample using a 
syringe and then slipped into the groove of the buoy. This assembly was floated in the 
dialysis buffer of choice. The dialysis buffer was used at 200-500 times the volume of 
the sample. The sample was dialyzed for 2 hours at 4 °C with continuous stirring of 
the buffer to promote rapid equilibration; then the dialysis buffer was changed and the 
sample was dialyzed for another 2 hours at 4 °C; the dialysis buffer was changed 
again and the sample was dialyzed overnight at 4°C. After dialysis, the sample was 
carefully removed with a syringe from the dialysis cassette. 
2.13.3 Protein concentration 
The Vivaspin Concentrators are disposable ultrafiltration devices for the 
concentration of biological samples (Viva Science). 
The Vivaspin concentrators with different molecular weight cut-off points were used 
to concentrate proteins. Firstly, several volumes of deionised water were passed 
through the concentrator by centrifugation using a fixed angle rotor to remove trace 
amounts of glycerine and sodium azide on the membrane. The concentrator was 
centrifuged at speed recommended for its membrane type and MWCO. Then the 
concentrator was filled with protein sample and inserted into the rotor with the printed 
window of the concentrator facing outwards. Once the desired concentration was 
achieved, the concentrator was removed and sample was recovered from the bottom 
of the concentrate pocket with a pipettete. 
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2.13.4 Protein concentration determination 
The BCA TM Protein Assay Kit (Pierce) was used to determine protein concentration. 
This detergent-compatible method combines the reduction of Cu+2 to Cu+1 by protein 
in an alkaline medium (the biuret reaction) with colorimetric detection of the cuprous 
cation (Cu+1) using a unique reagent containing bicinchoninic acid (BCA). The 
chelation of two molecules of BCA with one cuprous ion produces a water-soluble 
complex exhibiting a strong absorbance at 562 nm, which is nearly linear with 
increasing protein concentrations over a broad working range (20-2,000 !J.g/ml). The 
'Test Tube Procedure' for this Kit (Pierce) was adopted, which is summarized as 
follows. 
0.1 ml of each standard and unknown protein sample were transferred into a test tube 
and mixed with 2ml of the BCA working reagent. The tubes were then incubated at 
37°C for 30 minutes to allow colour development. After the incubation period, 
reactions were cooled to room temperature and the absorbance of all the samples at 
562 nm were measured against a dH20 blank. The average 562 nm absorbance 
measurement of the blank standard replicates was subtracted from that of all other 
individual standard and unknown sample replicates. A standard curve was prepared 
by plotting the average blank-corrected 562 nm measurement for each BSA standard 
vs. its concentration in !J.g/ml. Then the standard curve was used to determine the 
protein concentration of each unknown sample. 
2.14 Protein molecular weight and Stokes' radius determination by analytical 
gel filtration chromatography 
Analytical gel filtration is an accurate method for determination of the molecular 
weight and Stokes' radius of native proteins under a wide variety of conditions of pH, 
ionic strength and temperature. The basic principle lies in that there is a sigmodial 
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relationship between the various elution volume parameters of protein molecules and 
the logarithm of their molecular weights. A standard calibration curve can be prepared 
by measuring the elution volumes of several standard protein molecules, calculating 
their corresponding Kav values, and plotting the Kav values versus the logarithm of 
their molecular weights. The molecular weight of an unknown protein molecule can 
be determined from the calibration curve once its Kav value is calculated from its 
measured elution volume. However, if the unknown protein molecule does not have 
the same molecular shape as the standards, the relationship between its molecular size 
(elution volume) and molecular weight may be different from that of the standards, 
and thus its molecular weight may not correlate well to the calibration .curves 
established by the standards. For such a protein molecule, the molecular size 
parameters, such as Stokes' radius, may provide useful information. A 
1 
calibration 
curve can be prepared by plotting [-log (kav)] 1!2 versa Stokes' radius to determine the 
Stokes' radius of proteins (Amersham Biosciences ). 
The analytical gel filtration chromatography column Superdex 200 PC 3.2/30 column 
and Low Molecular Weight Gel Filtration Kit (Amersham Biosciences) were used to 
determine the molecular weight and oligomerization state of proteins in the native 
state. The protocol used is described below (Amersham Biosciences). 
A fresh, filtered solution of Blue Dextran 2000 (1 mg/ml) was prepared in the running 
buffer. Thirty J.ll of Blue Dextran 2000 was applied to the column equilibrated with 
running buffer. The column was eluted at a flow rate of 20 J.ll/min to determine its 
void volume (Vo). The protein standards of Ribonuclease A (Mr 13.7 kDa, A 16.4), 
Chymotrypsinogen A (Mr 25 kDa, A 20.9), Ovalbumin (Mr 43 kDa, A 30.5) and 
Albumin (Mr 67 kDa, A 35.3) were dissolved in running buffer at concentrations of 
1 Omg/ml, 3mg/ml, 7mg/ml and 7mg/ml, respectively; a few minutes were allowed for 
dissolution with gently stirring. The Ribonuclease A and Ovalbumin, 
Chymotrypsinogen A and Albumin were mixed separately at the ratio of 1:1. Thirty J.ll 
mixtures of Ribonuclease A and Ovalbumin were applied to the column and the 
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column was eluted at a flow rate of 20 J.Lll mm. The elution volumes (Ve) of 
Ribonuclease A and Ovalbumin were determined by measuring the volume of the 
eluent from the point of application to the centre of the elution peak; and then thirty J.Ll 
mixtures of Chymotrypsinogen A and Albumin were applied to the column to 
determine their elution volumes. The Kav values for the protein standards were 
calculated as follows: Kav = (Ve-Vo )/ (Vt-Vo ), where Ve = elution volume for the 
protein, Vo =column void volume =elution volume for Blue Dextran 2000, Vt =total 
bed volume. The Microsoft Excel program was used to prepare a calibration curve of 
Kav versus the logarithm of their molecular weights and calculate the linear 
regression equation of the curve. Thirty J.Ll of protein sample were applied to the 
column to determine its elution volume. The corresponding Kav of protein was 
calculated and its molecular weight was determined from the calibration curve. The 
'· 
same data were used to prepare a standard curve of [-log (kav)] 112 versa Stokes' 
radius and calculate the linear regression equation of the curve. 
2.15 Crystal growth techniques 
The protocols from Hampton Research were adopted for crystal growth, which are 
outline below: 
The hanging drop and sitting drop vapour diffusion technique are two popular 
methods for the crystallization of macromolecules. In these techniques, a small 
droplet composed of protein and crystallizing solution (usually buffer, salt and 
precipitant) is placed in vapour equilibration with a liquid reservoir containing 0.5-1.0 
ml of crystallizing solution. Typically the drop contains a lower crystallizing reagent 
concentration than the reservoir, which drives the system toward equilibrium by 
diffusion through the vapour phase. Both the protein and crystallizing reagent increase 
in concentration as water leaves the drop for the reservoir. The protein sample 
undergoes an increase in relative supersaturation and crystals start to form when the 
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drop and reservoir are at or close to equilibrium. Vapour diffusion drops can be 
prepared in two ways described below. 
2.15.1 Hanging drop vapour diffusion crystallization 
The Crystallization Tool (Nextal Biotechnologies) was adopted to set up 
crystallization trails usmg the hanging drop vapour diffusion method. The 
Crystallization Tool includes a 24 well plate with 24 Crystallization Supports. The 
greaseless sealing technology of the Crystallization Tool offers a fast and clean way 
to perform crystallization trials, as well as a safe environment for the crystal recovery. 
One ml of crystallization solution was placed with a pipettete into reservoir A1 of the 
Crystallization Tool. One drop of 1-4 f..Ll protein sample was placed into the centre of a 
Siliconized Crystallization Support. The droplet was made as spherical as possible. 
Then 1-4 f..Ll of crystallization solution from reservoir A 1 was place into the drop on 
the Crystallization Support containing the protein sample. The pipettete tip was left in 
the drop while gently aspirating and dispensing the drop with the pipettete. The 
Crystallization Support was inverted carefully yet without delay so the drop is 
hanging from the Crystallization Support, then the Crystallization Support was gently 
screwed into the well of Crystallization Tool and tightened to ensure a complete seal. 
This operation was repeated for reservoir 2 through 24. 
2.15.2 Sitting drop vapour diffusion crystallization using Micro-Bridge 
The pregreased XRL Plate and Micro-Bridge (Molecular Dimensions) were adopted 
to set up crystallization trails using the setting drop vapour diffusion method. The 
Micro-Bridge is a small bridge (inverted U) containing a smooth, concave depression 
in the centre of'the top region of the bridge. The Micro-Bridge is inserted into the 
reservoirs of the XRL Plate to perform a sitting drop vapour diffusion experiment. 
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One ml of crystallization solution was placed with a pipettete into reservoir A 1 of the 
XRL Plate. A clean Micro-Bridge was placed into the bottom of reservoir A1 such 
that the concave depression in the Micro-Bridge was facing up. One drop of 1-4 ).tl 
protein sample was placed into the Micro-Bridge in reservoir A 1. Then 1-4 ).tl of 
crystallization solution from reservoir A 1 was placed into the drop in the 
Micro-Bridge Al. The pipettete tip was left in the drop while gently aspirating and 
dispensing the drop with the pipettete. The cover slide was positioned onto the bead 
of grease on reservoir A 1, gently pressed down onto the grease and twisted 45° to 
ensure a complete seal. This operation was repeated for the remaining 23 reservoirs. 
The Cooled Crystallization Incubators (RUMED) were used for crystal ~rowth and 
the dissecting stereomicroscopy (Carl Zeiss Ltd) was used to observe the 
crystallization drops. The crystallization drops were checked at 24h, the third day and 
the first week after setting up, and followed by weekly thereafter. 
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Chapter 3 
The crystal structure of the outer membrane protein V ceC from Vibrio cholerae 
3.1 Introduction to the tripartite multidrug efflux pump VceCAB 
Isolates of the Gram-negative pathogen Vibrio cholerae have been described that are 
resistant to antibiotics (e.g. ampicillin, penicillin, streptomycin, nitrofurantoin and 
erythromycin) and toxic metals (e.g. Pb2+ and Zn2+) (Choudhury et a!., 1996). 
Accordingly, multidrug efflux pumps are likely to be important in drug resistance of 
this cholera pathogen (Baranwal eta!., 2002). Several multidrug efflux pumps from 
Vibrio cholerea have been characterized, such as the MF family transporter V ceCAB 
! 
(Woolley et a!., 2005), the RND family transporter AcrAB (Chatterjee et al., 2004), 
the ABC family transporter V caM (Huda et a!., 2003), the SMR family transporter 
QacE~1 (Kazama et al., 1999) and the MATE family transporters VcmB, VcmD, 
VcmH and VcmN (Begum et al., 2005). 
The tripartite pump V ceCAB of Vibrio cholerae is composed of the inner membrane 
anti porter V ceB, the membrane fusion protein V ceA and the outer membrane channel 
VceC (Woolley et al., 2005). The vceA and vceB genes were initially identified by 
Colmer et al. (Colmer et al., 1998), which share homology with the emrAB genes that 
encode a multidrug efflux pump in E.coli (Lomovskaya et al., 1992). The DNA 
sequences of both chromosomes of Vibrio cholerae have been determined (Heidelberg 
et al., 2000). Examination of the Vibrio cholerae DNA sequence revealed four 
adjacent open reading frames (ORF): The ORF VC1409 (accession no.: NP _231052), 
VC1410 (accession no.: NP _231053) and VC1411 (accession no.: NP _231054) 
correspond to vceC, vceA and vceB, respectively; and the ORF VC1408 (accession no.: 
NP _ 231051 ), termed veeR, was suggested to be a transcriptional regulator of the 
vceRCAB operon. The vceRCAB operon occupies a total of 4909 bp of the genome 
(vceR=603 bp, vceC=1455 bp, vceA=1221 bp and vceB=1536 bp). The vceA and vceB 
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genes are separated by 9 bp, while the 3' terminus of vceC and 5' terminus of vceA 
overlap by 20 bp. The veeR gene is transcribed divergently in relation to the vceCAB 
operon. A 28 bp inverted repeat in the vceR-vceCAB intergenic region was identified 
to be the promoter area of the vee CAB operon. Figure 3.1 shows a schematic 
representation of the veeR CAB operon. 
VeeR Vee Vee A VceB 
Figure 3.1 Schematic representation ofthe vceRCAB operon 
Although the function of the V ceCAB pump in V. cholerae has not been demonstrated, 
its components were found to collectively complement the multidrug resistance 
phenotype in E. coli null mutants of talC, acrB and emrB (Colmer J et al., 1998). 
Among the compounds to which the V ceCAB pump confers resistance are the 
uncoupler cyanide m-chlorphenylhydrazone (CCCP), the detergent sodium 
deoxycholate, phenylmercuric acetate (PMA) and several antibiotics such as 
chloramphenicol, nalixidic acid, erythromycin and rifampicin. 
To investigate the role of the V ceCAB pump in the multidmg resistance of Vibrio 
cholerae, I have characterized functionally and structurally the members of the 
V ceCAB pump. In this chapter, I report the overexpress10n, purification and 
crystallization of the outer membrane component V ceC. 
3.2 PCR amplification of vceA, vceB, vceC and veeR genes from V. cholerae 
genomic DNA 
The published sequences of vceC, vceA, vceB and veeR genes were used to design 
PCR primers for the specific amplification of the genes from genomic DNA. The V. 
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cholerae vaccme strain CVD 101 (Hase et a!., 1994) was used as the source of 
genomic DNA for PCR. Figure 3.2 shows the successful amplification of the complete 
region of the operon and four individual genes, with the size and nucleotide sequences 
consistent with those published data for vceCAB and veeR. 
The desired restriction sites were added to both termini of the target genes by PCR 
using oligonucleotide primers in order to subclone the amplified sequences from the 
initial cloning vector pGEM-T Easy into an expression vector. The amplified 
sequences were extracted from an agarose gel and ligated into the T-A cloning vector 
pGEM-T Easy. The ligation reaction was then transformed into competent E.coli 
NovaBlue cells to propagate the target genes. 
3.3 Overexpression and purification of V ceC 
3.3.1 The pET-VceC expression construct 
The pET21a vector was obtained from a commercial source (Novagen) and used to 
generate a recombinant expression construct for V ceC. The vceC gene was amplified 
by PCR from genomic DNA of the Vibrio cholerae vaccine strain CVD 101 usmg 
primers VceCF1NceCR and ligated into pGEM-T Easy vector (Promega).- After 
restriction enzyme digestion of the vector with Ndel and Xhol, the resulting vceC 
fragment was ligated into pET21a (Novagen), generating a 1479 bp open reading 
frame in which the native vceC gene (lacking the C-terminal termination codon) was 
fused to a short C-terminal sequence encoding a hexahistidine tag. The N-terminal 
ATG start code of vceC gene is located downstream of a bacteriophage T7 promoter, a 
lac operator sequence and an optimized E.coli ribosome binding site. Figure 3.3 
shows the restriction digestion analysis of pET-vceC. 
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Figure 3.2. PCR amplification of veeR, veeA, veeB and veeC genes. Lane 1: 1 Kb 
Plus DNA Ladder (Invitrogen); Lane 2: veeA amplified using primers 
VceAFNceAR2; Lane 3-4: veeB amplified using primers VceBFNceBR2; Lane 5: 
veeC amplified using primers VceCFlNceCR; Lane 6-7: veeCAB amplified using 
primers VceCF2NceBR1; Lane 8-9: veeR amplified using primers VceRF/VceRR. 
93 
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Figure 3.3. Restriction analysis of pET-vceC plasmids. The Ndel/Xhol bounded vceC 
gene was ligated into Ndel/Xhol digested pET21 a vector and transformed into 
NovaBlue competent cells. The potential pET21a recombinants were analyzed by 
PCR first, then recombinant plasmids were prepared from PCR positive colonies and 
analyzed using Ndel and Xhol restriction digestion (37 °C for 3 hours). All 
recombinant plasmids exhibit vceC inserts. 
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3.3.2 Recombinant expression of V ceC 
The pET-vceC construct was transformed into E.coli strain BL21-AI (Invitrogen). 
Transformed colonies were selected on the basis of vector-encoded ampicillin 
resistance, and isolated plasmids were screened for the presence of the inserted vceC 
sequence by restriction digestion. 
A single BL21-AI/pET-vceC colony from a freshly streaked plate was picked and 
used to inoculate 10 ml 2xYT broth containing carbenicillin (1 OO~g/ml) in a 25 ml 
universal container. The cells were grown in an orbital shaker at 37°C, 220 rpm 
overnight. One liter of pre warmed 2 x YT broth (with antibiotic) in 2 liter baffled flask 
was inoculated with 2 ml of the overnight culture. The cells were grown ip an orbital 
shaker at 37 °C, 220 rpm, and their growth was monitored by measuring the 
absorbance of the culture at 600 nm (A6oo). 
The cells were induced at mid log phase (approx. A6oo=0.5-0.6) with 0.2 mM 
isopropyl-~-D-thiogalactopyranoside (IPTG) and 0.02% L-arabinose. Then the 
temperature was dropped to 25 °C and the growth was continued with shaking at 200 
rpm overnight. The cells were harvested by centrifugation at 4,350 xg for 8 min at 4 
°C,resuspended in buffer A (20 mM Na2HP04 pH: 7.4, 300 mM NaCl, 20% Glycerol, 
5 U/ml DNasel, 1 tablet /50ml EDTA-free protease inhibitor mixture tablet) and 
stored at -80 °C or purification continued. 
3.3.3 Purification of the His6-tagged V ceC using Ni2+ affinity chromatography 
Purification of VceC-His6 by Ni2+ affinity chromatography was performed using a 
pre-pack IMAC matrix, the HiTrap Chelating HP 1 ml column, purchased from 
Amersham Pharmacia Biotech. 
The cells were lysed by three passages through a Constant System Cell Disrupter (15 
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Kpsi, model Z-plus 1.1 kW, Constant System). Cellular debris was removed by 
centrifugation at 24,000 xg for 30 min at 4 °C. The supernatant liquid, containing 
soluble proteins and membrane vesicles, was carefully decanted so as not to disturb 
the pelleted material. The supernatant was further fractionated into membrane and 
soluble components by high-speed ultracentrifugation at 122,400 xg for 90 min at 4°C. 
This procedure resulted in the generation of a supernatant containing cytosolic 
proteins and small molecules and a pellet of membranous material. 
The membrane pellet was emulsified in a small volume of buffer B (20 mM Na2HP04 
pH: 7.4, 300 mM NaCl, 10% Glycerol, 0.5 mM THP) by repeated passage through a 
syringe needle, and then the emulsified membrane was diluted by buffer B to a final 
concentration of total protein of about 5-1 0 mg/ml. A powder of the detergent 
I, 
n-Dodecyl-13-D-maltoside (DDM) was added to the emulsified membrane to a final 
concentration of 2% to solubilize the membrane. The mixture was gently stirred at 4 
°C for 1.5 hours and then ultracentrifuged at 122,400 xg for 1 hour at 4 °C. The 
membrane solution was carefully decanted so as not to disturb the pelleted material. 
NaCl was added to the membrane solution to a final concentration of 500 mM, and 
imidazole (6 M, pH: 7.4) to a concentration of 15 mM. 
Extracted hexahistidine-tagged V ceC was purified using the Hi Trap chelating HP 1 ml 
column immobilized with Ni2+ equilibrated with buffer C (20 mM Na2HP04, pH: 7.4, 
500 mM NaCl, 10% Glycerol, 0.5 mM THP, 0.2% DDM). The membrane solution 
was loaded onto the HiTrap chelating HP 1 ml column using a peristaltic pump at a 
speed of 0.8 ml/min. The column was connected to the AKTA Purifier (Amersham 
Pharmacia Biotech) FPLC system. The column was washed with 100 mM imidazole 
in buffer C until the baseline of UV-absorbance at 280 nm (A280) had no further 
change, and then VceC was eluted from the column with 500 mM imidazole, 0.2% 
DDM in buffer B. The eluates were collected in 0.5 ml fractions and analyzed by 
SDS-PAGE. 
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The full-length VceC is composed of 485 amino acids and the predicted molecular 
weight is about 52.2 kDa; the molecular weight of mature V ceC should be lower with 
its signal peptide sequence being removed. Figure 3.4 illustrates an SDS-PAGE 
analysis of the eluates. The main protein band on SDS-PAGE is about 90% of total 
proteins. The molecular weight of this protein is approximately 50 kDa, which is 
within the size range of that expected for recombinant V ceC-His6. 
3.3.4 Western blot identification of V ceC-His6 
The Western blotting method was employed to confirm that the candidate 50 kDa 
protein was indeed VceC-His6. The same sample shown in figure 3.4 was separated 
by SDS-PAGE, transferred to a polyvinglidene difluoride (PVDF) mep1brane by 
electroblotting, and then immunoblotted with a mouse monocloned primary antibody 
raised against the polyhistidine tag epitope. The blot was developed using an enzyme 
conjugated secondary antibody in conjunction with a chemiluminescent substrate (see 
chapter II). The result of Western blotting is shown in figure 3.5, which indicates that 
the candidate 50 kDa protein reacts strongly with the anti-polyhistidine tag antibody 
with high specificity, suggesting that this protein is VceC-His6. 
N-terminal sequencing of the protein further confirmed that the candidate protein is 
VceC-His6, and revealed that the first amino acid corresponds to residue 42 of the 
cloned gene. 
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Figure 3.4. Coomassie blue stained SDS-PAGE gel showing partial IMAC 
purification of candidate VceC-His6 protein from DDM solubilised membranes. Lane 
El-E7 show elution fractions (0.5x7 ml) with buffer containing 500 mM imidazole. 
The left arrows mark the positions of protein standards; the right arrow marks the 
position of candidate V ceC-His6 protein. 
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.,_--+- VceC-His6 
(approx.50 kDa) 
Figure 3.5. The Western blot above illustrates the strong reaction between an anti-His6 
antibody and an approximately 50 kDa protein with high specificity, suggesting that 
this protein is VceC-His6. 
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3.3.5 Purification of V ceC-His6 by anion exchange chromatography 
The purity of V ceC protein purified by the Ni2+ affinity chromatography step is about 
90% of total proteins, as seen on the SDS-PAGE analysis. It is obvious that a further 
purification step is inevitable to make the protein pure enough for crystallization. I 
adopted an anion exchange chromatography step using a RESOURCE Q 6 ml high 
resolution anion exchange column to purify V ceC. 
Buffer exchange of VceC into buffer D (20 mM Tris-HCl, pH: 7.8, 100 mM NaCl, 
10% Glycerol, 0.5 mM THP, 0.2% DDM) was carried out on a HiTrap Desalting 
column. The RESOURCE Q 6 ml column was connected to AKTA Purifier system. 
The column was washed with 5 column volumes (CV) distilled water aqd 5 CV of 
buffer E (20 mM Tris-HCl, pH: 7.8, 500 mM NaCl, 10% Glycerol, 0.5 mM THP, 
0.2% DDM), then equilibrated with 5 CV of buffer D. 
The eluate from the HiTrap Desalting column was loaded onto the RESOURCE Q 
column equilibrated with buffer D. The column was washed with the same buffer, and 
then eluted at a flow rate of 1 ml/min with a gradient of 100-400 mM NaCl over 15 
column volumes. Fractions containing purified V ceC were pooled, diluted 2-fold with 
buffer D without NaCl, loaded onto the RESOURCE Q column again and eluted with 
300 mM NaCl in the same buffer. Figure 3.6a shows the elution profile of anion 
exchange charomatography for VceC. Figure 3.6b shows the SDS-PAGE analysis of 
VceC polished by anion exchange charomatography. There are mainly two peaks on 
the profile, the sharp peak A correspond to the pure fraction of VceC, the purity of 
which is over 99% of total proteins; the broad peak B correspond to V ceC and other 
contaminating protein. 
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Figure 3.6a. The elution profile of anion exchange chromatography for VceC using a 
RESOURCE Q 6 ml column. Buffer D: 20 mM Tris-HCl, pH: 7.8, 100 mM NaCl, 
10% Glycerol, 0.5 mM THP, 0.2% DDM; Buffer E: 20 mM Tris-HCl, pH: 7.8, 500 
mM NaCl, 10% Glycerol, 0.5 mM THP, 0.2% DDM. Flow rate: 1 ml!min. Gradient: 
0-70% buffer E in 15 CV. 
1 2 3 4 5 6 7 8 9 10 11 12 13 
._39 kDa 
Figure 3.6b Coomassie blue stained SDS-PAGE gel showing VceC protein polished 
by anion exchange charomatography. Lane 1-4 correspond to fractions from peak A in 
Fig.3.6a; Lane 5-13 correspond to fractions from peak B in Fig.3.6a. 
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3.4 The production of a V ceC derivative for phasing 
The isomorphous replacement method is a commonly used technique for crystal 
phasing, which needs one or more heavy-atom crystal derivatives. In order to 
facilitate the binding of mercury compounds to V ceC for phasing, a site-directed 
mutagenesis method was adopted to make a vceC cysteine mutant. The residue Glu92 
is predicted to be inside the V ceC channel according to the structure of its homolog 
protein TolC. The Glu92-+Cys mutation was introduced into vceC using the 
QuikChange® Site-Directed Mutagenesis method (Stratagene) with PCR primers 
E92CF/E92CR. The construct pET-vceC was used as template for the site-directed 
mutagenesis experiments. The resulting construct pET-vceCE92c was transformed into 
E.coli strain BL21-AI. The VceC carrying the mutation Glu92Cys was prpduced and 
purified with the same protocol as native V ceC. 
3.5 Mutagenesis assays ofVceC 
Two rings of clustered negative charge of V ceC locate approximately near the 
equatorial domain (residues Glu303 and Glu397) and at the boundaries between the 
a-barrel and P-barrel domains (residues Asp 115, Asp 153 and Asp328), respectively. 
The residues Met93, Arg97 and Glu382 of VceC are supposed to be involved in the 
interactions with nalidixic acid according to the structure of V ceC in complex with 
nalidixic acid (Figure 3 .16). The site-directed mutagenesis method was adopted to 
produce vceC mutants to identify the functional role of these residues. 
The vceCAB genes were amplified by PCR using the primer pairs VceCF2NceBR1 to 
introduce Sac! and Hindlll sites at the 5' and 3' ends of the amplified DNA, which 
was purified and ligated into pGEMT-Easy (Promega). The vceCAB genes were 
rescued from pGEMT -easy by restriction digest with Sac! and Hindlll; the fragment 
was ligated int6 Sacl/Hindlll-digested pQElOO (Qiagen) to create pQE-vceCAB. 
Figure 3.7 shows the restriction digestion analy~is ofpQE-vceCAB. 
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Figure 3.7. Restriction analysis ofpET-VceCAB plasmids. The Sacl/Hindlllbounded 
vceCAB genes were ligated into Sacl/Hindlll digested pQElOO vector and 
transformed into NovaBlue competent cells. The potential pQElOO recombinants 
were analyzed by PCR first, then recombinant plasmids were prepared from PCR 
positive colonies and analyzed using Sacl and Hindiii restriction digestion (37 °C for 
3 hours). All recombinant plasmids exhibit vceCAB inserts. 
Table 3.1. The effect of vceC mutants on the susceptibility of the acrA mutantion 
strain N43 to various chemical compounds and antibiotics. 
Minimum inhibitory concentration (Jig m1' 1) 
Compound 
pQElOO vceCAB vceCrM9JA.R97A £JRJA0 B vee Co" IJA.DJ JJA.DJ~aA0 B vceCr£JoJA.£J97A0 B 
CCCP 16 64 64 64 32 
Nalidixic acid 10 10 10 10 10 
Rifampicin 4 4 4 4 4 
Erythromycin 4 4 4 4 4 
chloramphenicol 0.8 0.8 0.8 0.8 0.8 
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The Aspl15Ala+ Asp153Ala+ Asp328Ala (primers: D115AF/ D115AR, D153AF/ 
D153AR and D328AF/ D328AR), Glu303Ala+ Glu397Ala (primers: E303AF/ 
E303AR and E397AF/ E397AR) and Met93Ala+ Arg97Ala+ Glu382Ala (Primers: 
M93AF/ M93AR, M93R97AF/ M93R97AR and E382AF/ E382AR) mutations were 
introduced into vceC, resulting in constructs pQE-vceCroJJ5A,DI53A,D32BA;AB, 
pQE-vceC(E303A,E397A;AB and pQE-vceC(M93A,R97A,E382A;AB, respectively. 
These constructs were checked by automated DNA sequencing and were transformed 
into E. coli strain N43. MICs were measured according to the Microdilution Broth 
Method established by the National Committee for Clinical Laboratory Standards 
(NCCLS) (NCCLS Document M7-A2, Methods for dilution antimicrobial 
susceptibility tests for bacteria that grow aerobically vol. 10, No. 8.). Brie{ly, a single 
colony was picked from an LB/ampicillin-plate and used to inoculate 20 ml 
LB/ampicillin-medium and grown to an A6oo of 0.1. Cells were transferred to a 
microtitre plate and mixed with serial two-fold dilutions of the drug to be tested; 
bacterial growth, in the presence of 0.1 mM IPTG, was monitored after 18 hours 
incubation at 3 7 a c. 
The N43 cells transformed with pQE-vceCAB, pQE-vceC(M93A,R97A,E382A;AB and 
pQE-vceCrou5A,Dl53A,D32BA;AB were resistant to CCCP, the well-known substrate ofthe 
VceCAB pump, with an increase in the MICs from 16 llg mC1 for N43/ pQE100 to 
64 llg ml-1 for N43/ pQE-vceCAB, pQE-vceC(M93A,R97A,E382A;AB and 
pQE-vceCrou5A,DI53A,D32BA;AB; while the N43 cells transformed with 
pQE-vceC(EJOJA,EJ97A;AB was partially resistant to CCCP with an increase in the MIC 
to 32~-tg ml-1( Table 3.1). 
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3.6 Crystallization and data collection 
Crystallization and data collection were carried out by Dr. Ben Luisi and his group at 
Cambridge University (Federici et al., 2005). 
The V ceC protein purified by anion exchange chromatography was dialyzed against 
buffer F (20 mM Hepes pH 7.5, 300 mM NaCl, 0.05% DDM) and concentrated to 10 
mg/ml using 100 k.Da MWCO membrane. 
The hanging drop vapour diffusion method and the screen kits Crystal Growth 
Matrices Wizard™ Screens I-II (Emerald BioSystems) were used to screen the initial 
crystallization conditions. Typically 1 ml of screen solution was pipetteted into the 
.\ 
reservoir well. 1 J..Ll of protein sample was mixed with 1 J..Ll of a reservoir solution on a 
silinated cover slip and then the cover slip was sealed on a well. The crystals were 
grown in an incubator at 22 °C. The VceC protein yielded crystals in the condition of 
buffer G (35% 2-methyl-2,4-pentanediol [MPD] v/v, 100 mM Tris pH 7.0, 200 mM 
NaCl)(buffer no.24 in the Wizard™ Screens I kits). Crystals appeared after one month 
and reached a final size of0.1x0.05x0.05 mm3 (Figure 3.8a). Such crystals diffract up 
to 2.75 A. 
After the initial hits the condition that produced crystals were optimised to improve 
the diffraction quality of the crystals. Several additives, detergents and precipitants 
were tested in the crystallization trials for optimization. The crystals were also 
obtained in the conditions using PEG 4000 as precipitants (15-20% PEG 4000 at pH 
7 .5). V ceC carrying the mutation Glu92Cys proved to be crystallized more easily, 
which also yielded crystals of bigger size (up to 0.3x0.2x0.2 mm\ 
The best crystals yielded in the following condition: a droplet made of 1 J..Ll of protein 
solution, 1 J..Ll of octyl-glucoside 245 mM and 1 J..Ll of reservoir solution ( 45 % MPD 
v/v, 100 mM HEPES pH 7.0, 200 mM NaCl). Such crystals diffract up to 1.8 A. They 
105 
appeared after two days and reached their final dimensions after a week (Figure 3.8b). 
Crystals were directly frozen after looping from the droplet. 
The V ceC-E92C crystals was soaked for 24 hours with 50 ).!M phenylmercuribenzoate 
or Hg acetate after treatment with reducing agent TCEP, but no Hg was found in 
Patterson map or in MR difference map. The reducing agent TCEP was chosen 
because it has no thiols, which can form a strong complex with Hg. The strategy was 
then changed to crystallize V ceC-E92C in the presence of Hg salts and other 
heavy-atom compounds. After pre-treatment of the protein sample with TCEP, the 
V ceC-E92C was successfully crystallized m the presence of 50 I!M 
phenylhydroxyHgbenzoate. 
Data collected using an in house X-ray diffractometer (Cambridge University) for the 
native and Hg labeled V ceC-E92C crystals yield a resolution limit to 3.1 A. Then data 
were collected at the ID14-4 beamline of ESRF synchrotron source (Grenoble). 
Complete data of V ceC crystals were collected to a resolution of 1.8 A. Figure 3.9 
shows the diffraction map of the V ceC crystal. Data were processed and scaled using 
DENZO and SCALEPACK, respectively. Unit cell dimensions together with statistics 
about the data processing are summarized in table 3.2. 
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Figure 3.8a. A picture of the crystals from Vibrio cholerae VceC. The reservoir 
solution contained 35% MPD v/v, 100 mM Tris pH 7.0 and 200 mM NaCl. The bar 
represents about 0.1 mm. 
Figure 3.8b. A picture of the crystal from Vibrio cholerae VceC. The reservOir 
solution contained 45% MPD v/v, 100 mM Tris pH 7.0, 200 mM NaCl; the additives 
are 81.7 mM 00 and 50 J..!M phenylhydroxyHgbenzoate. The bar represents about 
0.15 mm. 
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Figure 3.9 X-ray diffraction pattern of V ceC crystal. The space group of the crystal is 
P321, with unit cell lengths a=b=71.93 A, c=191.21 A and angles a.=~=90°, y=120°. 
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Table 3.2. Data collection and refinement statistics* 
Data collections 
Wavelength (A) 
Resolution (A) 
(last shell) 
Rmerge 
Unique reflections 
Completeness 
Multiplicity 
Ilcr(J) 
Cell dimensions 
Space group 
Refinement 
R (working set) 
Rrree (test set) 
R.m.s. deviations 
Bond lengths (A) 
Bond angles (A) 
Ramachandran statistics 
Model 
% of residues m 
allowed regions 
% of residues m 
generously allowed 
% of residues in not 
allowed 
Native 
In house 
1.5418 
26.17-3.30 
3.42-3.30 
0.093(0.367) 
9230 
99.6 (99.7) 
4.2 
14.6 
a=b=71.929, c=191.213 
P321 
Hg derivative 
ESRF at ID14.4 
0.9686 
63.63-1.80 
1.90-1.80 
0.076(0.419) 
53173 
100 (100) 
8.0 
5.5 
a=b=71.458, c=190.702 
P321 
0.1887 
0.2212 
0.019 
1.751 
96.2 
3.8 
0 
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amino acids 
water molecules 
octyl-~-glucosides 
mercury atoms 
*Adapted from Federici eta!., 2005. 
3.7 Structure solution and refinement 
410 of 441 
424 
1 
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Structure solution and refinement were carried out by Dr. Ben Luisi and his group at 
Cambridge University (Federici eta!., 2005). 
Initially, Dr. Ben Luisi's group tried to obtain phase by anomalous scattering from Hg 
derivative crystals of VceC. Two partially occupied mercury sites were identified by 
calculating the anomalous difference Patterson map. The phase extracted from 
anomalous scattering data was used to calculate the electron density maps. However, 
the resulting maps were not of sufficient quality to allow building of the protein 
model. 
Then they changed strategy to solve the structure by molecular replacement using a 
polyalanine model of the E. coli TolC protomer (pdb code 1ek9) as phasing model 
(Molrep version 6.2.5 and CNS) (Vagin eta!., 2004; Brunger eta!., 1998). The best 
solutions were obtained using data collected in-house on a V ceC-Glu92Cys crystal, 
which indicates that one V ceC proto mer occupies the asymmetric unit and the V ceC 
trimer is generated by 3-fold crystallographic axis. 
The V ceC model obtained by molecular replacement was then used as a starting 
model for refinement against the ESRF 1.8 A resolution dataset collected on the 
V ceC-Glu92Cys' crystal soaked with mercury. Two refinement and model building 
procedures were adopted. In the first procedure, the calculated phase from the 
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molecular replacement was used as initial phase to build the V ceC model 
automatically using ARP/wARP (Perrakis et al., 2001), which provided roughly 80% 
of the model. The rest of the model was then completed manually. In the second 
procedure, the original polyalanine model of V ceC was rebuilt manually using 
program COOT (Emsley et al., 2004). The ARP/wARP map was used as a guide for 
model building and the restrained refinement of the model was carried out using 
REFMAC5 (Murshudov et al., 1999). These two procedures result in the same 
structure. The density of mercury atoms bound to Cys92 was found, which is 
consistent with the anomalous Fourier calculations. The density of an 
octyl-~-glucoside molecule between the ~-barrel domains of two symmetry-related 
molecules was also identified. The final Rwork is 18.9% and Rrree is 22.1 %. The V ceC 
model includes residues 63-480 of the cloned coding sequence and ~ 424 water 
molecules. The first N-terminal 21 residues, the last 4 C-terminal residues and the 
residues 288-294 of the loop in the equatorial domain of the mature protein are 
missing due to the absence of clear density. The final quality of the model was 
checked using PROCHECK (Vaguine et al., 1999), which indicates an excellent 
model. Statistics relative to the refinement and the quality of the model are shown in 
Table 3.2. 
The programs JOY (Mizuguchi et al., 1998), ODA (Fernandez-Recio et a!., 2005), 
COMPARER (Zhu et al., 1992), GRASP (Nicholls et al., 1991), PYMOL (DeLano 
Scientific, San Carlos, CA, USA), COOT and ICM (www.molsoft.com) were used to 
prepare figures. 
3.8 Structure of V ceC 
3.8.1 Overall architecture of V ceC 
The mature form of V ceC from Vibrio cholerae contains 442 amino acid residues. The 
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crystal structure of VceC was determined by molecular replacement at 1.8 A 
resolution. The final model of V ceC consisted of 410 amino acid residues comprising 
93% of the mature protein. The first N-terminal 21 residues, the last 4 C-terminal 
residues and the residues 288-294 of the loop in the equatorial domain are missing. 
The asymmetric unit in the unit cell of crystal is a V ceC protomer. The functional unit 
ofVceC is a trimer, which is generated by the crystallographic 3-fold axis. The VceC 
trimer has a cannon-like appearance with a total length of~ 140 A. V ceC shares the 
same overall architecture as TolC. The trimeric V ceC consisted mainly of three 
domains: the ~-domain, the a-domain and the equatorial domain (Figure 3.1 0). 
In the V ceC trimer, the strands of the ~-domain associate in an anti parallel orientation 
! 
to form a 12-stranded ~-barrel that is right-twisted. The a-helices also form a 
12-stranded antiparallel barrel, but this a-helix barrel is left-twisted. The ~-sheet and 
a-helix clusters are connected by four short loops consisting of three to seven amino 
acid residues. 
The a-helix barrel is composed of two types of helix. The long helices (H3 and H7) 
extend for the entire length of the helical barrel, while short helices (H2-H4 and 
H6-H8) stack end-to-end so that they resemble pseudo-continuous helices that 
traverse the length of the helical barrel. 
The N-terminal half of VceC (residues 63-286) and the C-terminal half (residue 
295-480) share 19.8% sequence identity and the superimposition of the two halves 
yields an RMS deviation of 2. 7 A between related Ca atoms, suggesting that the 
protein arose as a result of an intragenic tandem duplication event. 
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Figure 3.1 0. Structure of the V ceC trimer. Three protomers are individually coloured 
(blue, green and red). (A) Side view of a ribbon representation, perpendicular to the 
molecular three-fold axis. (B) A ribbon representation of VceC trimer, viewed from 
the periplasmic side showing the closure of the a-barrel domain. (C) Space filling 
representation of the trimer, viewed from the extracellular space (Adapted from 
Federici et al. , 2005). 
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The porin-like B-barrel domains of VceC trimer pack in laminar sheets in the crystal 
(Figure 3.11A), commonly referred to as "type I crystal packing". Two 
octyl-B-glucoside molecules line end-to-end and span the height of the B-barrel 
domain, nestling between two adjacent B-barrel domains. (Figure 3.11A). The 
hydrophobic interactions between the aliphatic chains of detergent molecules with the 
protein, as well as the hydrogen bond interactions between the sugar moieties of 
detergent molecules with the protein (Figure 3.11B), might mimic 
protein-lipopolysaccharide interactions that could occur in the outer membrane of 
Gram-negative bacteria. 
Figure 3 .11. (A) Crystal packing of V ceC in sheets that mimic the lipid bilayer. The 
octyl-B-glucoside molecules are coloured yellow. (B) A potion of the 2F0 -Fc electron 
density map is shown for the octyl-B-glucoside molecule at the interface between 
symmetry related protomers. The map is contoured at 1.5 cr (Adapted from Federici et 
al., 2005). 
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3.8.2 The P-barrel domain 
The ~-barrel domain of V ceC is inserted in the outer membrane and it spans -40 A. 
The ~-barrel is assembled from three protomers, with each protomer contributing four 
anti-parallel ~-strands, which organize in a highly twisted and curved ~-sheet that 
extend to two-thirds the distance along the ~-barrel. The aromatic amino acid residues, 
such as Phe 11 \ Phe 156, Phe325 and Phe36\ cluster in a ring around the base of the 
~-barrel, delimiting the position of the inner edge of the lipid bilayer. A number of 
prolines and glycines participate in the precise transitions from right-twisted ~-barrel 
into left-twisted a-helix barrel at the junctions of H2-S1, S2-H3, H6-S3 and S4-H7, 
respectively. 
Strands 1-2 and 3-4 are connected by two long extracellular loops consisting of 13 
and 10 residues, respectively. The loop between ~-strands S 1 and S2 rests over the 
concave face of the barrel. Three such loops in the trim eric V ceC form a pore with 
diameter of -6A. The residues Ala134 and Thr135 of each protomer provide the 
boundaries of this pore. Dr. Ben Luisi's group tried to manually dock a variety of 
well-known substrates of the V ceCAB pump, such as carbonyl cyanide 
m-chlorophenylhydrazone (CCCP), onto this pore constriction of V ceC and found that 
they are too large to freely diffuse through the pore if this is considered rigid (data not 
shown). It is likely that the opening of the porin domain is necessary during transport 
of these drugs. 
3.8.3 The a-helix domain 
The a-helical barrel domain is contiguous with the ~-barrel domain and protrudes into 
the peri plasm. The a-barrel domain has a length of -100 A and constitutes the 
periplasm exit duct for substrates. The a-helices form a 12-stranded antiparallel barrel, 
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with each protomer contributing four a-helices (two continuous long helices H3 and 
H7, and two pairs of shorter helices H2-H4 and H6-H8). 
From the ~-barrel domain to the equatorial domain, the internal diameter is virtually 
uniform, which is about 30 A. However, from the equatorial domain to the 
periplasmic periphery, the inward twist of helices H7 and H8 tapers the channel 
gradually, which is almost completely occluded at its periplasmic end. A small pore 
remains with a diameter of roughly 3.5 A (Figure 3.1 OB). This pore is rich in 
hydrophobic residues from the loop between helices H7 and H8, such as Val445 , Ala438 
and Gl/35 . The peri plasmic end is the narrowest point of the channel, which ends 
with a ring made by Leu441 . A charged ring made by Asp442 locates just before the 
periplasmic end, which might act as an anionic selectivity filter. The hel~x pairs H7 
and H8 form a conventional antiparallel coiled-coil, curving towards the symmetry 
axis in their C-terminal and N-terminal parts, respectively. Another helix pair 
comprise a straight helix (H3) around which its partner (H4) is coiling. 
This conformation represents the resting state of the protein that must encounter a 
conformational switch to allow substrates to diffuse into the channel, possibly due to 
interaction with its partner proteins VceA and VceB. 
3.8.4 The equatorial domain 
The segments of equatorial domain connect the helices forming the a-barrel domain. 
We distinguished a helix HI and a short helix 310 (G5) in this region; however the 
loop 288-294 was found to be flexible and could not be modelled due to lack of 
density. Interestingly this loop is located exactly between the two halves of the V ceC 
sequence that constitute structural repeats. 
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3.9 The open state of V ceC 
The open state model of V ceC was devised by Dr. Ben Luisi's group at Cambridge 
University. The sequence of the N-terminal halve of V ceC resembles that of the 
C-terminal halve, suggesting that the protein arose as a result of an intragenic tandem 
duplication event, so that the two halves could make similar interhelical interactions. 
Dr. Ben Luisi's group aligned the N-terminal repeat (residues 63-286) with the 
C-terminal repeat (residues 295-480) using CLUSTAL-X (Thompson et al., 1997). 
The homolog models for the C-terminal repeat were produced based on the crystal 
structure of theN-terminal repeat using Modeller version 6.2 (Fiser et al., 2003). The 
resulting 15 models were ranked by energy and violations from ideal geometry, the 
best of which was further validated using Verify3D (Eisenberg et al., 1997) and 
I, 
PROCHECK. The 'open-state' model of VceC was obtained by merging the 
experimental and modelled coordinates. The superimposition of the 'open-state' 
model to the crystal structure of V ceC revealed that the ~-barrel domain and the first 
part of the a-barrel domain were perfectly aligned whilst the terminal part of helices 
H7 and H8 adopted an open conformation. 
In the 'open-state' model of VceC, the curvature of helices H7-H8 resembles that of 
helices H3-H4. The uncoiling movement of the helices H7 and H8 in this model 
produce a channel aperture of -20 A at the periplasmic side, allowing access of 
substrates into the channel. In Figure 3.12A, the superimposition of the 'open-state' 
model to the crystal structure ofVceC illustrates how the channel may be opened. 
The inward twisting of helices H7 and H8 seems to be maintained by two 
inter-protomer hydrogen bonds between residues Gln236 -Ser449 , Ser243 -Gln453 (Figure 
3.12B), as well as two intra-protomer polar interactions at the interface of helices 
H7/H8 and helix H3: a hydrogen bond between residues Tyr433 -Glu229 and a salt 
bridge between Arg455-Glu24\Figure 3.12C). In the 'open-state' model ofVceC, these 
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hydrogen bonds and salt bridge are disrupted so that the H4 lose its contact with 
H7/H8 of the adjacent protomer and the H3 lose its contact with H7/H8 of the same 
protomer. The hydrophobic residues at the interface ofH4-H7, Ile428 , Ala425 and Val445 , 
become exposed to the solvent upon opening of the channel, which might play a role 
in binding the adaptor protein V ceA when the pump assembles. 
3.10 Electrostatic properties of the V ceC 
In figure 3.13, Dr. Ben Luisi's group has represented the electrostatic potential surface 
of V ceC. In this figure, the front protomer is removed to show the channel interior. 
The channel interior is generally electronegative. Two rings of clustemd negative 
charge locate approximately near the equatorial domain and at the boundaries between 
the a-barrel and ~-barrel domains, respectively. The ring near the equatorial domain is 
made by residues Glu397 and Glu303 ; the ring at the boundaries between the a-barrel 
and ~-barrel domains is made by residues Asp 153, Asp115 and Asp328 . These charge 
distribution of V ceC might facilitate substrate movement across the channel. 
118 
A 
Figure 3.12. (A) The superimposition of the 'open state ' model to the crystal structure of 
V ceC illustrates how the channel may be open. The helices H7 and H8 of one protomer 
are coloured in purple for the closed state and magenta for the open state, respectively. 
(B) Polar interactions of inter- and intra-protomers that stabilize the closed state of V ceC 
(Adapted from Federici et al. , 2005). 
Figure 3.13. Surface representation ofthe VceC trimer, illustrating the charge distribution 
The front protomer was removed to show the channel interior. Charges are shown in red 
for electronegativity, blue for electropositivity, and white for neutrality (Adapted from 
Federici et al., 2005). 
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3.11 Superimposition ofVceC, TolC and OprM 
The structure of V cee was superimposed on the structures of Tole and OprM 
(Koronakis et al., 2000; Akama et al., 2004). The superimposition of aligned ea 
atoms of Vcee and Tole yields an RMS deviation of 2.0 A; the superimposition of 
Vcee and OprM yields an RMS deviation of 1.7 A; the RMS deviation between Tole 
and OprM was found to be 1.8 A. In figure 3.14A, the protein sequence alignment of 
V cee, Tole and OprM is shown. Despite the very low RMS deviations found, with 
the overall fold essentially conserved in both the P-barrel and a-barrel domains 
(Figure 3.14B and 3.14e), the sequence identity between structurally aligned 
segments is only 8.3%. Moreover, most of the conserved residues of the thtee proteins 
are hydrophobic and are likely to play a structural rather than a functional role. For 
example, the conserved leucine residues play a role in the knobs-into-holes 
intermeshing between coiled-coiled helices; two conserved prolines participate in the 
transitions from right-twisted P-barrel into left-twisted a-helix barrel. 
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Figure 3.14. Structural comparisons ofVceC, TolC and OprM monomers. (A) Sequence 
alignment of the three proteins. The helices, strands and helix 310 are coloured red, blue 
and dark red, respectively, and the identical residues are coloured yellow. (B) and (C) 
Superimposition of monomer structures of VceC (blue), TolC (red) and OprM (green), 
viewed parallel and perpendicular to the membrane plane, shows the variation in the 
intra-strand loops of the P-barrel (Adapted from Federici et al., 2005). 
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3.12 Proposed transport mechanism ofVceC 
This conformation of V cee represents the resting state of the protein that must 
encounter a conformational switch during transport to open the two closed ends of the 
channel. 
The V cee channel is almost completely occluded at its peri plasmic side by the inward 
twisting of helices H7 and H8. The helix pair H7 and H8 in the e-terminal half have a 
similar sequence to that of the helix pair H3 and H4 in theN-terminal half, suggesting 
that they could make similar interhelical interactions. The structure of theN-terminal 
repeat was used as a template for generating a model of the e-terminal repeat. In the 
resulting V cee model, the curvature of helices H7 and H8 resembles that of helices 
! 
H3 and H4. The uncoiling movement of the helices H7 and H8 in this model produce 
a channel aperture of ~20 A at the periplasmic side, and thus allow access of 
substrates into the channel. 
The interaction between V cee and its protein partners in the V ceeAB pump may 
trigger the uncoiling movement of the helices H7 and H8. The optimal desolvation 
energy for the V cee trimer was calculated using the procedure previously adopted for 
Tole (Fernandez-Recio et a!., 2004). The Tole a-helical barrel end is predicted to 
interact with a protein partner, such as the Tole docking domain of AcrB, the 
corresponding area in V cee is not (Figure 3 .15). This result suggests that V ceB and 
V cee are not in direct contact in the assembled tripartite pump. It is likely that the 
direct interaction between V cee and V ceA is involved in the opening of the 
periplasmic end of the channel. 
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Figure 3.15. Two perpendicular views of the optimal desolvation areas (ODAs) 
calculated on the surface of TolC (A and C) and VceC (B and D). Residues are 
coloured red for ODA values <-15.0 kcaVmol, and blue otherwise (Adapted from 
Federici et al., 2005). 
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The inward twisting of helices H7 and H8 seems to be maintained by inter-monomer 
hydrogen bonds between residues Gln236-Ser449, Ser243-Gln453 , as well as two 
intra-protomer polar interactions at the interface of helices H7/H8 and helix H3: a 
hydrogen bond between residues Tyr433 -Glu229 and a salt bridge between Arg455 
-Glu247 . In the model of the V ceC open state, these polar interactions are disrupted so 
that H4 loses its contact with H7/H8 of the adjacent protomer and H3 loses its contact 
with H7/H8 of the same proto mer. These could be replaced by contacts with V ceA. 
The coiled-coil domain of V ceA could re-pack against the unwound coiled-coils at the 
proximal end ofVceC and thus stabilize its open state. 
In the V ceC structure, the loop between ~-strands S 1 and S2 rests over the concave 
face of the barrel, forming a pore with diameter of -6A. These loop regions have the 
~ 
thermal factors in the same range of the contiguous ~-strands. Therefore it is hard to 
exclude that these loops play a role in controlling the diffusion of substrates. For 
instance, the hydrogen- bonding capability of Thr135 at the boundaries of the pore 
might be instrumental to bind selected substrates. The interaction might then promote 
a conformational change, allowing substrates to diffuse out into the solvent. 
The substrate specificity in the tripartite pumps is supposed to be determined by the 
inner membrane component (Yu et al., 2003). Once past the entrance of the outer 
membrane channel, substrates could readily diffuse in the extracellular space. The 
interior of the channel of V ceC is generally electronegative. Two rings of clustered 
negative charge locate approximately near the equatorial domain and at the 
boundaries between the a-barrel and ~-barrel domains, respectively. These negative 
rings should attract positively charged drugs into the outer membrane pore, 
facilitating their movement along the channel (Figure 3.13). The negative ring near 
the equatorial domain is made by residues Glu303 and Glu397 . The VceCAB pump 
partly loses it activity when these two residues were replaced with alanine, indicating 
their functional role during transport (Table 3.1 ). 
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The question remains as to how negatively charged substrates of the V ceCAB pump, 
such as nalixidic acid, might diffuse along the channel. Dr. Ben Luisi's group obtained 
the crystal structure of V ceC in complex with nalixidic acid. Nalidixic acid was 
identified inside the a-helical barrel domain of VceC (Figure 3.16). Mutagenesis 
experiments are in progress to test the importance of the surrounding residues. This 
structure suggests that the negatively charged substrates could be actively transported 
across the channel. The outer membrane protein V ceC can not directly use energy 
. from the proton motive force; however, the proton motive force could produce 
conformational change of V ceB that may be transduced to V ceC by a conformational 
coupling ofVceA and thereby transport substrates across the channel. 
The antimicrobial resistance feature afforded by two tripartite multidrug pumps, the 
MexA/MexB/OprM (Zhao et al., 1998; Zhao et a!., 2002) and MtrC/MtrD/MtrE 
(Rouquette-Loughlin et a!., 2002) effiux pump, were shown to require 
TonB/ExbB/ExbD proteins, which has been identified in many Gram-negative 
bacteria and probably represents a conserved mechanism for the transfer of energy 
from the proton motive force to high affinity receptors within the outer membrane 
(Biswas et al., 1997; Mey et al., 2003). It is possible that the TonB/ExbB/ExbD 
complex facilitate the opening of the V ceC channel and the substrates transport across 
the channel, in analogy to the function of OprM (Zhao et al., 1998). 
The VceC trimers pack in laminar sheets in the crystal. Within this membrane-like 
layer, the molecules of octyl-~-glucoside line tail-to-tail (end-to-end), bridging two 
V ceC protomers. The hydrophobic interactions between the aliphatic chains of 
detergent molecules with the protein, as well as the hydrogen bond interactions 
between the sugar moieties of detergent molecules with the protein, might mimic 
protein-lipopolysaccharide interactions that could occur in the outer membrane of 
Gram-negative bacteria . 
. 
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Figure 3.16. The structure of VceC in complex with nalidixic acid. The electron 
density map is shown for nalidixic acid, which was identified inside the a-helical 
barrel domain of V ceC. 
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Chapter 4 
Overexpression, purification and characterization of V ceB and V ceR 
The crystal structures of the three components of tripartite multidrug efflux pump, 
AcrB, AcrA and TolC, have been determined. The question remains as to how the 
three components assemble to form a functional pump. Obviously, the crystal 
structures of the IMP-MFP-OMP complex or the complex of either of the two 
components will be critical to decipher the molecular mechanism of these pumps. 
Different models of the protomer stoichiometry for tripartite pumps have been 
proposed (Higgins et al., 2004; Akama et a!., 2004; Fernandez-Recio et a!., 2004), 
however, these models are based on the structure of the RND family~ transporter 
protein AcrB, which in contrast to other types of transporter has a big periplasmic 
domain. 
V ceB is the inner membrane component of the V ceCAB pump, which belongs to the 
MF family of proton anti porters. Like other MF family proteins, V ceB is predicted to 
lack the extensive periplasmic domain that is typical of proteins belonging to the 
RND family (Colmer et al., 1998). It seems likely that the MFS-based pumps have a 
different organization and use different types of protein-to-protein interactions in the 
tripartite pumps. 
Membrane transport proteins are difficult for overexpreswn, purification and 
crystallization, and the lack of structures of multidrug efflux pumps has retarded our 
understanding of these transporters. The cytosolic multidrug-binding transcriptional 
regulators ofthese pumps provide an alternative in studying the multidrug recognition 
mechanisms. 
VeeR is established as a repressor of the vceCAB operon (Woolley et a!., 2005; 
Borges-Walmsley et al., 2005), which belongs to the TetR/CamR family of 
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transcriptional regulators. These regulators typically function as dimers that bind 
palindromic operators in which the termini of the inverted repeats are about 15 bp 
apart. However, some of these family regulators, such as QacR, function as a pair of 
dimers and bind to 28 bp palindromic operators (Grkovic et al., 2001). 
In this chapter, I report the successful overproduction of the complex of V ceA 
(12-406) and V ceB-V ceA fusion protein, which could be a candidate to co-crystallize 
these two components of the V ceCAB pump. I analyzed the oligomerization states of 
DNA-bound and drug-bound VeeR. 
4.1 Overexpression and purification of V ceB-V ceA fusion protein 
4.1.1 Construction of the pET-B-A plasmid 
The pET-B-A construct that was used to express the VceB-VceA fusion protein was 
generated by several steps. The vceB gene was amplified by PCR from genomic DNA 
of the V cholerae vaccine strain CVD101 (primers: VceBFNceBR2) and ligated into 
pGEM-T Easy vector. After restriction enzyme digestion of the vector with Nde! and 
Xho!, the resulting vceB fragment was then ligated into pET21a, generating the 
construct pET-B-I. The vceB gene in pET-B-I was amplified again using primer pairs 
VceBF/HisR, the resulting vceB-6His fragment bounded by Nde! and Sac! was ligated 
into Nde! and Sac! digested pET21a vector, generating the construct pET-B-II. The 
forward and reverse primers were designed so as to introduce an N-terminal 
enterkinase-tag to vceA, and the Sac! and Hindi!! restriction sites were incorporated 
into these primers to allow fragment ligation into pET-B-II via Sac! and Hindi!! sites 
(primers: VceA-EKFNceAR2), generating the construct pET-B-A. This construct 
generated a fusion protein with V ceA following the C-terminus of V ceB and a 
His6-enterkinase'linker (LEHHHHHHELDDDDK) between them. 
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4.1.2 Recombinant expression of V ceB-V ceA fusion protein 
The E. coli strain C43 (DE3) was used as the host strain to express the V ceB-V ceA 
fusion protein. The pET-B-A construct was transformed into C43 (DE3). Transformed 
colonies were selected on the basis of vector-encoded ampicillin resistance, and 
isolated plasmids were screened for the presence of the inserted vceB-vceA sequence 
by restriction digestion. 
A single C43 (DE3)/pET-B-A colony from a freshly streaked plate was picked and 
used to inoculate 10 ml 2xYT broth, containing carbenicillin (1 OOJ.Lg/ml), in a 25 ml 
universal container. The cells were grown in an orbital shaker at 37°C, 220 rpm. 
overnight. One liter of prewarmed 2xYT broth (carbenicillin 100J.Lg/ml) in a 2 liter 
baffled flask was inoculated with 2 ml of the overnight culture. The cells were grown 
in an orbital shaker at 37 °C, 220 rpm, and their growth was monitored by measuring 
the absorbance of the culture at 600 nm (A6oo). The cells were induced at mid log 
phase (approx. A600=0.5-0.6) with 0.3 mM IPTG. The temperature was dropped to 25 
°C and the growth was continued with shaking at 200 r.p.m. for 4-5 hours. The cells 
were harvested by centrifugation at 4,350 xg for 8 min at 4 °C, resuspended in 
buffer A (NazHP04 20 mM, pH: 7.2, NaCl 300 mM, Glycerol 10%) at 5 ml per gram 
wet weight. DNase I (5U/ml) and EDTA-free protease inhibitor mixture tablet (1 
tablet/1 00 ml) were added to the cell suspension and either stored at -80 °C or 
purification continued. 
4.1.3 Purification of the His-tagged V ceB-V ceA fusion 
Purification of V ceB-V ceA fusion protein by Co2+ affinity chromatography was 
performed using'TALON Metal Affinity Resin purchased from Clontech. 
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The cells were lysed by three passages through a Constant System Cell Disrupter (15 
Kpsi, model Z-plus 1.1 kW, Constant System). Cellular debris was removed by 
centrifugation at 24,000 xg for 30 min at 4 °C. The supernatant, containing soluble 
proteins and membrane vesicles, was carefully decanted so as not to disturb the 
pelleted material. The supernatant was further fractionated into membrane and soluble 
components by high-speed ultracentrifugation at 122,400 xg for 90 min at 4°C. This 
procedure resulted in the generation of a supernatant containing cytosolic proteins and 
small molecules and a pellet of membranous material. 
The membrane pellet was emulsified in a small volume of buffer A by repeated 
passage through a syringe needle, and then the emulsified membrane was diluted by 
buffer A to a final concentration of total protein of about 5-10 mg/ml. A po~der of the 
detergent DDM was added to the emulsified membrane to a final concentration of 
1-2% to solubilize the membrane. The mixture was gently stirred at 4 oc for 1-2 hours 
and then ultracentrifuged at 122,400 xg for 1 hour at 4 °C. The membrane solution 
was carefully decanted so as not to disturb the pelleted material. Imidazole (500 mM, 
pH 7.2) was added to the membrane solution to a final concentration of 10 mM. 
Extracted histidine-tagged V ceB-V ceA fusion protein was purified using the TALON 
Metal Affinity Resin immobilized with Co2+. Two ml of Talon affinity resin were 
washed twice with 20 ml of deionised water and twice with 10 ml buffer B (Na2HP04 
20 mM, pH: 7.2, NaCl 300 mM, Glycerol 10%, DDM 0.2%) by centrifugation at 
4,000 xg for 10 min. The Talon affinity resin was equilibrated in 10 ml buffer B for 1 
hour on ice, and then sedimented by centrifugation at 4,000 xg for 10 min. 
Two ml of equilibrated Talon affinity resin were add to 50 ml of membrane solution 
and mixed gently by stirring at 4°C for 2 hours. Then the sedimented Talon affinity 
resin was washed, using a batch-wise procedure, three times with 10 ml of 30 mM 
imidazole in buffer B. The Talon affinity resin was then loaded onto a column with 
the bottom outlet capped. The bottom cap was removed and the column flow-through 
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was collected. The column was washed twice with 10 ml of 50 mM imidazole in 
buffer B, the wash fractions were collected for SDS-PAGE analysis. The protein was 
eluted 6 times with 0.5 ml of elution buffer (500 mM imidazole in buffer B). The 
eluates were collected for SDS-PAGE analysis. 
4.2 Overexpression and purification of V ceR 
The veeR gene was amplified by PCR usmg the forward and reverse pnmers 
VceRFNceRR, respectively. I incorporated BamHI and Xhol restriction sites into 
these primers to allow fragment ligation into pET21 a, generating a construct 
pET-V ceR to express the V ceR with a C-terminus hexahistidine-tag. 
The pET-V ceR construct was used to transform E. coli strain C41 (DE3), providing 
expression of the His6-tagged protein. A single colony of C41 (DE3)/pET-V ceR was 
picked from a freshly streaked plate and used to inoculate 20 ml of LB broth, 
containing 100 ~J.g/ml carbencillin. The culture was grown at 37°C overnight with 
vigorous shaking. One liter of prewarmed 2xYT broth (with antibiotic), in a 2 liter 
baffled flask, was inoculated with 3 ml of the noninduced overnight culture. The 
culture was grown at 37°C with vigorous shaking until an OD600 of 0.5-0.6 was 
reached, at which point IPTG was added to a final concentration of 0.5 mM, and the 
growth continued for 3-4 hours at the reduced temperature of 25 °C. The cells were 
harvested by centrifugation at 4,350 xg at 10 oc for 8 min and resuspended in buffer 
C (50 mM Tris pH 7.0, 300 mM NaCl, 10% (v/v) glycerol, 1 mM THP, 1 tablet/100 
ml protease inhibitor cocktail tablet, 5 U/ml DNase 1). 
The cell suspension was passed three times through a Constant Systems cell disrupter 
(15 Kpsi, model Z-plus 1.1kW, Constant Systems) at 4 octo disrupt the cell, and then 
incubated on ice'for 15 min. The lysate was centrifuged at 122,400 xg for 60 min at 4 
°C to pellet the cellular debris. V ceR was isolated from the supernatant using a Hi Trap 
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chelating HP 1 ml column immobilized with Ni2+ that had been equilibrated with 
buffer D (50 mM Tris pH 7.0, 300 mM NaCl, 10% Glycerol, 0.5 mM THP). 
Imidazole (5 M, pH 7.0) was added to the supernatant to a final concentration of 15 
mM and the mixture was loaded onto the column using a peristaltic pump at a speed 
of 1 ml/min. The column was washed with 10-15 ml of 50 mM imidazole in buffer D. 
The VeeR was then eluted from the column with 300 mM imidazole in buffer D. The 
eluates were collected as 1 ml fractions and analyzed by SDS-PAGE. Positive 
identification was achieved through Western blotting with Mouse-Anti-His (BioRad). 
Figure 4.1 shows the SDS-PAGE analysis ofVceR. 
51 kDa____. 
28 kDa 
VeeR 
Figure 4.1. A Coomassie blue stained SDS-PAGE gel showing IMAC purification of 
V ceR. The left side arrows mark the position of protein standards; the right side arrow 
marks the position ofVceR protein. 
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4.3 Expression of V ceB-V ceA fusion protein 
The vceB gene is 1536 bp long and encodes a protein of 511 amino acids. The V ceB 
protein contains 48.92% hydrophobic amino acids (AILFWV), strongly suggesting 
that it associated with the cell membrane. Hydropathy analysis using the program 
TMPred indicated that V ceB contains 14 transmembrane a-helices that may span the 
cytoplasmic membrane, with its N- and C-terminus in the cytoplasm (Figure 4.2). 
VceB shares 39.5% amino acid sequence identity, 60.3% sequence similarity to a 
characterized 14-TMS MF family transporter EmrB from E. coli, suggesting that VceB 
is a 14-TMS MF family transporter. 
Figure 4.3 shows the SDS-PAGE analysis of the VceB-VceA fusion protein. On 
SDS-PAGE, the VceB-VceA fusion protein migrated at around 75 kDa, rather then at 
the predicted monomeric mass of 1 01.2 kDa. It is typical for membrane transporter 
proteins to migrate at 65-75% of their molecular weight on SDS-PAGE (Saidijam M 
et al., 2003; Mokhonov Vet al., 2005), and thus the migration of the VceB-VceA 
band on SDS-PAGE would be expected at 65.8-75.9 kDa. 
Matrix Assisted Laser Desorption Ionization Time-of-flight Mass Spectrometry 
(MALDI MS) analysis confirmed that the band 1 and band 2 were VceB-VceA and 
VceA (12-406), respectively (Figure 4.3). It is obvious that the construct pET-B-A 
expressed two proteins: the VceB-VceA fusion protein and VceA (12-406). VceA 
( 12-406) was co-purified with V ceB-V ceA because it does not contain a His6-tag. 
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TMpred output for VceB 
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o->i ·· 
500 600 
STRONGLY prefered model: N-terminus inside, 14 strong transmembrane helices, 
total score: 26198 
helices from to length score orientation 
1 14 33 (20) 2260 1-0 
2 56 79 (24) 1278 0-1 
3 87 105 (19) 2430 1-0 
4 110 133 (24) 1299 0-1 
5 143 166 (24) 1712 1-0 
6 175 194 (20) 1737 0-1 
7 208 224 (17) 1302 1-0 
8 239 256 (18) 2806 0-1 
9 277 300 (24) 2293 1-0 
10 314 334 (21) 1834 0-1 
11 340 361 (22) 1842 1-0 
12 368 391 (24) 1853 0-1 
13 404 426 (23) 707 1-0 
14 480 499 (20) 2845 0-1 
Figure 4.2. TMpred prediction of transmembrane regions and orientation of VceB. 
Prediction parameters: TM-helix length between 17 and 33. i-o: inside to outside 
helices; o-i: outside to inside helices. 
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191 kDa 
Band 1 
64kDa 
51 kDa 
H:mrl2 
39 kDa 
28 kDa 
Figure 4.3. Coomassie blue stained SDS-PAGE gel showing partial IMAC 
purification of V ceA(l2-406) and V ceB-V ceA fusion protein from DDM solubilized 
membranes. The left side arrows mark the position of protein standards; the right side 
arrows mark the position ofVceB-VceA fusion protein (band 1) and VceA (12-406) 
(band 2), respectively. 
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4.4 A pair of V ceR dimers binds the vee promoter 
The vee promoter was identified to be a 28 bp inverted repeat DNA sequence 
(Woolley et al., 2005; Borges-Walmsley et al., 2005). The complementary 
oligonucleotides corresponding to the 28 bp inverted repeat sequences of the vee 
promoter were annealed (oligonucleotides VceR-PFNceR-PR) for DNA binding 
experiments. Analytical gel filtration chromatography was used to estimate the 
molecular weight (Mr) of VeeR and of the VeeR-DNA complex using a Superdex 200 
PC 3.2/30 column, equilibrated with buffer E (50 mM Tris pH 7.0, 300 mM NaCl, 
1 mM THP). The protein standards ribonuclease A, chmotrypsinogen A, ovalbumin 
and albumin were solubilized in buffer E and used to prepare a calibration curve. The 
molecular weights of VeeR and VeeR-DNA complex were determinec4. using this 
calibration curve (see Materials and Methods). 
Passage of the V ceR protein through a gel filtration column produced a single protein 
peak, detected from the 280 nm absorbance, with a calculated Mr of 46.5 kDa that is 
consistent with a homodimer of VeeR (with a predicted Mr of 49.8 kDa). However, 
passage of the VeeR that was pre-incubated with molar ratios of between 0.1 and 0.5 
of the 28 bp promoter DNA of veeCAB, through gel filtration column produced two 
peaks. One peak consistent with a homodimer of V ceR, while the second peak had a 
calculated Mr of 118.9 kDa, which is in good agreement with the theoretical mass of 
118.0 kDa for four V ceR molecules bound to the veeCAB promoter DNA (Figure 4.4 
a and b). The increase of molar ratio of promoter DNA to V ceR shifted the profile so 
that more V ceR proteins were located to the tetramer form, consistent with this 
interpretation. I failed to determine whether the substrates of the V ceCAB pump, such 
as CCCP, could induce dissociation of the V ceR(tetramer)-( dsDNA) complex, as 
CCCP precipitated upon application to the column. Interestingly, I found that VeeR 
could bind ssDNA (e.g. either strand of the promoter dsDNA) to form a complex that 
had a calculated' Mr of 28.4 kDa, which is in agreement with the theoretical mass of 
34.1 kDa for one V ceR molecule bound to the ssDNA, suggesting that the dimer 
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interface was destabilized by the presence of ssDNA (Figure 4.4b ). 
The oligomeric state of V ceR was also examined in the absence of both DNA and 
drug, in the presence of dsDNA and in the presence of both dsDNA and drug, using 
an alternative technique of dynamic light-scattering (DLS). The DLS experiments 
were performed in a Zetasizer Nano instrument (Malvern Instruments, UK). The 
measurements were carried out in buffer E with 1 or 10% glycerol at 25 °C after 
filtration through a 0.22 J.tm filter. Test calibrations of the instrument were performed 
with lysozyme. The molecular weight (Mr) of V ceR could be calculated from the 
particle size determined by DLS. 
The DLS measurements of the VeeR in buffer E containing 10% (v/r) glycerol 
yielded a molecular mass of 24.4 kDa (radius 2.330 nm) that is highly consistent with 
that predicted for the monomer (24.9 kDa), but there was no change in particle size 
upon addition of dsDNA (Figure 4.4c ); while the DLS measurement of the V ceR in 
buffer E containing 1% (v/v) glycerol yielded a molecular mass of 68.9 kDa (radius 
3.634 nm). The addition of dsDNA caused a further increase to 141.1 kDa (radius 
4.937 nm), and then the addition of CCCP reduced the molecular mass to 67.5 kDa 
(Figure 4.4c ). In the absence and presence of dsDNA, the molecular weights of V ceR 
are higher than expected for the VeeR dimer (49.8 kDa) and tetramer-DNA complex 
(118 kDa). The VeeR dimer and VceR(tetramer)-dsDNA complex may adopt an 
elongated conformation that leads to the Mr being over-estimated by this technique. 
Upon addition of CCCP to the VceR(tetramer)-dsDNA complex, the Mr was reduced 
to 67.5 kDa, indicating that two dimers of VeeR are induced to dissociate from the 
dsDNA. 
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Figure 4.4. The oligomeric state of VeeR. (a) The elution profile ofVceR-dsDNA on 
a Superdex 200 PC 3.2/30 size-exclusion column. VeeR and dsDNA were 
preincubated with a molar ratio of2:1. Running buffer: 20 mM Tris pH 7.0, 300 mM 
NaCl, 1 mM THP. Flow rate: 20 )..1.1/min. Peak D and peak T indicate VeeR dimer and 
VeeR (tetramer)--dsDNA complex, respectively. (b) A standard curve constructed 
from the elution volumes of the Low Molecular Weight Gel Filtration Kit. The 
positions of V ceR, V ceR--dsDNA and V ceR- ssDNA complexes are shown on the 
curve. (c) Size distribution curves of VeeR determined by dynamic light-scattering 
assays. Peak A, B and C show V ceR in running buffer with 10% glycerol, 1% 
glycerol and 1% glycerol/dsDNA, respectively. Upon addition of CCCP to the 
VceR(tetramer)- dsDNA complex, a curve produced that was superimposed upon that 
for V ceR alone in the presence of 1% glycerol (Adapted from Borges-Walmsley et al., 
2005). 
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4.5 Discussion 
VceB 
Overexpression of polytopic IMPs in E. coli is still a challenge. Several factors likely 
account for this difficulty. First, the biogenesis of most polytopic IMPs depends on the 
Sec-translocase. Heterologous expression of polytopic IMPs in E.coli will 
competitively exclude production of vital host membrane proteins, leading to toxicity 
(Van den Berg et al., 2004; Roosild et al., 2005). Second, the signal sequence of the 
IMP is critical for its targeting and insertion in the inner membrane. The signal 
sequence of helerologous IMPs may not be effectively recognized by E. coli (Dalbey 
et al., 2004; Roosild et al., 2005). Thirdly, the IMP needs to properly lold in the 
membrane and assemble with it partner subunits. Misfolding and misassembling of 
helerologous IMPs expressed in E.coli can be toxic to the cell. There is a quality 
control system that removes misfolded and misassembled helerologous IMPs. It has 
been discovered that FtsH, an ATP-dependent protein, is involved in such a quality 
control (Kihara et al., 1999). Besides, the expression of toxic proteins in E. coli strains 
causes plasmid instability: bacteria which have lost the expression plasmids rapidly 
overgrow those retaining it (Dumon-Seignovert et al., 2004). 
The toxicity problem of expression was overcome for a number of membrane proteins 
using two host strains, called C41 (DE3) and C43 (DE3). By induced mutation of 
BL21 (DE3), these two host strains were selected that grew to high saturation density 
and continue to produce proteins at an elevated level without toxic effects (Miroux et 
al., 1996; Dumon-Seignovert L et al., 2004). Fusion partner proteins have been used 
to aid production of recombinant membrane proteins. The fusion partner protein 
Mistic bypasses the Sec-dependent pathway of IMP biogenesis. By using Mistic as a 
fusion partner protein, several IMPs have been overexpressed, which fully fold in the 
native conformation (Roosild et al., 2005). The co-expression of IMPs with their 
partner subunits may improve the expression level of functional protein (Kihara et al., 
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1995). 
Overexpression of VceB in E.coli was highly toxic. We failed to overproduce this 
protein alone using several E.coli strains and expression vectors (data not shown). 
This problem was overcome by expression of the V ceB-V ceA fusion protein using 
C43 (DE3) as host strain. Like other tripartite multidrug effiux pumps, VceA and 
VceB could assemble together in the inactive state. The misassembling ofVceB could 
result in toxicity to the cell when it is expressed alone. 
The C-terminus end of V ceB is supposed to be located at the cytoplasm side of the 
inner membrane, and V ceA has anN-terminal in-outward transmembrane a-helix, it is 
reasonable for the VceB-C-terminus-fused VceA to express its periplasmiG domain in 
the periplasm. However, the construct pET-B-A expressed two proteins: the 
VceB-VceA fusion protein and VceA (12-406). Colmer et al. (1998) identified two 
possible ribosome-binding sites 10-20 bp upstream of the ATG code of Met12. It is 
likely that the vceA gene starts at Metl2 rather then postulated Met1 (Heidelberg eta/., 
2000). 
The characterized MFS transporters function as monomers and lack the large 
periplasmic domain present in RND-transporters (Abramson et al., 2003; Huang et al., 
2003; Hirai eta!., 2004; Yin et al., 2006). VceB could also function as a monomer. 
The peri plasmic gap may vary between 100 and 250 A according to the physiology of 
the Gram-negative bacteria (Dubochet et a!., 1983; Graham et a!., 1991). It is 
necessary for VceA to function as an oligomer to form a channel between VceB and 
V ceC, so that the tripartite pump could span the peri plasm. I have found that the 
periplasmic domain ofVceA forms a trimer (this study). Therefore, it is not surprising 
that VceA (12-406) co-purified with VceB-VceA. 
The key to understanding the mechanism of tripartite multidrug efflux pumps will lie 
in the structural solution of the IMP-MFP-OMP complex; however, this represents a 
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considerable challenge. Although it was shown that the three components of tripartite 
multidrug efflux pump form a stable complex in the inactive state (Tikhonova et a!. 
2004; Touze eta!., 2004; Gerken eta!., 2004), they are very easy to dissociate in vitro, 
resulting in the difficulty to co-crystallize the complex. The V ceB-V ceA fusion 
protein and VceA (12-406) form a stable complex during purification, which could 
provide an invaluable way for co-crystallization of these two components of the 
VceCAB pump. 
VeeR 
The rate of the CCCP-induced conformational change of V ceR determined by 
stopped-flow fluoresce spectroscopy revealed that the binding of CCCP to VeeR in 
both the presence and absence of DNA is a highly co-operative process that occurs 
with a Hill coefficient of about four, suggesting that each functional unit of V ceR 
interacts with four CCCP molecules (Borges-Walmsley et a!., 2005). The gel filtration 
and DLS experiments indicated that in the absence of promoter dsDNA, the protein 
exists predominantly as a dimer, while in the presence of promoter dsDNA, the 
protein exists as V ceR (tetramer)-dsDNA complex. The DLS experiments also 
indicated that VeeR (tetramer)-dsDNA complex dissociates into VeeR dimers in the 
presence of CCCP. Taken together, these findings suggest that each V ceR subunit has 
multiple drug-binding sites. Another TetRJCamR family transcriptional regulator, 
QacR, has also been shown to have multiple over-lapping sites that can 
simultaneously accommodate bound drugs (Schumacher et a!., 2001; Schumacher et 
a!., 2004). Taking into account the fact that the binding ofCCCP to dimeric VeeR is a 
co-operative process with a Hill coefficient of 4, it is reasonable to propose that the 
V ceR monomer possesses a pair of binding-sites that can be simultaneously occupied 
by CCCP, and that these sites interact with one another and with those in the second 
subunit of the dimer. This is in contrast to QacR, in which the two subunits of the 
dimer do not appear to interact. 
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Chapter 5 
Overexpression, purification and characterization of V ceA 
The membrane fusion protein (MFP) is a component of the tripartite multidrug efflux 
pump in Gram-negative bacteria. MFPs are anchored to the inner membrane by a 
single transmembrane helix, or via a fatty acid attached to its N-terminal cysteine 
residue (Borges-Walmsley et al., 2003; Yoneyama et al., 2000). MFPs contain a large 
periplasmic domain, which is predicted to have a a-helix hairpin and lipoyl structure 
(Johnson et al., 1999). 
Different models of the protomer stoichiometry for tripartite pump have been 
proposed. The MFP was predicted to be a trimer, hexamer or enneamer in an 
assembled tripartite pump (Fernandez-Recio et al., 2004; Akama et al., 2004; Higgins 
et al., 2004). These models are based on the structure ofRND family transporter AcrB, 
which has a big periplasmic domain. The problem remains as to how the MFPs of 
MFS-transporters or ABC-transporters interact with their IMP and OMP because they 
lack the large periplasmic domain present in RND-transporters. It is likely that 
different arrangement of MFPs can be expected in MFS and ABC-based tripartite 
pumps. 
In this chapter, I report the initial structural characterization and oligomeric state of 
VceA, the MFP of an MF tripartite pump VceCAB. 
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5.1 Overexpression and purification of V ceA 
5.1.1 Construction of plasmids to overexpress V ceA 
V ceA is predicted to anchor to the inner membrane by a single a-helical domain. 
Different vceA constructs were made to test this hypothesis. The full length vceA and 
two truncated fragments, vceA (12-406) and vceA (53-406), were generated by PCR 
usmg pnmers VceAFNceAR2, VceA12FNceAR2 and VceA53FNceAR2, 
respectively. The plasmid pQE30 was used as expression vector to overexpress vceA, 
vceA (12-406) and vceA (53-406) in E. coli strain M15 (pREP4). 
The pQE30-vceA, pQE30-vceA (12-406) and pQE30-vceA (53-406) wer~ generated 
by subcloning the fragments of pGEMT!vceA, pGEMT!vceA (12-406) and 
pGEMT/vceA (53-406), bounded by Sacl and Hindiii, into the MCS of expression 
vector pQE30. These resulted in the generation of constructs to express vceA, vceA 
(12-406) and vceA (53-406) with anN-terminal hexahistidine tag. Figure 5.1 shows 
the restriction enzyme analysis of these constructs. 
5.1.2 Overexpression of the V ceA 
A single colony of M15 (pREP4)/ pQE30-vceA or M15 (pREP4)/ pQE30-vceA 
(12-406) or M15 (pREP4)/ pQE30-vceA (53-406) was picked from a freshly streaked 
plate and used to inoculate 20 ml of LB broth containing 1 00 ~-tg/ml carbencillin and 
25~-tg/ml kanamycin. The culture was grown at 37°C overnight with vigorous shaking. 
One liter of prewarmed 2xYT broth (with antibiotics) in a 2 liter baffled flask was 
inoculated with 3 ml of the non-induced overnight culture. The culture was grown at 
37°C with vigorous shaking until an OD600 of 0.5-0.6 was reached. The cells were 
induced by adding 1 M IPTG to a final concentration of 0.2 mM, and then the culture 
was incubated tor an additional 2-3 hours at 30 °C. The cells were harvested by 
centrifugation at 4,350 xg at 4 °C for 8 min and the cell pellets were resuspended in 
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buffer A (20 mM Tris pH: 7.5 , 300 mM NaCl, 20% Glycerol, 5 U/ml DNase I, 1 
tablet/1 00 ml protease inhibitor). 
1 2 3 4 5 
~ pQE30 
1.6 kb ___. 
1.0 kb 
vceA 
vceA(12-406) 
Figure 5.1. Restriction analysis of pQE30-vceA, pQE30-vceA (12-406) and 
pQE30-vceA (53-406) plasmids. The Sacl/Hind!II bounded vceA, vceA (12-406) and 
vceA (53-406) genes were ligated into Sacl/Hind!II digested pQE30 vector and 
transformed into NovaBlue competent cells. The potential pQE30 recombinants were 
screened by PCR first, then recombinant plasmids were prepared from PCR positive 
colonies and analyzed using Sacl and Hindiii restriction digestion (37 °C for 3 hours). 
All recombinant plasmids exhibit target gene inserts. 
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The cells were lysed by passing the cell suspension three times through a Constant 
Systems cell disrupter at a pressure of 15 Kpsi. The crude lysate was then fractionated 
into insoluble cellular debris, soluble cytosolic components of the cell and cellular 
membrane by differential centrifugation (see Materials and Methods). The VceA 
(53-406) was isolated from the soluble cytosolic components; the V ceA and V ceA 
(12-406) were isolated from the cellular membrane fraction. 
5.1.3 Purification of His-tagged V ceA using Ni2+ affinity chromatography 
For purification of VceA (53-406), NaCl was added to the soluble cytosolic 
components to a final concentration of 500 mM, imidazole (500 mM, pH;, 7.5) to 15 
mM and THP to 0.5 mM, and then 2 ml ofNi-NTA (Qiagen) slurries were added to 
100 ml of the mixture and mixed gently by stirring at 4°C for 2 hours. The mixture 
was loaded into a column with the bottom outlet capped. The bottom cap was 
removed and the column flow-through was collected. The column was washed with 
40 ml of 40 mM imidazole in buffer B (20 mM Tris pH: 7.5, 300 mM NaCl, 20% 
Glycerol, 0.5 mM THP) and 20 ml of 60 mM imidazole in buffer B; wash fractions 
were collected for SDS-PAGE analysis. The protein was eluted 6 times with 0.5 ml 
elution buffer (500 mM imidazole in buffer B). The eluates were collected and 
analyzed by SDS-PAGE. 
For purification of VceA and VceA (12-406), the membrane pellets were emulsified 
in a small volume of buffer B by repeated passage through a syringe needle, and then 
the volume of membrane mixture was adjusted using buffer B at 10 ml per gram of 
membrane (wet weight). DDM was added to the membrane suspension to a final 
concentration of2% and THP to 0.5 mM. The mixture was rotated at 4°C for 2 hours 
to solubilize the membrane. The mixture was then ultracentrifuged at 122,400 xg for 
60 min to sediment insoluble membrane debris. NaCl was added to the membrane 
solution to a final concentration of 500 mM, and imidazole (500 mM, pH: 7.5) to 15 
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mM. Then 2 ml of Ni-NTA slurries were added to 100 ml of the mixture and mixed 
gently by stirring at 4°C for 2 hours. The mixture was loaded into a column with the 
bottom outlet capped. The bottom cap was removed and the column flow-through was 
collected. The column was washed with 40 ml of 40 mM imidazole, 0.2% DDM, in 
buffer B and 20 ml of 60 mM imidazole, 0.2% DDM, in buffer B; wash fractions 
were collected for SDS-PAGE analysis. The protein was eluted 6 times with 0.5 ml 
elution buffer (500 mM imidazole, 0.2% DDM in buffer B). The eluates were 
collected and analyzed by SDS-PAGE. Figure 5.2 shows an SDS-PAGE analysis of 
VceA, VceA (12-406) and VceA (53-406). VceA was also extracted from DDM 
solubilised cellular membranes without THP in the buffer during purification. There 
were mainly two protein bands (Figure 5.2 D1-3). After treating the protein sample 
(protein sample 20 ~1 +~-mecaptoethanol 1 ~1+ protein loading buffer 4 .,._1, 99°C 30 
min), one band disappeared (Figure 5.2 D4-6). 
5.1.4 Western blotting identification of V ceA 
The Western blotting method was employed to confirm that the protein was indeed 
VceA. The VceA sample was separated by SDS-PAGE, transferred to a 
polyvinglidene difluoride membrane by electroblotting, and then immunoblotted with 
a mouse monoclonal primary antibody raised against the polyhistidine tag epitope. 
The result of Western blotting is shown in Figure 5.3. Western blotting analysis of 
untreated and treated (e.g. 20 ~1 protein, 1 ~1 ~-mecaptoethanol, 4 ~I protein loading 
buffer, 99°C 30 min) V ceA samples established that the higher molecular mass band is 
a V ceA dimer that dissociates when treated with ~-mercaptoethanol and boiling. 
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Band 1 
Figure 5.2 Coomassie blue stained SDS-PAGE gel showing partial purification of 
VceA, VceA (12-406) and VceA (53-406). (A) VceA (53-406) isolated from soluble 
cytosolic components of the cell. (B) and (C): VceA and VceA (12-406) extracted 
by DDM from cellular membrane, respectively. (D) V ceA extracted by DDM from 
cellular membrane without THP in the buffer during purification. There are mainly 
two protein bands (lane 1-3). After treating the protein sample (20 ~-tl protein, 1 f.ll 
~-mecaptoethanol, 4 f.!l protein loading buffer, 99°C 30 min), band 1 disappeared (lane 
4-6). 
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VceAdimer 
Figure 5.3. The Western blotting above illustrates the strong reaction between an 
anti-His6 antibody and the approximately 50 kDa and 100 kDa proteins with high 
specificity. Lane 1-3: untreated VceA samples; Lane 4-6: treated VceA samples (20 
f.ll protein, 1 f.ll P-mecaptoethanol, 4 f.ll protein loading buffer, 99°C 30 min). The 
higher molecular mass band disappears after treating the samples, indicating that it is 
VceAdimer. 
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5.2 Secreted expression and purification of the peri plasmic domain of V ceA 
5.2.1 Construction of the pBAD/giii-VceAp plasmid 
VceA (53-406) was predicted to be the periplasmic domain of VceA (VceAp). The 
secreted expression of V ceAp in the peri plasm of E. coli strain TOP 10 was conducted 
using expression vector pBAD/glll. The pBAD/glll is a pBR322-derived expression 
vector. The araBAD promoter (PsAD) and the araC gene of the vector provide tight, 
dose-dependent regulation of heterologous gene expression, while the genelll signal 
sequence allows secreted recombinant protein expression into the periplasmic space 
of E. coli (Invitrogen). 
The forward and reverse primers were designed so as to introduce an N-terminus 
hexahistidine-enterokinase tag to VceAp (primers: VceApFNceAR2). I incorporated 
Sacl and Hindlll restriction sites into these primers to allow fragment ligation into 
pBAD/g!II, generating a construct pBAD/g/JJ-VceAp to express the VceAp with an 
N-terminus secretion signal peptide G III and hexahistidine-enterokinase tag. Figure 
5.4 shows the restriction enzyme analysis ofpBAD/gJJJ-VceAp. 
5.2.2 Overexpression and purification of V ceAp-His6 by Ni2+ affinity 
chromatography 
A single colony of TOP10/pBAD/g!I/-VceAp was picked from a freshly streaked 
plate and used to inoculate 20 ml LB broth containing 100 J..tg/ml carbencillin. The 
culture was grown at 37°C overnight with vigorous shaking. One liter of prewarmed 
2xYT broth (with antibiotic) in a 2 liter baffled flask was inoculated with 3 ml of the 
noninduced overnight culture. The culture was grown at 37°C with vigorous shaking 
until an OD600 'of 0.5-0.6 was reached. The cells were induced by adding 20% 
L-arabinose to a final concentration of 0.02%, and then the culture was incubated for 
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an additional 2-3 hours at 30 °C. The cells were harvested by centrifugation at 4,350 
xg at 10 oc for 8 min. 
The cold osmotic shock procedure (Qiagen) was used to purify V ceAp from the 
periplasm ofTOPlO. The cell pellets ofTOP10 /pBAD/gJJJ-VceAp was resuspend in 
buffer C (30 mM Tris·Cl, 20% sucrose, pH 8.0) at 60 ml per gram wet weight. The 
cells were kept on ice and 500 mM EDT A was added dropwise to a final 
concentration of 1 mM. The cells were incubated on ice for 20 min with gentle 
agitation. The cell suspension was centrifuged at 4,350 xg for 20 min at 4°C, all the 
supernatant was removed and the pellet was resuspended in the same volume of 
ice-cold 5 mM MgS04• The mixture was stirred for 20 min at 4°C and then 
centrifuged at 4,350 xg for 20 min at 4°C. The supernatant is the osmotic $hock fluid 
containing periplasmic proteins. Protease inhibitor was added to the supernatant (1 
tablet per 500 ml). Tris·Cl (1 M, pH: 7.5) was added to the supernatant to a final 
concentration of20 mM, NaCl to a concentration of200 mM and imidazole (500 mM, 
pH: 7.5) to a concentration of 10 mM, and then 3 ml ofNi Sepharose™ 6 Fast Flow 
slurries were added to 500 ml of the mixture and mixed gently by stirring at 4°C 
overnight. The mixture was loaded onto a column with the bottom outlet capped. The 
bottom cap was removed and the column flow-through was collected. The column 
was washed with 80 ml of 30 mM imidazole in buffer D (20 mM Tris pH: 7.5, 300 
mM NaCl, 20% Glycerol) and 20 ml of 45 mM imidazole in buffer D; wash fractions 
were collected for SDS-PAGE analysis. The protein was eluted 8 times with 1 ml 
elution buffer (500 mM imidazole in buffer D). The eluates were collected and 
analyzed by SDS-PAGE. Figure 5.5 illustrates an SDS-PAGE analysis of VceAp 
purified by this procedure. Detection with Western-blotting confirmed that the major 
band on the SDS-PAGE gel was VceAp-His6. 
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Figure 5.4. Restriction analysis of pBAD/giii-VceAp plasmids. The Sacl/Hind!II 
bounded vceAp gene was ligated into Sacl/Hindl!I digested pBAD/giii vector and 
transformed into TOPlO competent cells. The potential pBAD/giii recombinants were 
analyzed by PCR first, then recombinant plasmids were prepared from PCR positive 
colonies and analyzed using Sac! and Hind!II restriction digestion (37 °C for 3 hours). 
All recombinant plasmids exhibit vceAp inserts. 
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51 kDa 
Figure 5.5. A Coomassie blue stained SDS-PAGE gel showing the purification of 
VceAp protein from the periplasm of E.coli strain TOPlO using the cold osmotic 
shock procedure. The protein was isolated from six liter cultures of 
TOPlO/pBAD/giii-VceAp. The left arrows mark the positions of protein standards; 
the right arrow marks the position of V ceAp protein. 
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Figure 5.6A. An elution profile ofVceAp on a HiLoad 16/60 superdex 200 prep grade 
size-exclusion column. Running buffer: 10 mM Tris, pH: 7 .6, 300 mM KCl. Flow rate: 
1 ml/:min. 
1 2 3 4 5 6 7 8 9 
51 kDa 
Figure 5.6B. Coomassie blue stained SDS-PAGE gel showing VceAp protein polished 
by size-exclusion charomatography. Lane 1-9 correspond to fractions from peak A in 
Figure 5.6A. 
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5.2.3 Purification of V ceAp by gel filtration chromatography 
The V ceAp purified by immobilized Ni2+ absorption chromatography was subjected 
to gel filtration chromatography on a HiLoad 16/60 superdex 200 prep grade column 
run on an AKTA purifier (Amersham Biosciences) automated chromatography system. 
Three ml of proteins were loaded on the column equilibrated with buffer E (1 0 mM 
Tris, pH: 7.6, 300 mM KCl) and eluted at a flow rate of 1 ml/min. One ml fractions 
were collected at the peak area of elution profile shown in Figure 5.6A. Figure 5.6B 
shows the SDS-P AGE analysis of V ceAp corresponding to fractions from peak A on 
the elution profile. The purity of V ceAp polished by gel filtration chromatography 
reached up to 99%, which make it a good candidate for structural and functional 
research. The purified V ceAp was concentrated to 25 mg/ml using Vivaspin 
concentrators with molecular weight cut-off point of 20 kDa MWCO, frozen in liquid 
nitrogen and stored at -80°C. 
5.3 Overexpression and Purification of an ECFP-V ceAp-EYFP fusion protein 
The construct pQE-CApY and E.coli strain M15 (pREP4) were used to overproduce 
an ECFP-VceAp-EYFP (CApY) fusion protein. ECFP (primers: ECFP-F/ECFP-R) 
and EYFP (primers: EYFP-F/EYFP-R) were amplified by PCR from plasmids pECFP 
and pEYFP (Clontech). The resulting ECFP fragment bounded by BamHI and Sac!, 
and the EYFP fragment bounded by Sal! and Hindi!!, were inserted into pQE80L via 
BamHI/Sacl and Sall/Hind!II sites, generating construct pQE-CY. vceAp was 
amplified using primers VceAFNceARI to introduce Sac! and Sal! restriction 
enzyme sites at its two ends and this fragment was inserted into pQE-CY via the Sac! 
and Sal! sites, generating a construct to express a fusion protein with ECFP 
preceeding the N-terminus of VceAp and EYFP following the C-terminus. The 
procedure for purification of VceA (53-406) from strain M15 (pREP4)/pQE30-VceA 
(53-406) was adopted to overexpress and purify CApY. Gel filtration chromatography 
was used to purify CApY. Figure 5.7A shows the elution profile of CApY and the 
154 
SDS-PAGE analysis of CApY fractions corresponding to the peak I of the elution 
profile are shown in Figure 5.7B. 
-('ApYIIOdl:OO~Ibt...dl660~lOOp.ql011 l"\"1 l:IO.I.L\IP 
"'' 
lOO 
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Figure 5.7A. Elution profile ofCApY on a HiLoad 16/60 superdex 200 prep grade gel 
filtration column. Running buffer: 10 rnM Tris, pH: 7.6, 300 rnM KCI. Flow rate: 1 
mVmin. 
190kD~ 
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CApY 
Figure 5.7B. Coomassie blue stained SDS-PAGE gel showing CApY protein polished 
by size-exclusion charomatography. Lane 1-7 correspond to fractions from peak I in 
Figure 5.7A. 
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5.4 Secondary structure prediction of V ceA 
The vceA gene is 1221 bp long encoding a protein of 406 amino acids. We used the 
secondary structure prediction program PSIPRED (McGuffin et al., 2000) 
(http://bioinf.cs.ucl.ac.uk/psipred) to analyze the amino acid sequence of VceA. As 
shown in Figure 5.8, VceA consists of large a-helices sandwiched by ~-sheet 
structures at theN- and C-termini. 
We used the program TMPred (http://www.ch.embnet.org/ software/ TMPRED _ 
form.html) to perform hydropathy analysis of V ceA, which indicated that residues 
33-52 have a higher probability to form a transmembrane helix. 
The program COILS was used to predict the probability ofVceA to form a coiled-coil 
(Lupas et al., 1991). The coiled-coil motif is composed of right-handed a-helices. The 
amino acid residues in the helix show characteristic heptad repeat (abcdefg) n· The 
positions a and d tend to be hydrophobic residues, which form a hydrophobic core 
with the other coil; whilst the positions e and g are predominantly charged residues, 
which form ion pairs with oppositely charged residues on the other coil (Berger et al., 
1995). A schematic diagram of coiled-coil motif is shown in Figure 5.9A (Cohen et 
al., 1990). Figure 5.9B shows the heptad repeat of a coiled-coil in 3D (David Gossard, 
Protein Folding Problem, MIT's OpenCourseWare, 2003 fall). 
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Figure 5.8. The secondary structure prediction ofVceA using the program PSIPRED. 
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Figure 5.9A. Schematic diagram of coiled-coil motif, showing the hydrophobic 
residues at positions a and d and the charged residues at positions e and g (Adapted 
from Cohen et al. , 1990). 
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Figure 5.9B. Heptad repeat of coiled-coil in 3D (Figure adapted from David Gossard, 
Protein Folding Problem, MIT's OpenCourseWare, 2003 fall) . 
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Figure 5.1 0. The probability of forming coiled-coils as a function of residue number 
of V ceA. The graph was generated by the program COILS with a window of 28 
residues. 
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The two long a-helices in the peri plasmic domain of V ceA are of similar length. As 
shown in Figure 5.1 0, these a-helices were predicted by COILS to have a high 
probability of forming a coiled-coil. The MULTI COIL program was used to analyze 
the oligomeric state of these coiled-coils, which indicated a high probability for the 
a-helices to form a dimeric coiled-coil (Wolf et a!., 1997). The prediction results 
indicated that the two long a-helices of V ceA fold back to form a dim eric coiled-coil, 
with a gap of 10 amino acids between them. The dimeric coiled-coil includes a four 
heptad repeat. 
5.5 V ceA is anchored to the inner membrane by a single a-helical domain 
The hydropathy analysis indicated that residuces 33-52 of VceA have a high 
probability of forming a transmembrane helix. To test whether V ceA is anchored to 
the IM via this transmembrane helix, several constructs were made to overexpress the 
whole and truncated V ceA. 
Sub-cellular fractionation of cells expressmg VceA, VceA (12-406) and VceA 
(53-406) indicated that VceA and VceA (12-406) were located in the cellular 
membrane, while VceA (53-406) was located in the soluble cytosol. There is no 
cysteine amongst the N-terminal 52 residues, ruling out the possibility of a lipid 
moiety. All these evidences suggested that V ceA is anchored to the IM via the 
transmembrane helix. 
The amino acid residues that flank a transmembrane domain of a membrane protein, 
especially the positively charged residues, are critical for membrane protein 
biogenesis (Dalbey et al., 2004). Therefore, I did not try to construct a truncated VceA 
so as to locate the precise position ofthe transmembrane helix. 
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5.6 The peri plasmic domain of V ceA forms a trimer 
To gain insight into the oligomeric state of the peri plasmic domain of V ceA, V ceAp 
was expressed and purified from the periplasm of E. coli. 
Analytical gel filtration chromatography was used to determinate the molecular 
weight and Stokes' radius ofVceAp using Superdex 200 PC 3.2/30 column. The Blue 
Dextran 2000 and protein standards of Ribonuclease A, Chymotrypsinogen A, 
Ovalbumin and Albumin were dissolved in running buffer to prepare the calibration 
curve (see Materials and Methods). The VceAp sample was diluted to a concentration 
of 4 mg/ml and applied to the Superdex 200 PC 3.2/30 column equilibrated in running 
buffer F (20 mM Tris, pH: 7.0, 300 mM NaCl). The flow rate was kept a~ 20 !Jllmin. 
Figure 5.11 A shows the elution profile for V ceAp. 
The Microsoft Excel program was used to prepare a standard curve of [-log (kav)] 112 
versa Stokes' radius and calculate the linear regression equation of the curve. The 
same data were used to calculate the molecular mass of V ceAp using the plot of Kav 
versus the logarithm of their molecular weights. Figure 5.11 B and C show the 
standard curves. 
The corresponding Kav of VceAp was calculated to be 0.41. Its Stokes' radius was 
determined from the standard curve to be 40.2 A, and its molecular weight was 
determined to be 96.1 kDa. Considering that the monomeric V ceAp has a molecular 
mass deduce from its amino acid sequence of 37.98 kDa, our findings indicate that 
V ceAp forms a trimer. 
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Figure 5.11A. The elution profile of VceAp on a Superdex 200 PC 3.2/30 
size-exclusion column. Running buffer: 20 mM Tris, pH: 7.0, 300 mM NaCl. Flow 
rate: 20 llllmin. 
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Figure 5.11B. A standard Kav:logMr curve constructed from the elution volumes of 
the Low Molecular Weight Gel Filtration Kit. 
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Figure 5.11 C. A standard [-log (Kav)] 112 :stokes' radius curve constructed from the 
elution volumes of the Low Molecular Weight Gel Filtration Kit. 
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5.7 FRET evidence for the conformational state ofVceAp 
To gain insight into the conformational state of VceAp, I employed a GFP-based 
fluorescence resonance energy transfer (FRET) method. FRET is a radiationless 
transfer of excitation energy from a donor fluorescent molecule to an acceptor by way 
of dipole-dipole interactions during excitation of the donor molecule. It is a 
distance-dependent interaction between the donor and acceptor chromophores. The 
efficiency of energy transfer (E) is proportional to the inverse sixth power of the 
intermolecular separation, as described by the Forster equation: E=Ro6/ (Ro6+ R6), 
where R is the donor-acceptor radius and Ro is the radius at which FRET efficiency is 
50% (Forster radius). FRET typically occurs in the 10-100 A region and small 
changes in R (1-2A) and small orientation changes between the donor aQ.d acceptor 
fluorophores can dramatically affect the efficiency of FRET. This means that FRET is 
a good indicator of close proximity and changes in intermolecular distances (Green et 
a!., 2005). 
The GFP variants ECFP and EYFP were used as the fluorescence protein pairs for 
FRET. The ECFP variant has fluorescence excitation maxima at 433 nm (major peak) 
and 453 nm (minor peak), and the emission maxima at 475 nm with a small shoulder 
at 501 nm; the EYFP variant has fluorescence excitation maxima at 513 nm, it also 
can be efficiently excited at 488 nm, and its emission maxima is at 527 nm. These 
protein pairs have excitation and emission properties favorable for FRET (Clontech). 
Fig5.12A and B show the emission spectra ofECFP and EYFP. 
A spectrofluorometer based method was adopted to detect FRET (Zheng eta!., 2004). 
The experiments were performed in buffer G (20 mM Tris, pH 7.5, 150 mM NaCl) at 
room temperature. The fluorescence spectra were recorded on a JASCO FP-750 
spectrofluorometer using a 10 mm path-length quartz cuvette. The excitation and 
emission band widths were set up to 5 nm. The fluorescence emissions for ECFP and 
CApY were monitored between 450 and 550 nm with excitation at 433 nm; whilst the 
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fluorescence ermsswn for EYFP was monitored between 510 and 560 nm with 
excitation at 500 nm. By exciting at 433 nm, the emission spectrum of CAp Y showed 
two peaks at 475 nm and 527 nm, respectively. Figure 5.12C shows the emission 
spectrum of CApY protein excited at 433 nm; Figure 5.12D shows the 
superimposition of the emission spectra of ECFP and CAp Y proteins excited at 433 
nm. It is obvious that the peak at 475 nm corresponds to ECFP and the peak at 527 
nm arises mainly from EYFP. The result indicated that strong FRET between ECFP 
and EYFP existed without substrate induction, suggesting that the N-terminus of 
V ceAp is in close proximity to its C-terminus. 
I tried to determine the drug-induced FRET change of CAp Y. The fusion protein 
CAp Y assumed strong FRET, but substrates induced no change in FRET. ( 
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Figure 5.12. (A) Emission spectrum of ECFP (excitation at 433 nm). (B) Emission 
spectrum of EYFP (excitation at 500 nm). (C) Emission spectrum of CApY 
(excitation at 433 nm). (D) A superimposition of emission spectra of ECFP and 
CApY(excitation at 433 nm). 
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5.8 Discussion 
Structural information on membrane fusion proteins is essential to understand their 
functional role in the tripartite transporters. In this study we provide an initial 
structural characterisation of V ceA, the MFP of the tripartite multidrug extrusion 
pump VceCAB. 
Sub-cellular localization of the whole and truncated V ceA indicated that V ceA is 
anchored to the inner membrane by residues 1-52, consistent with the prediction that 
residues 33-52 form a transmembrane a-helix. As the amino acid residues flank a 
transmembrane helix, especially the positively charged residues, are critical for 
membrane protein biogenesis (Dalbey et al., 2004), I did not try to ~onstruct a 
truncated V ceA in order to locate the precise position of the transmembrane helix. 
Two models of MFP function have been proposed (Figure 5.13). In the first model, 
the MFP is presumed to fold upon itself using its coiled-coil domain to allow a 
transient interaction between the IMP and OMP for substrate transfer, with the 
N-terminus anchored in the inner membrane and C-terminus interacting with the OMP 
or outer membrane. In the second model, the MFP is supposed to form a channel 
between the IMP and OMP, allowing direct transfer of the drug (Johnson et al., 1999; 
Elkins et al., 2003). I used the FRET method to test which of these hypothetical 
models is reasonable. I fused the ECFP and EYFP to the two termini of the 
peri plasmic domain V ceAp. Strong FRET between ECFP and EYFP existed without 
substrate induction, indicating that theN-terminus of VceAp is in close proximity to 
its C-terminus. FRET evidence does not support the first model of MFP function 
which requires the MFP to span the periplasm in the inactive complex so that its N-
and C-terminus are not in close proximity. The crystal structures of AcrA and MexA 
have been solved recently, which provide structural evidence that MFP form a channel 
between the IMP and OMP. 
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Figure 5.13. Schematic representation of two models of the MFP function. (A) 
The MFP is postulated to fold upon itself using its coiled-coil domain, allowing a 
transient interaction between IMP and OMP for substrate transfer. (B) The MFP 
is supposed to form a channel between IMP and OMP, allowing direct transfer of 
the drug (Adapted from Elkins et al., 2003). 
167 
EmrA has been reported to bind drug molecules directly (Borges-Walmsley et al., 
2003). FRET can detect small changes in distance (1-2A) and orientation between the 
donor and acceptor fluorophores. I adopted this method to determine if V ceA also 
binds drug molecules using ECFP and EYFP as donor and acceptor fluorophores. The 
fusion protein CAp Y assumed strong FRET, but substrates induced no change in 
FRET. The CAp Y monomer has a similar molecular weight with the V ceAp trimer, 
and ran on the gel filtration column with similar elution volumes (Figure 5.6A, Figure 
5. 7), indicating that CAp Y is a monomer. It is likely that the oligomeric interfaces of 
V ceAp were destabilized by the fusion of the GFP variants, which may account for 
the inability ofVceAp to interact with drugs. 
The peri plasmic domain of MFP expressed in the cytoplasm can exist as 'l monomer, 
dimer and trimer (Borges-Walmsley et al., 2003). I expressed V ceAp in the peri plasm 
to test its oligomeric state. By using analytical gel filtration chromatography, the 
molecular mass of V ceAp was calculated to be 96.1 kDa. Considering that the 
monomeric V ceAp has a molecular mass deduce from its amino acid sequence of 
37.98 kDa, my findings indicate that VceAp forms a trimer. Cross-linking of in vivo 
complexes using the short-arm chemical cross-linker DSG has identified MFP trimers 
in both drug efflux and protein export tripartite system (Thanabalu et al., 1998; 
Zgurskaya et al., 2000). By using a blue native PAGE method, several MFP were also 
identified to be homo-trimers (Stenberg et al., 2005). These findings suggest that 
trimeric MFP is its oligomeric state in the tripartite pump, which support the structural 
model for tripartite multidrug efflux pumps proposed by Fernandez-Recio et al 
(2004). 
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Chapter 6 
Crystallographic analysis of the RND family multidrug transporter MtrD from 
Neisseria gonorrhoeae 
The mtr (multiple transferable resistance) operon of Neisseria gonorrhoeae encodes 
an energy-dependent tripartite efflux pump, which is composed of the membrane 
fusion protein MtrC, the inner membrane protein MtrD and the outer membrane 
protein MtrE. Expression of the mtrCDE operon is negatively regulated by the 
product of the mtrR gene, which is divergently transcribed (Hagman et al., 1995). The 
inner membrane component, MtrD, belongs to the RND family transporter (Hagman 
et al., 1997). The MtrC/MtrD/MtrE efflux pump confers broad-spectrum rfsistance to 
hydrophobic antibiotics, dyes and detergents similar to that of the MexA!MexB/OprM 
efflux pump of P aeruginosa and AcrA/AcrB/TolC efflux pump of E.coli. Besides, 
the MtrC/MtrD/MtrE pump also exports cationic antimicrobial peptides (CAMPs), 
such as PG-1 and LL-37 (Shafer et al., 1998). 
Multiple alignments of amino acid sequences from multidrug transporters of the RND 
family have identified four strongly conserved motifs: motifs A, B, C and D (Figure 
6.1. Putman et a!., 2000). The conservation of these motifs suggests that they play an 
important structural or functional role in the transporters. MtrD is an exception, which 
contains motif A only (Paulsen et al., 1996). Phylogenetic analysis revealed that the 
majority of RND family multidrug efflux proteins fall within a single closely related 
cluster, with only MtrD being somehow divergent (Paulsen et al., 1996). It is likely 
that there are structural and/or functional differences between MtrD and other RND 
family transporter, such as AcrB, MexB and AcrD. 
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Figure 6.1. Schematic two-dimensional representation of a typical member of the 
RND family transporters in the cytoplasmic membrane (gray). The locations of the 
conserved motifs A, B, C, and D are highlighted in black (Putman eta!. , 2000). 
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The detennination of the structure of AcrB may represent the most significant 
advances on the understanding of drug efflux pumps in recent years. The knowledge 
of the difference between MtrD and AcrB will be critical for understanding the 
mechanism of these family transporters. In this chapter, I report the successful 
overexpression, purification and crystallization of MtrD, and the optimisation of 
resolution of MtrD crystals to 7-1 0 A. 
6.1 Overexpression and purification of MtrD 
6.1.1 Recombinant expression of MtrD 
The pET21a vector was used to make a recombinant expression constructJ>ET-MtrD. 
The mtrD gene (bounded by Nde! and Xho!) was inserted into pET21a, resulting in a 
construct which expresses the mtrD gene with a C-terminal hexahistidine tag. The 
pET-MtrD construct was transformed into the E. coli strain C43 (DE3). 
A single C43 (DE3)/pET-MtrD colony from a freshly streaked plate was picked and 
inoculated into a 25ml universal container containing 10 ml of 2xYT broth and 
Carbenicillin (1 OOJ.!g/ml). The cells were grown in an orbital shaker at 37°C, 220 rpm. 
overnight. 1 liter ofprewarmed 2xYT broth (with antibiotic) in a 2 liter baffled flask 
was inoculated with 2 ml of the overnight culture. The cells were grown in an orbital 
shaker at 37°C, 220 rpm, and their growth was monitored by measuring the 
absorbance ofthe culture at 600 nm (A600). 
The cells were induced at mid log phase (approx. A6oo=0.5-0.6) with 0.5mM IPTG. 
The temperature was dropped to 25°C and growth was continued with shaking at 200 
r.p.m. for 4-5 hours. The cells were harvested by centrifugation at 4,350 xg for 8 min 
at 4 °C, resuspended in buffer A (20mM Tris pH: 7.0, 20% Glycerol, 5 U/ml DNase I, 
1 tablet /100ml EDTA-free protease inhibitor mixture tablet) and stored at -80°C or 
purification continued. 
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6.1.2 Purification of the His-tagged MtrD using Ni2+ affinity chromatography 
Purification of MtrD by Ni2+ affinity chromatography was performed using a HiTrap 
Chelating HP 1 ml column. 
The cells were lysed by three passages through a Constant Cell Disruptor System and 
the cell debris was removed by centrifugation at 24,000 xg for 30 min at 4 °C. The 
supernatant, containing soluble proteins and membrane vesicles, was carefully 
decanted so as not to disturb the pelleted material. The supernatant was further 
fractionated into membrane and soluble components by high-speed ultracentrifugation 
at 122,400 xg for 90 min at 4°C. 
The membrane pellet was emulsified in a small volume of buffer B (20mM Tris pH: 
7.0, 20% Glycerol, 0.5mM THP) by repeated passage through a syringe needle. The 
emulsified membrane was then diluted by buffer B to a final concentration of about 
10 mg/ml of total protein. Imidazole (5 M, pH: 7.0) was added to the emulsified 
membrane to a final concentration of 15mM, NaCl was added to 1 OOmM, and the pH 
of the mixture was adjusted to 7.0 using 50 mM NaOH. A detergent powder of the 
n-Dodecyl-13-D-maltoside (DDM) was added to the emulsified membrane to a final 
concentration of 2% to solubilise the membrane. The mixture was gently stirred at 4 
oc for 45 min and then ultracentrifuged at 122,400 xg for 1 hour at 4 °C. The 
membrane solution was carefully decanted so as not to disturb the pelleted material. 
Extracted histidine-tagged MtrD was purified using a HiTrap chelating HP 1 ml 
column immobilized with Ni2+ equilibrated with buffer C (20 mM Tris pH: 7.0, 20% 
Glycerol, 0.2% DDM). The membrane solution was loaded onto the column using a 
peristaltic pump at a speed of 0.8 ml/min. The column was washed with 10 ml of 50 
mM imidazole in buffer C, and then with 20 ml of 1 OOmM imidazole in buffer D (20 
mM Tris pH: 7.5, 300 mM NaCI, 20% Glycerol, 0.2% DDM). The MtrD was eluted 
from the column with 400 mM imidazole in buffer D. The eluates were collected at 
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0.5 ml fractions and analyzed by SDS-PAGE. MtrD is composed of 1068 amino acids 
and the predicted molecular weight is about 114 kDa. Figure 6.2 illustrates an 
SDS-PAGE analysis of the MtrD. 
191 kDa _____. 
64kDa 
51 kDa 
El E2 E3 E4 E5 E6 E7 
Figure 6.2. Coomassie blue stained SDS-PAGE gel showing IMAC purification of 
MtrD-His6 protein from DDM solubilised membranes. Lane El-E7 show elution 
fractions (0.5 x7 ml) with buffer containing 400 mM imidazole. The left arrows mark 
the positions of protein standards; the right arrow marks the position of MtrD-His6 
protein. 
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6.1.3 Protein buffer exchange and concentration 
The purity of the MtrD protein purified by Ni2+ affinity chromatography is about 98% 
of total proteins, as indicated by the SDS-PAGE analysis in Figure 6.2. Buffer 
exchange ofMtrD into buffer E (10 mM Tris, pH: 7.5, 50 mM NaCl, 10% Glycerol, 
0.1% DDM) was carried out on a HiTrap Desalting column. The protein was then 
concentrated using a RESOURCE Q 6 ml anion exchange chromatography column. 
The column was washed with 5 column volumes (CV) of distilled water and 5 CV of 
buffer F (10 mM Tris-HCl,pH: 7.5, 500 mM NaCl, 10% Glycerol, 0.1% DDM), then 
equilibrated with 5 CV of buffer E. 
The eluate from the HiTrap Desalting column was loaded onto the RESpURCE Q 
column equilibrated with buffer E at a flow rate of 2 mllmin. The column was washed 
with 2 CV of the same buffer, and then eluted in 0.5 ml fractions with 400 mM NaCl 
in buffer E at a flow rate of 1 ml/min. During this step the MtrD protein was 
concentrated to 2-3 mg/ml. Figure 6.3 shows the SDS-P AGE analysis of MtrD 
concentrated by ion exchange chromatography. 
The buffer of MtrD was exchanged again into buffer G (10 mM Tris-HCl, pH: 7.5, 
100 mM NaCl, 10% Glycerol, 0.1% DDM) using the Hi Trap Desalting column, and 
the eluate was dialyzed against buffer G using a Slide-A-Lyzer 10 kDa MWCO 
Dialysis Cassettes at 4°C for 3-4 hours. The MtrD protein was then concentrated to 
25-30 mg/ml using VIVASPIN Concentrators with 100 kDa MWCO. The protein was 
used to set up crystallization trials or frozen in liquid nitrogen and stored at -80°C. 
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191 kDa---+ 
64kDa 
51 kDa 
Figure 6.3. The SDS-PAGE analysis of MtrD concentrated by amon exchange 
chromatography. 
6.2 Crystallization and data collection 
MtrD purified in DDM was subjected to crystallization screens using the membrane 
protein crystal growth screens kits MbClass and MbClass II Suites (Nextal 
Biotechnologies). Crystallization trials were set up using the hanging drop vapour 
diffusion and sitting drop vapour diffusion methods. 
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Initially, I directly concentrated MtrD to 10-1 OOx times usmg the Vivaspin 
Concentrators with 100 kDa MWCO. The DDM micellar aggregations appeared in 
some of the crystallization drops, indicative of a high DDM concentration (Figure 6.4 ). 
The DDM may have been concentrated because of its large micelle size, which may 
result in the inability to crystallize the protein. Then I changed strategy to concentrate 
the protein with two steps: the MtrD protein was concentrated to 2-3 mg/ml using an 
anion exchange chromatography column, then it was farther concentrated to lOx 
times using the Vivaspin Concentrators with 100 kDa MWCO, and we obtained MtrD 
crystals. 
Crystals were obtained from the hanging drop vapour diffusion method by mixing 1 
Jll of protein sample on a silinated Crystallization Support (Nextal Biotefhnologies) 
with 1 Jll of a reservoir solution buffer H (30% PEG 400 v/v, 100 mM MES pH 6.5). 
The Crystallization Support was sealed on a well of the Crystallization Tool (Nextal 
Biotechnologies) containing 1.0 ml of the same reservoir solution and equilibrated at 
18°C. Crystals appeared after two weeks with initial MtrD crystals growing as 
rectangular rods, finally reaching a size of O.lx0.05x0.05 mm3 after one month 
(Figure 6.5a). The crystals diffracted X-rays to 15-20 A. However, this crystallization 
condition was less reproducible. The additives were screened using the Additive 
Screen™ Kits (Hampton Research). Improvements in the reproducibility were made 
with several additives. The addition of 1, 6-Hexanediol (3%), Jeffamine M-600 (5%, 
pH: 7.0), Heptane-1,2,3-triol (1.5%) and Polypropylene Glycol P400 (4%) in the 
drops improved the reproducibility of crystallization condition, but the crystals grew 
as needles, thin sheets or microcrystals (Figure 6.5b ). 
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Figure 6.4. The DDM micellar aggregations with birefringence resembling crystalline 
birefringence. 
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Figure 6.5a. A picture of the MtrD crystals. The reservoir solution contained 30% 
PEG 400 v/v, 100 mM MES pH 6.5. The bar represents about 0.1 mm. 
Figure 6.5b. A picture of the MtrD crystals. The reservoir solution contained 30% 
PEG 550 MME v/v, 100 rnM HEPES pH 7.5 . The bar represents about 0.1 mm. 
Figure 6.5c. A picture of the MtrD crystals. The reservoir solution contained 30% 
PEG 400 v/v, 100 mM MES pH 6.5. The ratio ofMtrD/reservoir solution/CYMAL-6 
in the drop is 1:1:1. The bar represents about 0.4 mm. 
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The crystallization conditions were optimized with a series of screens that consisted 
of PEG or its MME derivative as the precipitant: PEG 400, PEG 550MME, PEG 1500, 
PEG 2000MME or PEG 4000 and pH from 6.5 to 8.0 at 0.5 unit increments. The 
precipitant concentrations in the PEG/pH screening kits ranged from 10% to 30% for 
PEG 400, PEG 550MME, PEG 1500 and PEG 2000MME in steps of 5%, and 4% to 
12% for PEG 4000 in steps of 2%. The crystals were obtained using PEG 550 MME 
(30% PEG 550 MME, 100mM HEPES pH 7.5) and PEG 4000 (6% PEG 4000, 
100mM HEPES pH 7.5) as precipitants. The crystals also grew as needles and thin 
sheets (Figure 6.5b). 
Several detergents, such as cyclohexyl-n-hexyl-~-D-maltoside (CYMAL-6), 
n-decanoylsucrose, n-nonyl-~-D-thiomaltoside or n-octyl-~-D-thiomaltoside (at 
l 
1.9mM , 8.3mM, 10.7mM and 30mM final concentration, respectively), were also 
tested in the crystallization trials to improve the diffraction quality of the crystals. The 
best results were obtained by the hanging drop vapour diffusion method under the 
following condition: a droplet made of 1 ~I of protein solution, 1 ~I reservoir solution 
and 1 ~1 ofCYMAL-6 (5.6mM) was equilibrated against a reservoir solution buffer H. 
Crystals appeared after 7-10 days and reached their final size of 0.4x0.15x0.15 mm3 
after three weeks (Figure 6.5c). The crystals diffracted X-rays up to 7-10 A. 
The MtrD crystals were soaked in cryo-protectant buffer (30% PEG 400 v/v, 1 OOmM 
MES pH 6.5, 1 OOmM NaCI, 10% Glycerol v/v, 0.1% DDM) for about one minute and 
frozen in liquid nitrogen. The diffraction data of MtrD crystals were collected by Dr. 
Rick Lewis at the ID14-4 beamline ofESRF synchrotron source (Grenoble). 
6.3 Discussion 
Membrane protein crystallography is still a challenge. To date, over 30,000 soluble 
protein structures have been determined; however, about 100 membrane protein 
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structures have been solved. 
The integral membrane proteins are extracted from lipid bilayers using detergents. 
Above the critical micelles concentration (CMC), detergent monomers aggregate to 
form micelles, into which membrane proteins can insert. Lipids typically co-purify 
with membrane proteins, with complete delipidation of membrane proteins often 
causing denaturation and aggregation. Therefore, membrane proteins are solubilised 
in aqueous solution in the form of a protein/detergent/lipid complex. 
It is critical for a membrane protein to crystallize that it is in a homogeneous state. 
Lipids can stabilize the membrane protein during purification; however, it results in 
the heterogeneity of the protein-lipid complex (Wang et al., 2003; Lemieux et al., 
! 
2003). The degrees of delipidation of membrane proteins are different after each 
chromatography purification step. Membrane proteins are usually purified by less 
than two chromatography steps. Purification with a third chromatography step may 
result in protein aggregation due to complete delipidation, especially for polytopic 
membrane proteins (Boulter et al., 2001; Lemieux et al., 2002). 
Initially, we developed a procedure to purify MtrD by two chromatography steps: a 
Ni2+ affinity chromatography step followed by an anion exchange chromatography 
step. The protein was stable and the purity was over 99% of the total protein, but it 
could not be crystallized. We therefore developed a procedure of one step purification 
of the protein by Ni2+ affinity chromatography. The protein purity was less then that 
purified by the two chromatography steps, but it was crystallized easily. It is likely 
that the number of phospholipids molecules co-purified with MtrD is critical for its 
crystallization. 
The presence of unbound detergent in solution is another source of the heterogeneity 
of membrane protein, when in excess, it may prevent proper packing of 
protein-detergent micelles in the crystal lattice (Scarborough, 1994; Wang et al., 2003; 
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Lemieux et al., 2003). We adopted the Vivaspin Concentrators with 100 kDa MWCO 
to one step concentrate MtrD. Because of the large micelles size, DDM may have 
been concentrated simultaneously. The DDM micellar aggregation appeared in some 
of the crystallization drops, resulting in the inability to obtain MtrD crystals. We 
therefore adopted two steps to concentrate MtrD: first, MtrD was concentrated to 2-3 
mg/ml by anion exchange chromatography, and then further concentrated to 25-30 
mg/ml using the Vivaspin Concentrators. No DDM micellar aggregation appeared 
under the same conditions and we obtained MtrD crystals (Scarborough, 1994). The 
reproducibility of the crystallization trials was greatly improved by the addition of 
Heptane-!, 2, 3-triol in the drops, which may be because Heptane-!, 2, 3-triol reduces 
the size of detergent micelles so that improves the packing of protein-detergent 
micelles into the crystal lattice. 
The mixture of DDM and CYMAL-6 in the crystallization drops improved the 
resolution of the MtrD crystals to 7-10 A. The mixture of detergent improved the 
crystal packing, which presumably was due to the more favourable packing or newly 
exposed protein surface areas for crystal contacts (Koronakis et al., 2000; Huang et al., 
2003; Wang et al., 2003). 
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Chapter 7 
Final Discussion 
Inbacteria, multidrug efflux systems have been identified as significant determinants 
of resistance. These resistance pumps are widely distributed in bacterial species and 
many pathogenic bacteria possess them, which play an important role in their intrinsic 
and acquired multidrug resistances (Poole, 2004 ). The RND and MATE family 
transporters have also been shown to be involved in the pathogenicity of bacteria 
(Piddock et al., 2006). Knowledge of the structure and mechanism of these transporter 
proteins would be exceedingly useful in the design of inhibitors. In recent years, the 
structural determination of several multidrug efflux pumps and their regulators, such 
as AcrB, EmrD, Sav1866, TalC, MexA, AcrA and QacR, etc., probably represent the 
most significant progress in understanding the structural basis of mutidrug resistance 
in bacteria (See Chapter I). 
To investigate the role of the V ceCAB pump in the multidrug resistance of Vibrio 
cholerae, I have characterized functionally and structurally the three components of 
the V ceCAB pump and the regulator protein V ceR. 
The crystal structure of V ceC, the outer membrane component of the V ceCAB pump, 
was determined at 1.8 A resolution. V ceC shares the same overall architecture as TalC 
and OprM (Koronakis et al., 2000; Akama eta!., 2004), consisting of three domains: 
the ~-domain, the a-domain and the equatorial domain, despite the very low degree of 
sequence identity between them (8.3%). The conserved residues of the three proteins 
are mainly hydrophobic and are likely to play a structural rather than a functional role. 
The residues that maintain the closed state of the channel of TolC and V ceC are 
completely different. In TolC, the intra-monomer hydrogen bonds between residues 
Asp 153-Try382 and Gln136-Glu359, as well as the inter-monomer salt bridge interaction 
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between Asp153 of a monomer and Arg367 of the adjacent one, are shown to stabilize 
the closed state (Andersen et al., 2002); while V ceC is likely stabilized in its closed 
conformation by the inter-monomer hydrogen bonds between residues 
Gln236-Ser449and Ser243-Gln453 , as well as an intra-monomer hydrogen bond between 
residues Tyr433 -Glu229 and an intra-monomer salt bridge interaction between 
Arg455 -Glu247 . It seems that different members of these family proteins reach their 
close conformation through different subsets of interactions. 
The channel interiors of V ceC, TolC and OprM are generally electronegative 
(Koronakis et al., 2000; Akama et al., 2004). In addition, VceC contains two rings of 
clusters of negative charge. The ring made by residues Glu397 and Glu303 is conserved 
in OprM, but is not present in TolC. The VceCAB pump partly loses it activity when 
I, 
these two residues of V ceC were replaced with alanine, indicating their functional role 
during transport. However, it will be necessary to rule out the possibility that the 
mutations of these residues lower the expression level of V ceC so affecting the 
function ofthe VceCAB pump. 
In the resting state of the proteins, the a-barrel of V ceC, TolC and OprM at the 
peri plasmic ends are all closed; the ~-barrel region of V ceC and OprM are also closed, 
whereas the ~-barrel region of TolC is widely open to the extracellular medium. 
Obviously, both ends of V ceC and OprM need to be opened during transport. The 
interaction of the OMP with its partner IMP and MFP could induce opening of the 
a-barrel closures. The opening mechanism ofthe ~-barrel closure is not clear yet. It is 
noticed that the intrinsic multidrug resistance of P. aeruginosa is compromised in a 
tonE deletion strain and that the operation ofMexAB-OprM is facilitated by the TonB 
protein (Zhao et al., 1998). It is likely that drug efflux via these pumps require a TonB 
or a TonB-like protein for the operation of the outer membrane components, which 
may facilitate the opening of the ~-barrel closures ofVceC and OprM. 
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The optimal desolvation area (ODA) on the surface ofVceC was calculated, which is 
different from that of TolC (Federici et al., 2005), indicating distinct architectures of 
VceC-based and TolC-based tripartite pumps. TolC is the outer membrane component 
of different tripartite pumps in E. coli, such as EmrAB-TolC, AcrAB-TolC, 
MacAB-TolC and HlyDB-TolC systems. The genes encoding TolC and other 
components are not present in the same operons. The inner membrane component 
EmrB is a MF family transporter which functions as a monomer (Lomovskaya et al., 
1992); AcrB belongs to the RND family transporter that functions ·as trimer 
(Murakami et al., 2002); while MacB and HlyB belong to ABC family transporters 
which function as dimers (Thanabalu et al., 1998; Kobayashi et al., 2003). AcrB and 
MacB have an extensive periplasmic domain, whereas EmrB and HlyB lack it. These 
pumps must have a different organization and use different types of protein-to-protein 
~ 
interactions in the tripartite pumps, and the surface of TolC must match these distinct 
architectures. The genes encoding V ceR, V ceC, V ceA and V ceB are present in the 
same vee operon, indicating that V ceC is the outer membrane component of the 
V ceCAB system only. This might explain the difference in ODAs between V ceC and 
TolC. 
MFPs are anchored to the inner membrane by a single transmembrane helix, or via 
fatty acids attached to its N-terminal cysteine residue (Borges-Walmsley eta/., 2003; 
Yoneyama et al., 2000). The function of the MFP is determined mainly· by the 
periplasmic domain (Yoneyama et al., 2000). Sub-cellular fractionation of cells 
expressing full length and truncated V ceA suggested that V ceA is anchored to the IM 
via a transmembrane helix. I expressed the peri plasmic domain of V ceA (V ceAp) in 
the periplasm of E.coli. Analytical gel filtration chromatography experiments 
indicated that V ceAp is a trimer, which could represent its oligomeric state in the 
VceCAB pump, and thus the VceC:VceA:VceB ratio in the assembled tripartite pump 
could be 3:3:1. 
The crystal structures of the IMP-MFP-OMP complex or the complex of either of the 
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two components will be important to understand the molecular mechanism of these 
pumps. The fact that the three components of tripartite pumps are easy to dissociate in 
vitro, make it difficult to co-crystallize them. I tried to overproduce and crystallize 
V ceB-V ceA and V ceC-V ceA fusion proteins. The V ceB-V ceA fusion protein was 
successfully overexpressed. It is still necessary to determine if this fusion protein 
functions as wild type V ceB and V ceA. I tried to express a fusion of the peri plasmic 
domain of V ceA to the C-terminus of V ceC, but I failed to produce this fusion protein 
(data not shown). Some amino acid residues at the C-terminus of bacterial outer 
membrane proteins, such as phenylalanine, have been shown to have important roles 
in protein folding, oligomerization and outer membrane incorporation (de Cock et al., 
1997). This may also be the case for VceC. The fusion ofVceA to the C-terminus of 
V ceC could impair the efficient and correct assembly of V ceC into
1 
the outer 
membrane, resulting in failure to overproduce it. 
Analytical gel filtration and DLS experiments indicated that the basic functional unit 
ofVceR is a dimer. Stopped-flow fluoresce spectroscopy experiment revealed that the 
binding of CCCP to V ceR occurs with a Hill coefficient of about four 
(Borges-Walmsley et al., 2005). These evidences suggested that four CCCP molecules 
bind to dim eric V ceR, and thus each V ceR subunit binds at least two CCCP 
molecules. The basic functional unit of QacR is also a dimer. In QacR, each subunit 
can bind two different drug molecules, but it binds only one molecule of the same 
drug. Moreover, the binding of drug to QacR induces a coil-to-helix transition, which 
shift the position of the C-terminus of that subunit such that it blocks the entrance of 
the second drug-binding pocket within the same dimer (Schumacher et a!., 2001; 
Grkovic et al., 2002; Schumacher et al., 2004). Therefore, only one QacR subunit in 
the dimeric QacR binds drug. Another TetR/CamR family transcriptional regulator, 
TetR, was shown to bind two tetracycline molecules per dimer (Hinrichs eta!., 1994). 
The stoichiometry of drugNceR-subunit is different from that of other transcriptional 
regulators in the 'TetR/CamR family. 
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Multiple alignments and phylogenetic analysis of the amino acid sequences of RND 
family transporters reveal that there are differences between MtrD and other RND 
family multidrug efflux pumps. Knowledge of these differences will be important for 
understanding the mechanism of this family of transporters. In this study, we have 
successfully overexpressed, purified and crystallized MtrD. The resolution of MtrD 
crystals was optimised to 7-10 A at present. Different conditions, such as salts, 
temperatures, additives, precipitates, and detergents, still require optimisation in order 
to improve the crystal packing. 
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Appendix B: 
DNA and amino acid sequences of V ceCAB pump of Vibrio cholerae vaccine 
strain CVD101 
1. DNA sequence of V ceC 
ATGAAAAATAGCGTTCAAACGGTAGGTTTGTTGCATAAAGCAGCGCCTTATTTTACG 
GCTTCTCTATTGAGTGCTTTCGTTTTAACGGGTTGCTCAGTACCCGATCATTACCCT 
GATCTTGCGACGATGTGGGAAGCGAATGAGCTTAGCTCGACAAACACATTTTCTCAC 
CAAGCTGAAATGGACTGGCCATCAGTGAATTGGTGGCAACGCTATCAAGATGCACAA 
TTAAACCATCTGATTGAGGAAGCGTTGCAGCACTCACCATCGTTAGAGATGGCAATG 
GCTCGGCTTAAAGGGGCACAAGGTTTTGCTCGTCAAGCAGGCGCAATTCGATCATTT 
GATCTCGGGTTAGCGGCATCCGCCACGGAAAGTAAAGTCAGTGAACGTTATCAATCT 
GCTACGCCTCCCGATGGTTGGAATGACTATGGCACTCTAACCTTGAATTT~CAGTAT 
GACTTTGACTTTTGGGGAAAAAATCGCGCAGCGGTTGTTGCGGCGACTTCCGAGCTT 
GCTGCCGCTGAGGCAGAGAGTGTGGCTGCGCGTTTGATGATCAGCACATCGATTGCT 
AATGCTTATGCCGAATTAGCTCGTCTTTATGCCAATCAAGAGACCGTGCATGCCGCG 
CTACAAGTGCGCAACAAAACCGTTGAGCTTTTAGAAAAACGTTATGCCAATGGCTTA 
GAAACGCTAGGTTCTGTCAGCCAAGCGAAAGCGGTTGCTGCGAGTGTGGAAGCGGAG 
TTGCTTGGTATTCAAGAATCGATCCAATTACAGAAAAATGCTTTGGCCGCTTTGGTG 
GGGCAAGGGCCTGATCGCGCTGCATCGATTGAAGAACCCCATATCACCTTGACCTCT 
CGTTATGGCTTGCCGTCGGAGGCTGGCGTTGGATTACTGGGGCATCGTGCTGATATC 
ACCGCTGCGCGTTGGCGGGCAGAAGCCGCAGCACAGCAAGTCGGTATTGCGCAAGCA 
CAATTCTATCCAGATGTCACTTTGTCAGCGTTTATTGGTTATCAGGCATTTGGTCTG 
GATCATTTGTTTGATAGTGGTAATGACGCAGGTGCAATTGGGCCTGCGATCTACTTA 
CCACTATTTACGGGTGGGCGTTTAGAGGGGCAGTTGACTTCGGCAGAAGCTCGTTAC 
CAAGAAGCGGTCGCTCAATACAATGGCACGTTAGTGCAAGCCTTGCATGAAATCGCC 
GATGTGGTGACCAGTAGCCAAGCTCTGCAAGCGCGAATTAATAAAACCGAACAAGCC 
GTACAGCAAGCTGAACAAGCACTGCATATCGCGACGAACCGTTATCAAGGCGGTTTA 
GCCACCTATCTCGATGTTTTGGTAGCTGAAGAGTCTTTACTCAATAACCAAAGAGCA 
TTGGTCAATTTGCAGTCACGCGCTTTTAGTTTAGATCTTGCGCTGATCCATGCGCTA 
GGCGGCGGTTTTGAAACAACAGAATCTTAA 
2. Amino acid sequence of V ceC 
MKNSVQTVGLLHKAAPYFTASLLSAFVLTGCSVPDHYPDLATMWEANELSSTNTFSH 
QAEMDWPSVNWWQRYQDAQLNHLIEEALQHSPSLEMAMARLKGAQGFARQAGAIRSF 
DLGLAASATESKVSERYQSATPPDGWNDYGTLTLNFQYDFDFWGKNRAAVVAATSEL 
AAAEAESVAARLMISTSIANAYAELARLYANQETVHAALQVRNKTVELLEKRYANGL 
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ETLGSVSQAKAVAASVEAELLGIQESIQLQKNALAALVGQGPDRAASIEEPHITLTS 
RYGLPSEAGVGLLGHRADITAARWRAEAAAQQVGIAQAQFYPDVTLSAFIGYQAFGL 
DHLFDSGNDAGAIGPAIYLPLFTGGRLEGQLTSAEARYQEAVAQYNGTLVQALHEIA 
DVVTSSQALQARINKTEQAVQQAEQALHIATNRYQGGLATYLDVLVAEESLLNNQRA 
LVNLQSRAFSLDLALIHALGGGFETTES 
3. DNA sequence ofVceA 
TTGAAACAACAGAATCTTAATAGGTTATCTTCAATGAATTCAAATAATAGCAACACC 
GAATTTGATGGTGTACGCGCAGCTCAATCGCGTAAAAAAGGGTTTCTCGGATTAGCG 
GCCGCAATTGTGGTTGCCGGAGGGAGTTATGCACTCTATTGGCACTTTATCGGTTCA 
CGCTACATTTCCACCGACAACGCTTATGCTGCGGCGGAAATCGCCGAAGTCACGCCG 
GCCGTGGGCGGGATTATCGCGCAAGTGAATGTAGTGGATACCGAGTACGTCAAACAA 
GGCGACGTACTTGTACAGCTGGATGATACCGATGCGAGATTAGCTTTGCTTCAAGCT 
GAGGCGGATTTGGCACTCGCAAAACGCCGTGTACGTAGCTATCTCGCTAATGACGAA 
GGTTTAAGTGCTATGGTGGAAGCACAAGAAGCCAATGAGCAGCGTGTGAAAGCGCAG 
TTAAAAGCGGCGCAAGCGGACTTTGAACGAGCAAAAATCGATTTATCTCG1CGGGAA 
GACTTAGTGCGTTCCGGCTCCGTTTCTGGTGAAGAGCTGACGAATGCCAAAACCGGT 
TTTGCGCAGGCACAAGCAAACCTTAACGCGGCAAAAGCGGCTATGGCGCAAGCACAG 
GCAACTAAGCTCTCGACCATTGGCTCACAAAAAGCTAATGCAGCGTTGACCGATAAC 
ACGACCGTCGATAGCAACCCTGAAGTCTTACTGGCAAAAGCGCGTTATGAACAAGCG 
AAAATCGATCTCGAGCGTACGGTGATTCGTGCGCCGATCAGTGGAATCGTCGCTAAA 
CGCCAAGTACAAGTTGGGCGTCGTGTACAGGTGGGGATGCCTTTAATGACCGTGGTG 
CCTACTGACCATATTTATGCCGATGCCAATTTTAAAGAAGTGGAATTGCGCGATGTG 
AAAGTTGGACAACCCGTTACCTTAACGGCAGATCTGTATGGTGATGATGTGACCTAC 
CATGGTGTGGTCGCTGGTTTTTCCGGCGGTACGGGCTCCGCATTTTCGATGATCCCT 
GCACAAAACGCCACAGGCAACTGGATTAAAGTGGTGCAGCGTTTGCCGATCCGTATC 
GAGTTGGATCCCAAAGATTTGCAAGCCTATCCACTGCAGGTAGGATTATCTATGGTT 
GCCACGATAGATACTGCTGGAACTACCGATCCACAAACCTTAGTGCAGTACCGCGCC 
GCCAAAGTATCAGAGCAAATCTAA 
4. Amino acid sequence ofVceA 
MKQQNLNRLSSMNSNNSNTEFDGVRAAQSRKKGFLGLAAAIVVAGGSYALYWHFIGS 
RYISTDNAYAAAEIAEVTPAVGGIIAQVNVVDTEYVKQGDVLVQLDDTDARLALLQA 
EADLALAKRRVRSYLANDEGLSAMVEAQEANEQRVKAQLKAAQADFERAKIDLSRRE 
DLVRSGSVSGEELTNAKTGFAQAQANLNAAKAAMAQAQATKLSTIGSQKANAALTDN 
TTVDSNPEVLLAKARYEQAKIDLERTVIRAPISGIVAKRQVQVGRRVQVGMPLMTVV 
PTDHIYADANFKEVELRDVKVGQPVTLTADLYGDDVTYHGVVAGFSGGTGSAFSMIP 
AQNATGNWIKVVQRLPIRIELDPKDLQAYPLQVGLSMVATIDTAGTTDPQTLVQYRA 
AKVSEQI* 
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5. DNA sequence of V ceB 
ATGAGTCATAACGCTGACAATGAGATGCAACCTCTGTCAGGATGGGCACTGTTTTTC 
GGTGCCCTGTGTCTGGCAATGGCCAACTTTCTCGCTATTTTGGATACCACTATTGCT 
AACGTCTCTGTCTCCAATATCGCTGGTAGCCTAGGAACTTCAACTAGCCAAGGGACT 
TATGTGATTACCTCTTATGCGGTCGCAGAGGCGATCTCGGTACCTCTTACGGGTTGG 
TTGGCTTCGCGATTTGGCTCTATTCGAGTCTTTGTCACCTGTTTTCTGTTATTCGGT 
GTTTTTTCATTACTCTGTGGTTTAGCCAATAGCATGAGCACGCTGGTGATGTTTCGA 
GTGTTGCTTGGTTTCGTGGGAGGGCCTTTAATGCCACTTTCACAAACCTTGATGATG 
CGAATATTCCCCAAAAACAAAAGCCATGCTGCGATTGGTATCTGGTCGATGACCACG 
CTCGTGGCACCTATCATGGGACCTATTCTTGGCGGCGTGTTGTGTGACCAACTCAGT 
TGGCCATACATCTTTTTCATCAAAATGCCTTTCGCTATTGCCGCGGCGTTACTGTGT 
TGGAAATTGCTGAAAAAATTTGAAACCAAAACGACGCATTCAAAAATTGATAAAGTG 
GGGCTGGCGTTATTGGTCGTGTGGGTCGCCGCATTGCAATTAATGTTGGATGAAGGT 
AAGGATCATGACTGGTTTGAGTCATCGCGCATTGTGTTTTTGGCGGTGATTGCTGTG 
ATTGGTTTCATTGCATTCTTGATTTGGGAGCTAACGGAGCGAAACCCTGTCGTGGAT 
TTAAAGGTATTCCGACATCGAGGTTACAGTATTAGCATGGTGACGTTNTCACTCGCG 
TTCGGCGCTTTTTTTAGTATTTCTGTAGTAACACCTTTATGGTTGCAAA~TNACATG 
GGTTATACCGCCACCATTTCAGGCCACGCTACTGCCAGTATGGGGATTCTAGCGGTT 
TTTTTGGCACCGATAGTGGCCAATCTGTCCTCGAAATTTGATCCTCGGCCCTTTGTT 
TTTGCTGGCGTGATGTGGCTTGGGCTGTGGACTTTCATGCGTGGCTTTAACACAGTA 
GATATGACGTTTTCGCAAATCAGTTGGCCTTTATTTTTCCAAGGTATCGGCATGCCG 
TTGTTCTTTGTGCCATTGACTGCGATAGCCCTTGGTAGTGTCAAACCGCACGAAATG 
GAATCAGCAGCAGGATTGATGAACTTTATCCGAACCTTGTCCGGTGCGTTTGCGACC 
TCAATGATCAACACTTCATGGGAGCATGAAACACGTTATGTGCATGCTGAGTTGGCA 
GGCTTAACTGATAAAGCGGGTGTCGCGGCACAAGCGATGCAAAGTTCAGGAATGAGT 
GCCGAGCAGACGCGCTCTGCGATGGACTGGATATTGCAAAATCAGAGTGTGATGGTG 
GCAACCAACCAGTTGTTTATCGTGATTGCACTGATCTTTGTATTTGCAGCCTGCATG 
ATTTGGTTTGCGCCAAAACCCAAGCAAGCGGTGGATACCTCTGCTGTTCATTAA 
6. Amino acid sequence of V ceB 
MSHNADNEMQPLSGWALFFGALCLAMANFLAILDTTIANVSVSNIAGSLGTSTSQGT 
YVITSYAVAEAISVPLTGWLASRFGSIRVFVTCFLLFGVFSLLCGLANSMSTLVMFR 
VLLGFVGGPLMPLSQTLMMRIFPKNKSHAAIGIWSMTTLVAPIMGPILGGVLCDQLS 
WPYIFFIKMPFAIAAALLCWKLLKKFETKTTHSKIDKVGLALLVVWVAALQLMLDEG 
KDHDWFESSRIVFLAVIAVIGFIAFLIWELTERNPVVDLKVFRHRGYSISMVTXSLA 
FGAFFSISVVTPLWLQIXMGYTATISGHATASMGILAVFLAPIVANLSSKFDPRPFV 
FAGVMWLGLWTFMRGFNTVDMTFSQISWPLFFQGIGMPLFFVPLTAIALGSVKPHEM 
ESAAGLMNFIRTLSGAFATSMINTSWEHETRYVHAELAGLTDKAGVAAQAMQSSGMS 
AEQTRSAMDWILQNQSVMVATNQLFIVIALIFVFAACMIWFAPKPKQAVDTSAVH* 
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